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ABSTRACT 
The metabolism of fatty acids in humans is recognized as an important source of 
energy. It is especially vital to newborn infants when metabolic pathways are often 
stressed as the early stages of life demand fundamental changes and developments 
of body processes. Defective fatty acid oxidation pathways can rapidly lead to a 
life-threatening situation. It has been suggested that such disorders may be 
responsible for a proportion of "cot death" or sudden infant death syndrome (SID S) 
cases. 
Recently, it has been found that the levels of acylcarnidnes in body fluids and tissue 
are potential indicators of fatty acid metabolism status. This is due to carnitine 
esters being produced and excreted in an attempt to alleviate the toxic accumulation 
of incompletely metabolized acyl units in the mitochondrion. However, clinical 
studies have been limited by a lack of convenient, unambiguous, sensitive and 
affordable analytical techniques for the measurement of physiological 
acylcarnitmnes. The nature of carnitine and its acyl esters presents analysis 
problems. They are involatile, zwitterionic compounds which makes them 
unsuitable for direct gas chromatography (GC) and combined gas 
chromatography/mass spectrometry (GCIMS). The latter of these is the favoured 
technique for normal urinary organic acid assays and is ideal in terms of selectivity 
and sensitivity. The work reported here details the development of a simple 
unambiguous and novel derivatization procedure in which acylcarnitines are 
cyclized to give volatile lactones, amenable to GC and GC/MS. The technique was 
subsequently applied to acylcarnitines extracted from urine. As such, the method 
has been used to identify acylcarnitine metabolites in the urine of children with 
diseases of fatty acid oxidation and amino acid catabolism. Investigations of the 
metabolism of exogenous 3-phenylpropionic and valproic acids was also 
conducted. 
The preliminary results from the application of capillary zone electrophoresis 
methods to acylcarnitine analysis are also reported. 
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CHAPTER 1 
INTRODUCTION 
OH 
+1 
(CH3)3NCH2CHCH2000 
O a 
OCR 
+I 
(CH3)3NCH2CHCH2COO 
2 
1.1 THE PHARMACOLOGY OF CARNITINE 
1.1.1 History and Metabolic Function 
In 1905, Gulewitsh and Krimbergl assigned the empirical formula C7H15N03 to a 
compound isolated from meat extract. Carnitine (L -3-hydroxy-4-N 
trimethylaminobutanoic acid; (1)) had been discovered, but it was not until 1927 
that the correct structural formulae was proven. 2 For almost forty years after its 
discovery, carnitine was regarded solely as a constituent of vertebrate muscle. It 
required the identification of carnitine in insects to precipitate an interest which 
would lead to the ongoing interest in the pharmacological role of this compound 
throughout nature, and in particular, in man. 
Carter et a1., 3 in 1951, identified carnitine as the dietary factor named vitamin BT, 
which was regarded as essential for the growth of the mealworm, Tenebrio molitor. 
The requirement for carnitine by the mealworms to sustain growth was developed 
into a sensitive assay, "The Tenebrio Test. " The test was applied to an extensive 
range of biological material. It is interesting to note that this was the first reported 
method used to determine carnitine levels in human urine and blood, 4 an assay 
closely associated with the objectives of the project reported here. 
By 1954, hundreds of biological samples had been subjected to the Tenebrio Test. 
The results indicated that carnitine was universally distributed throughout nature 
with few exceptions 4s5 The quantities determined varied considerably between 
samples, with some (notably mammalian muscle tissue) presenting relatively large 
amounts .4 Subsequent analyses6 have found carnitine concentrations 
in 
mammalian tissue to vary between 0.1 and a few millimoles per litre. The highest 
concentrations are found in heart and skeletal muscle. When carnitine is found in 
plants, lower concentrations around the micromole per litre level are encountered? 
In 1957, Fraenkel and Friedman8 reasoned that a substance of apparently universal 
occurrence and of assumed important functional significance to the organisms 
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Scheme 1. Biosynthesis of carnitine 
which contain it, would have been described as a vitamin earlier if it were not 
synthesized by those organisms. Therefore, there began an interest in elucidating 
the endogenous biosynthesis pathway in mammals. Early investigations9 
demonstrated that the quaternary ammonium methyl groups were derived from 
methionine, but precursors for the four-carbon chain and the nitrogen moiety 
remained unknown. Conversion of y-butyrobetaine to carnitine was reportedt0 but 
it was not until the discovery that lysine served as a precursorl l that an acceptable 
biosynthetic pathway could be postulated and then experimentally confirmed. 12 In 
animals, the amino acid becomes available as a peptide residue in certain lysine-rich 
proteins. It is methylated by S-adenosylmethionine and a protein methylase before 
proteolysis liberates e-N-trimethyllysine (TML), Scheme 1. Through a further 
three enzyme-dependent steps, TML is oxidatively converted to y-butyrobetaine via 
ß-hydroxy-e-N-trimethylysine and y-butyrobetaine aldehyde. The final 
hydroxylation step to carnitine, requiring cytosolic hydroxylase, is restricted to 
liver, brain and human kidney tissue. 13 In humans the liver is the principle site for 
carnitine synthesis. Tissues which lack the hydroxylase enzyme can export the y- 
butyrobetaine precursor, via blood circulation, to the hydroxylating tissue, but rely 
on the return of newly synthesized product or dietary intake for their carnitine 
supply. In nutritional terms, there is also a role for four additional micronutrients, 
vitamin C, niacin, vitamin B-6 and iron, as cofactors required by the various 
enzymes involved in the biosynthesis. Thus, deficiencies of these nutrients along 
with lysine and methionine are all known to result in reduced plasma and/or tissue 
levels of carnidne. 14,15 
In 1955, Fritz16 began to establish the primary role of carnitine in man. He 
demonstrated that adding carnitine to liver slices and homogenates facilitated the 
oxidation of long-chain fatty acids. In the same year, Friedman and Fraenkel17 
reported the reversible enzymatic acetylation of carnitine by acetyl coenzyme-A 
(AcCoA) to form the acylcarnitine, acetylcarnitine, (2, R= CH3) as given in 
12 
0 I OH 
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Scheme 2. Enzymic acetylation of camitine 
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Scheme 2. After showing that isolated rat mitochondria from a variety of tissues 
would catalyze the same reversible reaction (Scheme 2), Bremer18 hypothesized 
that because the inner mitochondrial membrane is impermeable to coenzyme-A 
(CoA) and AcCoA, carnitine transports acetyl groups (as acetylcarnitine) across the 
membrane. This requires the intervention of an acetylcarnitine-CoA- 
acetyltransferase enzyme. Bremer also correctly postulated that because added 
camitine stimulates palmitate (hexadecanoate) oxidation, camitine also transports 
other acyl groups. The work of Fritz on long-chain fatty acid oxidation supported 
Bremer's theory. 19 That carnitine promotes long-chain fatty acid oxidation by 
translocating activated long-chain fatty acids into the mitochondrial matrix (the site 
of (3-oxidation), was accepted almost immediately. However, in the case of acetyl 
and other short-chain acid metabolism, the formation of carnitine esters (2) is now 
regarded of more relevance in removing acyl groups from the mitochondrial matrix. 
Oxidation of fatty acids is an essential energy supply for thecell, especially when 
glucose availability is low. Mitochondrial (3-oxidation is the only carnitine- 
dependent pathway for the oxidation of long-chain fatty acids, and it is the main 
metabolic route for the oxidation of all fatty acids. Extramitochondrial pathways are 
available for oxidation of fatty acids and consist of microsomal CU- and w-1- 
oxidation and peroxisomal ß-oxidation 2O Peroxisomal ß-oxidation is important for 
very long-chain fatty acids which are poor substrates for the mitochondrial pathway 
and may represent 35% of total palmitic acid oxidation 22Zfl (Whilst peroxisomal 
ß-oxidation does not require carnitine to transport fatty acids into the organelle, 
evidence does suggest that carnitine is involved in removal of chain shortened 
products out of peroxisomes 2.24) Microsomal w- and co-l-oxidation, under 
normal conditions, will only metabolize 4 to 5% of the fatty acids. 25 As the main 
metabolic route for fatty acid oxidation, mitochondrial ß-oxidation and its reliance 
on the carnitine transport shuttle system has attracted most attention over the past 25 
years. 
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Free fatty acids (FFA's) in plasma enter the cell by a diffusion process after binding 
to a lipoprotein receptor on the cell membrane. Once in the cell, the FFA's are 
activated by combination with CoA to form highly polar thiol esters, soluble in the 
aqueous phase of the cell. The fatty acyl group is then subject to the carnitine 
transport shuttle system, (Figure 1). The CoA esters pass through the outer 
mitochondrial membrane to the inter-membrane space. Here they are converted to 
fatty acylcarnitines, 2, facilitated by the enzyme, camitine acyl transferase I (CAT 
1). 26 Three separate CAT I enzymes exist with chain length specificities which 
overlap?? Recent evidence suggests that at least one of the CAT I enzymes resides 
in the outer mitochondrial membrane, as in Figure 1,28 rather. than the conventional 
assumption that all CATs are enzymes of the inner membrane. The carnitine esters 
formed are transported through the inner mitochondrial membrane, a process 
catalyzed by the trans-membrane protein, acylcarnitine translocase. Once within the 
mitochondrial matrix, the acyl groups are re-equilibrated with CoA by carnitine 
acyltransferase II (CAT II), situated on the matrix side of the inner mitochondrial 
membrane. 29 Analogous to the CAT I enzymes, three chain length specific CAT II 
enzymes are available. The free carnitine formed in the mitochondria may pass 
back to the cytosol to repeat its transport role. 
In both CAT I and CAT II cases, the identified, chain length specific, enzymes are: 
carnitine acetyl transferase, utilizing free fatty acyl groups of two or three carbon 
atoms in length; carnitine octanoyl transferase, utilizing free fatty acyl groups of six 
to ten carbon atoms in length; and carnitine palmitoyl transferase, utilizing free fatty 
acyl groups of fourteen to sixteen carbon atoms in length. Equimolar amounts of 
the respective CAT I and CAT II enzymes are present in the mitochondrial 
membrane. 29 
Once present in the mitochondrion, the acyl-CoA species may be progressively 
catabolized to acetyl-CoA by the ß-oxidation process (Scheme 3) generating cellular 
ATP directly through the citric acid cycle or through ketogenesis. Each cycle 
15 
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Figure 1. Camitine transport shuttle system 
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involves four enzymic reactions, the first stage being a dehydrogenation process. 
Three different fatty acyl-CoA dehydrogenase enzymes have been identified30,31,32 
with different chain length specificities and overlapping activities: short-chain acyl- 
CoA dehydrogenase (S CAD), medium-chain acyl-CoA dehydrogenase (MCAD) 
and long-chain acyl-CoA dehydrogenase (LCAD). The dehydrogenase process 
involves an enzymatic complex consisting of the relevant acyl-CoA dehydrogenase 
and two electron carriers, electron transfer flavoprotein (ETF)30,33,34 and electron 
transfer flavoprotein dehydrogenase (ETF DH), 35 all having flavin adenine 
dinucleotide (FAD) as coenzymes, as shown in Scheme 3. 
The transporting role of carnitine described above is the major function of this 
compound in humans. The naturally occurring isomer is the L- or (-) isomer, with 
an absolute configuration found to be R(-)-carnitine. 36 In a healthy, 70 kg, human 
adult, the total body pool of carnitine is approximately 100 mmol. 37 Muscle, 
incapable of complete carnitine synthesis, accounts for 98%, with only 1.5% of the 
carnitine in the liver and kidneys. The concentration in muscle is dependent on 
blood transport from synthesizing tissue such as the liver and kidneys and the 
absorption of exogenous dietary carnitine. Carnitine concentrations in skeletal and 
cardiac muscle are reported to be twenty to forty times higher than in plasma. 38 
This concentration gradient is unfavourable for transport from blood to muscle 
tissue and necessitates a special transport mechanism thought to be based on an 
exchange of y-butyrobetaine and/or acylcarnitines for carnitine 39 
The carnitine dietary requirements of a healthy adult are small. Strict vegetarian 
diets may contain less than 10% as much carnitine as a typical omnivorous diet in 
the developed nations. Nevertheless, studies of healthy well-nourished individuals 
in the United States eating vegetarian diets for prolonged periods, found they had 
normal plasma carnitine concentrations. The levels were similar to those of 
individuals consuming typical omnivorous diets 40 It is generally assumed that 
healthy vegetarians consuming diets with adequate lysine, methionine and 
17 
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micronutrients, required for carnitine biosynthesis, will maintain a normal carnitine 
status. 
Carnitine is not metabolized in humans although the degradation of the unnatural. 
S(+)-camitine enanfomer to trimethylaminoacetone has been observed in rats and 
mice 41 The only known route for removal of carnitine from the body is urinary 
excretion. The human kidney filters carnitine at a similar rate to creatinine. Renal 
clearance parallels, to an extent, the plasma concentrations of carnitine. A fall in the 
plasma concentration will usually be reflected in a fall in urinary carnitine. Over 
90% of the filtered carnitine is reabsorbed by the renal tubules, 42 a similar degree of 
conservation as that for the circulating amino acids. 
A comprehensive review of the biochemical aspects of carnitine and the camitine 
acyltransferase enzymes has been presented by Bremer. 27 
1.1.2 Impaired Fatty Acid Oxidation 
The consequence of defective fatty acid metabolism can be dramatic, especially 
when the cell is dependent on this energy source during periods of low glucose 
availability. These consequences initially affect the energy supply to vital tissue by 
reducing ketone body formation (hepatic hypoketogenesis). The diminished 
formation of acetyl-CoA will also impair glucogenesis, explaining the observation 
of severe hypoglycaemia in affected patients during crisis conditions. Onset of the 
condition is usually attributed to low carbohydrate supply resulting from incorrect 
diet, prolonged fasting, increased caloric requirements or vomiting. An increase in 
urinary dicarboxylic acid excretions (due to elevated microsomal ()-oxidation) has 
led to the term 'dicarboxylic aciduria'. These non-ketotic episodes of 
hypoglycaemia are often accompanied by excretion of äcyl-glycine conjugates. 
Seven inborn errors of fatty acid oxidation have been described to date: 
( 1) camitine deficiency; 
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(2) CAT deficiency, particularly relevant is camitine palmitoyl transferase 
(CPT), required for transport of the long-chain fatty acids into the 
mitochondrion; 
(3) long-chain acyl-CoA dehydrogenase deficiency (LCADD); 
(4) medium-chain acyl-CoA dehydrogenase deficiency (MCADD); 
(5) short-chain acyl-CoA dehydrogenase deficiency (SCADD); 
(6) riboflavin responsive defects of ß-oxidation or riboflavin responsive 
multiple acyl-CoA dehydrogenation deficiency (RR-MADD); 
(7) multiple acyl-CoA dehydrogenation deficiency (MADD) or glutaric 
aciduria type II (GA II). 
Figure 2 summarizes these disorders. 
The primary role of camitine, transport of long-chain fatty acids, is of direct 
relevance to carnitine deficiency disorders (i. e. Figure 2 [1]). However, over the 
past decade, additional functions of carnitine in humans have been identified. They 
are important in the mechanism of some of the other defective fatty acid oxidation 
diseases. These additional roles also rely on the ability to form acylcamitines (2) 
by ester bond formation through the hydroxy function of carnitine. 
It is now firmly estabished that carnitine is capable of removing incompletely 
metabolized acyl groups from the mitochondrion. The process is essentially the 
reverse of the transport of long-chain acyl groups into the mitochondrion but is also 
applicable to medium- and short-chain metabolites. A transfer of the CoA-bound 
acyl group to carnitine will result in an acylcarnitine, capable of passing out of the 
cell for urinary excretion or redistribution into other tissues for utilization. This is 
an important mitochondrial detoxification process in disorders (Figure 2, [3] to [7]) 
which present a metabolic block to complete catabolism of the fatty acyl group, 
20 
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Figure 2. Impaired fatty acid oxidation disorders (simplified scheme 
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in text 
21 
because incompletely metabolized acyl-CoA compounds are potentially toxic to the 
cell. 
The formation of acylcarnitines also serves as a mechanism to maintain a balance of 
free to esterified CoA, believed to be important for cell function 43 A more rapid 
renal clearance of acylcarnitines than of free carnitine supports the protective role of 
carnitine against metabolic acidosis. In states of elevated mitochondrial acyl-CoA 
concentrations, carnitine levels may be depleted to an extent that the ability to 
transport long-chain fatty acids across the inner mitochondrial membrane is 
reduced. This represents a life threatening situation whereby energy production is 
curtailed. Such carnitine depletion is not restricted to fatty acid catabolism. The 
metabolism of branched-chain amino acids involves a mitochondrial process44 and 
appropriate disorders may utilize carnitine in its detoxification role. Therefore, the 
analysis of urinary and plasma acylcarnitines constitutes a potentially excellent 
biochemical indication of many metabolic disorders. 
Impaired fatty acid oxidation and carnitine deficiency is likely to have consequences 
early in life. In the newborn, a life-dependent switch from carbohydrate to fatty 
acid oxidation for energy production takes place. The foetus and neonate are 
unable to biosynthesize carnitine due to low activity of cytosolic hydroxylase 45 
Activity of this enzyme, in infants of less than three months of age, is under 12% of 
adult activity. 46 In utero, foetal carnitine levels are dependent on maternal carnitine 
status45 and placental transfer. 47'48 Neonatal carnitine levels are dependent on 
exogenous dietary supplies a9 Studies have been conducted into breast milk 
carnitine content and its variation over the postpartum period. 50 Whilst it is 
interesting to note that the carnitine content of human breast milk increases over the 
first two to three days of suckling, the results are presently inconclusive since 
carnitine levels required for optimal fatty acid oxidation remain unknown. The 
clinical symptoms of carnitine insufficiency are recognized, however. 
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Separate carnitine deficiencies may be classified as follows: 
a) Carnitine deficient myopathy. Characterized by extreme muscle 
weakness, exercise intolerance and increased lipid storage in skeletal 
muscle. 51 The defect may be due to decreased synthesis of y- 
butyrobetaine in the muscle or defective uptake mechanism from the blood 
supply. 
b) Systemic carnitine deficiency. This syndrome is characterized by 
recurrent hepatic encephalopathy, lipid storage in liver and muscles and 
low plasma and tissue carnitine levels. Poor reabsorption by the renal 
tubules, resulting in a carnitine leak to the urine, seems to be the main 
pathogenic defect. 
c) Secondary carnitine deficiency. This deficiency is invariably associated 
with genetic defects of the mitochondrial (3-oxidation. The condition 
arises from excessive esterification with overproduced or underutilized 
acyl groups and subsequent urinary excretion. Such genetic disorders 
have been associated with Reye's syndrome and sudden infant death 
syndrome (SIDS). Medium-chain acyl-CoA dehydrogenase deficiency 
(MCADD) may be a contributive factor in up to 10% of SID cases52 
(although current views suggest a lower percentage). Administration of 
L-carnitine and/or fasting, results in increased excretion of urinary 
acylcarnitines which are disease specific. These disorders have the 
potential for rapidly reducing carnitine concentrations essential for 
mitochondrial ß-oxidation, hence the connection with cases of sudden 
unexpected deaths. 
The effects of carnitine deficiency may be reversible with exogenous L-carnitine 
administration. There are many reported cases to substantiate the supplementation 
of camitine, however, the degree of improvement is very variable. Further 
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investigations into the causes of carnitine deficiences and the diagnosis of f3- 
oxidation defects is likely to lead to advances in therapeutic treatment. Due to the 
metabolic role of acylcamitines, the analysis of these compounds in biological 
samples will be important to the investigations. Unfortunately, none of the 
analytical techniques reported to date are ideal for clinical application. There 
remains an urgent need for a simple, precise and unambiguous method of analysing 
urine (and other biological fluids) for acylcarnitines. 53 It is envisaged that an ideal 
method would be employed by a number of clinical screening laboratories. 
Therefore, the development of a routine procedure has to account for the 
equipment, workload, expertise and financial status of such a laboratory. 
1.2 DIAGNOSIS OF INBORN ERRORS OF FATTY ACID 
OXIDATION 
The clinical symptoms of carnitine deficiency are often indicative of fatty acid 
oxidation defects. However, precise diagnosis requires biochemical investigation 
of abnormal metabolites and identification of enzyme defects. Enzymatic 
characterization of fatty acid oxidation disorders has been reviewed? 0 The 
analysis of diagnostic metabolites in biological samples was the objective of this 
project. 
Many of the advances which have furthered the understanding and diagnosis of 
these diseases, have arisen from identifying and interpreting urinary organic acid 
profiles, especially dicarboxylic acids and acylglycine metabolites. 53' Attention 
has also been given to the measurement of free and total (free plus esterified) 
camitine in plasma. 55,56-57 Recently, however, the separation and identification of 
individual acylcarnitines in biological fluids, has become of major interest. 
The determination of carnitine and its esters presents a number of problems to the 
analyst. These highly polar, zwitterionic compounds, are non-volatile and therefore- 
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not directly amenable to gas chromatography (GC) techniques. The analyte does 
not contain any strong chromophoric function, thus limiting the sensitivity of high 
performance liquid chromatography (HPLC) with UV detection. In the case of 
neonatal urine, suitable analytical methods need to handle analyte levels of nmol 
ml-1, with low sample availability (typically 1 ml). A selective method is required 
because biological mixtures present a very complex matrix. Analysis of 
acylcarnitines in biological samples has been reviewed recently. 58 
Early investigations of carnitine determination included a number of chemical 
methods .8 
Such techniques usually utilized a solvent extraction of the biological 
material followed by chromatographic separation of carnitine. Once separated, the 
carnitine level could be estimated by any one of a number of methods. Liberation 
of trimethylamine from the reaction of carnitine with KOH and Zn dust at 120°C 
and subsequent colorimetric analysis has been reported. 59 The conversion of 
cainitine to crotonobetaine (4-N-trimethylammoniobut-2-enoate) and KMnO4 
titration of the product has been used, 60 as has a gravimetric method, based on the 
formation of carnitine reineckate 61(carnitine tetrathiocyanato-diamminochromate 
(III)). These early camitine determinations were complex, difficult to apply to 
physiological quantities, inaccurate, not applicable to camitine esters, and open to 
interference from other quaternary amines. 62 
A number of enzymic methods exploit the recognition of acylcarnitines by carnitine 
acetyltransferase in the presence of CoA. Unreacted CoA may be reacted with 5,5'- 
dithiobis-2-nitrobenzoic acid (DTNB)63 or coupled with other enzymic reactions, 
the products of which are determined spectrophotometrically. 56 Good sensitivity in 
such determinations may be obtained with radioisotopes but the techniques tend to 
be complicated and expensive 6-67 Many of the enzymatic methods are only 
appropriate to free and total carnitine determinations. Attempts to identify and 
quantify individual acylcarnitines using enzymatic reactions have achieved only 
limited success. 68 Enzyme inhibition, 69,70 camitine-affected equilibria and 
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restricted acylcarnitine range68 make the techniques unsuitable for many 
investigations. 
L-camitine administration to patients with certain organic acidurias may result in 
relatively large urinary acylcarnitine levels (mmol m1-1) as accumulating acyl groups 
in the mitochondria are removed. Such concentrations are amenable to proton 
nuclear magnetic resonance spectroscopy (1H NMR). 71,72 The method has been 
successfully applied to cases of propionic acidemia and methylmalonic acidemia. 72 
No sample pretreatment was required and the procedure allowed simultaneous 
measurement of all urinary metabolites including organic acids, glycine conjugates 
and acylcarnitines. Whilst the method is promising in terms of these advantages, 
the insensitivity to compounds below the millimolar range severely limits the 
technique. There are problems regarding carnitine administration on ethical and 
therapeutic grounds to patients with ill-defined disorders. Also, there is the 
possibility that the sudden presence of an unnaturally high concentration of carnitine 
may perturb the metabolic processes under test, leading to ambiguous and/or 
erroneous conclusions. These disadvantages, along with the requirement for 
complex and expensive 400 MHz NMR instruments, precludes the routine use of 
NMR techniques in the clinical laboratory. Separation of carnitine esters, present in 
biological samples, has been achieved by paper chromatography, 73 thin-layer silica 
chromatography74 and ion-exchange chromatography. 75 77 The lack of quantitative 
and structural information severely limits the application of these techniques, 
however. Analysis by desorption chemical ionization mass spectrometry after TLC 
separation78 has been reported, as has combined TLGMS 79 The non-routine 
nature of such analyses is a significant disadvantage for clinical applications. 
GC and gas chromatography/mass spectrometry (GC(MS) are routinely used in the 
clinical laboratory. The application of these techniques to investigations of inborn 
errors of metabolism include screening of organic acid profiles and analysis of 
derivatized acylglycines. 53' Acylcarnitines are not directly amenable to GC 
26 
+ OCOR + OH 
Me3NCH2CHCH2000 + H2O l Me3NCH2CHCH2000 + RCOOH 
Scheme 4 
27 
techniques because of their involatile nature but derivatization to volatile analogues 
seems to have been poorly investigated. An assay for carnitine itself, based on the 
conversion of carnitine into a volatile butyrolactone compound has been applied to 
tissue extract. 80 In the case of biological fluids and acylcarnitines, however, GC- 
based procedures have relied on hydrolysis of the acylcarnitines and examination of 
the liberated fatty acids81(Scheme 4). The procedure is lengthy and difficult to 
apply routinely and it is also possible that the fatty acid analytes originate from acyl- 
containing species other than acylcarnitines. 
The involatility of the analytes may suggest the application of HPLC. However, 
conventional HPLC detectors lack sensitivity and selectivity towards acylcarnitines. 
The known, naturally occurring acylcamitines in biological fluids are neither 
fluorophoric nor electmphoric to any useful degree and the carboxyl group is only 
weakly chromophoric (2 = 210 nm). Transesterification with CoA and max 
carnitine acetyltransferase has enabled HPLC resolution of the generated CoA 
esters 82 The method was applicable only to short-chain acylcarnitines for the 
diagnosis of acidemias when the accummulating acid(s) contained five or fewer 
carbon atoms. 
Chemical. derivatization is a common approach to gaining increased sensitivity in 
HPLC and it has been applied to both carnitine and acylcarnidne determinations. 
Precolumn77-83-85 and post column86-SS derivatization techniques have been 
employed. All reported derivatizations for HPLC analysis of carnitine compounds 
involve reactions with the carboxyl function. However, carnitine, acylcarnitines 
and other four-carbon trimethylammonium acids (TMA's; e. g. betaine) are 
unreactive towards common carboxyl-O-alkylating reagents. This is thought to be 
due to a folded structural conformation of these compounds in solution, permitting 
strong ionic interaction of the cationic quaternary ammonium group with the 
carboxyl function. The resulting close proximity of the two ends of the molecule 
thereby inhibits the approach of electrophiles to the acid group. Homologous two-, 
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five- and six-carbon TMA-carboxylates are readily derivatized, presumably because 
these molecules do not have the same folded conformation. 83 
Formation of 4'-bromophenacyl ester derivatives are among the most useful 
reported for carboxylates with no other functionality. Two methods have been 
reported for forming UV absorbing, bromophenacyl derivatives of carnitine and its 
esters. The reaction with 2,4'-dibromoacetophenone (Scheme 5) has been the most 
widely applied. The reaction usually occurs in the presence of 5-10% of 18-crown- 
6 crown ether catalyst and potassium ions. 89 The derivatization is performed after 
isolation of carnitine and/or acylcarnitines from the biological matrix, usually by 
ion-exchange extraction. Subsequent analysis by reverse-phase HPLC has enabled 
quantitative determination of physiological carnitine and acylcamitines in urine and 
plasma 9091 
In contrast, Minkler et al, 83 found the use of 2,4'-dibromoacetophenone 
inappropriate for carnitine determinations, especially at low concentrations. High 
temperatures and extended reaction times were said to be necessary for appreciable 
derivatization but this was accompanied by analyte decomposition. The use of a 
more reactive allcylating reagent suited to derivatization at lower sample 
concentration and at lower temperature was investigated. 
4'-Bromophenacyl trifluoromethanesulphonate (4'-bromophenacyltriflate), 
synthesized from 4'-bromo-2-diazoacetophenone and trifluoromethanesulphonic 
acid, 2 was used by Minkler and coworkers83-85 to derivatize camitine and 
acylcamidnes (Scheme 6) for subsequent reverse-phase HPLC analysis. The 
reaction was performed in the presence of NN-diisopropylethylamine, used to 
neutralize any residual acid present in the sample. This sterically hindered base was 
only slowly alkylated by the derivatization reagent under the mild conditions 
employed. Ten minutes at 25 °C was sufficient to convert approximately 95% of 
the carnitine present to the 4-bromophenacyl ester derivative. 83 The same 
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derivatization procedure has been used to determine urinary acylcarnitine profiles 
from patients having propionic acidemia, isovaleric acidemia and medium-chain 
acyl-CoA dehydrogenase deficiency. The investigations required selective 
extraction procedures to isolate carnitine and its esters from the urine matrix. This 
is essential since 4-bromophenacyl trifluoromethanesulphonate reacts readily with 
other urinary components and consequently leads to interpretation difficulties. The 
procedure allows sensitive HPLC analysis of acylcarnitines and has even been used 
to determine these metabolites in normal human urine samples. 85 Despite this, the 
technique is currently not as popular as derivatization with 2,4'- 
dibromoacetophenone, possible due to the synthetic steps required to prepare a 
usable reagent, although once formed it is claimed to be stable for more than 1 year 
when stored desiccated at room temperature. 85 
Reverse-phase HPLC with postcolumn derivatization has largely been restricted to a 
group of Japanese workers. 86.88 The derivatization apparatus and procedure has 
been collectively termed a carboxylic acid analyser and is equally applicable to 
organic acids as well as carnitine and acylcannitines. The carboxylate group is 
reacted with 2-nitrophenylhydrazine enabling specific colorimetric determination of 
acetylcarnitinc and glutarylcarnitine. 86 
Whilst further development of some of these HPLC methods appears to be 
worthwhile there is one fundamental disadvantage of any stand-alone 
chromatographic technique. The inability of HPLC (and GC) to provide any 
structural information limits the application. Such knowledge is essential if 
diagnostic interpretation of uncharacterized disorders are to be made. The 
requirement for structural information and a sensitive/selective detector suggests 
coupling of chromatography to mass spectrometry. 53 
Mass spectrometry is widely utilized in the clinical chemistry laboratory. The value 
of unambiguous structural information makes it an attractive technique in its own 
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right or as a chromatographic detector. 93 The major obstacle to acylcarnitine 
analysis by conventional mass spectrometry is once again the involatility and 
thermal lability of the analyte. 94 Application has largely awaited advances in mild 
ionization techniques. 
The technique of desorption chemical ionization mass spectrometry was one of the 
earliest applications of MS methods to intact acylcarnitine analysis-74 It consisted 
of the pyrolysis of the sample on a tungsten filament in a chemical ionization 
source. As the acylcarnitine analyte is heated on the filament, some evaporation of 
the molecules occurs but because of the thermal lability of these compounds, 
mostly decomposition products are released. In either case, the processes happen 
in the presence of reactant gas ions, such as NH4+ when ammonia is used. This 
results in ionization of the evaporated molecules and pyrolysis products, as in other 
chemical ionization techniques. Mass analysis of the ions produced gave 
characteristic mass spectra for individual acylcarnitines. By comparing such spectra 
from standard acylcamitine samples with those obtained from the analysis of 
isolated fractions of a clinical urine, octanoylcarnitine was identified in a case of 
MCADD. 74 No further applications have been reported, probably because of (i) 
poor sensitivity, (ii) the inability to couple to a chromatographic method and (iii) 
transient spectra are obtained which are not compatible with MS/MS (see later). 
The 1980's saw the advent of fast atom bombardment (FAB) as a mild method of 
producing ions from involatile and thermally labile compounds for mass 
spectrometric analysis. It soon became apparent that the ionic nature of carnitine 
and acylcarnitines made them excellent analytes for FAB techniques. Since the first 
application of FAB to the identification of physiological acylcamitines, 95 it has been 
used extensively to analyse for these compounds in biological samples. Early 
studies however, were hindered by suppression effects of Na+, K+ and urea in 
urine, reducing the abundance of ions from the acylcarnitines. Methylation of raw 
urine (3M- HCUMeOH, 80 °C, 15 min) overcame the sensitivity problem and 
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allows detection of acylcarnitines as their methyl esters at concentrations down to 
50 nmollml. 96 
Despite the popularity of the method there exists a degree of uncertainty in the 
specificity of FAB analysis of acylcarnitine methyl esters. This is because a given 
methyl ester has the same elemental composition and mass as the free acid of the 
next higher homologue. For example, the predominant ions [M]+ for the methyl 
ester of isovaleaylcarnitine and [M + H]+ for hexanoylcarnitine (both m/z = 260) are 
not distinguished by conventional FABMS. Incomplete methylation of the sample 
could therefore lead to erroneous conclusions. The formation of isotopically 
labelled methyl esters has recently overcome this disadvantage 97 Using 
perdeuteriomethanol, [2H3 - Me] methyl esters of the acylcarnitines are made which 
give an increase of 17 daltons to the molecular mass (instead of 14: one methylene 
unit), forming derivatives which are distinct in mass from other homologues. 
Subsequent isotopic dilution experiments have enabled quantitative acylcarnitine 
profiling of normal and disease-state urines using FABMS: n Whilst FAB has the 
ability to produce a good yield of intact acylcarnitine ions, this is not sufficient for 
clinical interpretation, especially when mixtures are analysed. More structural 
information is required to confirm that an ion of interest is an acylcarnitine and to 
distinguish between isomers. High resolution MS has been used to confirm the 
molecular formulae of the ions corresponding to the acylcarnitines97 but this 
method cannot distinguish isomers and the accuracy of the quantitative assay is 
variable for different acyl chain lengths. The favoured technique is to combine 
FAB with tandem mass spectrometry (FABMS/MS). In such an experiment, the 
intact acylcarnitine ions produced by FAB, are separated'according to mass then 
allowed or encouraged to fragment within the mass spectrometer before separation 
and detection of the resultant ions. This may be performed on a double-sector 
instrument using linked scanning, 95'98-99 or a triple quadrupole system105 or a 
hybrid instrument. 100.101 In each case, the objective is to gain information on how 
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suspected acylcarnitine ions fragment, confirming or otherwise the presence of the 
carnitine esters. MS/MS can be applied to mixtures since it effectively performs a 
separation based on the mass of the analyte(s). Another advantage is the speed of 
analysis associated with MS/MS experiments, seconds compared with, say, a 30 
minute GC/MS analysis. 
Typically, a normal FAB spectrum from a clinical urine sample may show an ion of 
m/z value corresponding to an intact and known acylcarnitine ion. This information 
would be combined with data from a constant neutral loss scan (CNL), for 
example, searching for losses of 59 daltons, i. e. loss of Me3N. If this procedure 
indicated that the suspected acylcarnitine ion observed in the normal FAB analysis 
did loose 59 daltons, this would support the identification of a carnitine ester. 
Further confirmation would require another experiment, a daughter ion scan, 
performed on the identified molecular ion and/or any other ion which lost 59 
daltons and hence was observed in the CNL scan. Alternatively, or additionally, a 
parent ion scan on an ion such as that occurring at m/z 85, due to +CH2- 
CH=CHOOH and common to all acylcarnitines, may be obtained. For reliable 
identification the process of performing those separate experiments may take longer 
than one might expect for an MS/MS investigation. The technique is also 
dependent on the yield of daughter ions from the parent molecular ion and in the 
case of acylcarnitines this usually requires high energy collisional activation with 
expensive and complex hybrid sector instruments. 100,101 This is certainly so for 
the differentiation of isomeric acylcarnitines100 as KeV collision energies are 
required to cause cleavage of the acyl chain. The difficulties associated with 
isomeric acylcarnitines are compounded when a mixture of isomers is encountered, 
for example if octanoylcarnitine and valproylcarnitine occur in the same sample. 
Therefore, for complete characterization workers have sometimes resorted to the 
complementary use of thermospray LC/MS 102 or hydrolysis followed by GCIMS 
of the liberated acids-103 
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The advances made in HPLC analysis of carnitine esters has led to the use of mass 
spectrometry as a detection system for reverse-phase HPLC separations. 
Thermospray (TSP) is currently the most popular LC/MS interface and capable of 
handling the high salt concentrations of eluent from reverse-phase columns. 
Successful analysis of acylcarnitines in biological fluids has been achieved using 
TSP/MS. 103.104-106 The technique has proven particularly useful in distinguishing 
isomeric acylcarnitines, which is not possible by conventional FABMS and is 
difficult by FABMS/MS techniques. 
Recently, a continuous flow FAB interface (CFFAB) has been used in conjunction 
with microbore reverse-phase HPLC columns. 107 The separation achieved with 
these short columns made necessary CFFABMS/MS for full analytical 
interpretation; requiring a complicated instrument set-up. 
LGMS approaches to acylcarnitine determinations are still proving themselves at 
the physiological levels present in urine and plasma. As with MS/MS methods the 
necessary equipment is not common in hospital screening laboratories and is 
unlikely to enjoy widespread and routine clinical application. 
None of the methods discussed is yet ideal for routine clinical analysis of 
acylcarnitines. Advances and further application of reverse-phase HPLC and 
FABMS/MS should continue to generate valuable data. It is believed however, that 
there is a role for an alternative, simple, unambiguous method of analysing 
individual acylcarnitines. In terms of technique, GC/MS and its associated 
capabilities of unrivalled separation efficiency with excellent structural specificity 
and sensitivity, is most likely to provide a definitive analysis at realistic cost. Any 
such method could be readily integrated into existing GGMS screening procedures 
for urinary organic acids. Addressing the requirement for a suitable derivatization 
procedure is paramount to the successful application of GGMS in this area. 
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1.3 NEW APPROACHES TO THE ANALYSIS OF 
PHYSIOLOGICAL ACYLCARNITINES. 
1.3.1 Derivatization for GC and GC/MS 
A suitable derivatization procedure for acylcarnitine analysis by GC and GC/MS 
must remove the zwitterionic, non-volatile nature of the analyte molecule. This is 
fundamental to the application of GC techniques, but also of diagnostic importance 
is the maintenance of molecular integrity in the formed derivative. As mentioned, a 
disadvantage of acylcamitine hydrolysis and GCIMS of the liberated acids, is the 
uncertainty of the examined analytes' origin. The development of a simple and 
novel derivatization procedure in which acylcarnitines are cyclized to give volatile y- 
butyrolactones, 3, (Scheme 7), is presented here. Importantly, the derivatives 
retain a structural'memory' of their origin, that is, the fatty acyl unit remains bound 
to a diagnostic residue of carnitine. 108 
The formation of y-butyrolactone compounds from camitine and acylcamitines was 
first reported by Hvistendahl er al. 94 The heated septum inlet system of a mass 
spectrometer was identified as the site of a pyrolysis reaction. Carnitine and 
acylcamitine HCl salts were reported to eliminate trimethylamine and cyclize to the 
corresponding lactone. The GC assay for carnitine alone, reported by Lewis et 
a!. 80 was also based on the formation of 4-butyrolactone derivative by the action of 
NaOH and NaBH4. One of the main objectives of this project was to develop such 
a cyclization reaction into a useful derivatization process for GC and GGMS 
analysis of a wide range of acylcarnitines. 
Structurally, the acylcamitine molecules are ideally arranged for the intramolecular 
cyclization shown in, Scheme 7. Analytical evidence (Section 2.1.1) and work of 
others on derivatization of camitine and its esters to HPLC amenable analytes 
(Section 1.3), suggests that these compounds exist in solution as a folded structure 
with the carboxyl tail of the molecule close to the quaternary ammonium head. 
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Nucleophilic attack of the carboxyl group on the methylene carbon attached to the 
nitrogen, eliminates trimethylamine and forms a y-butyrolactone. Considerable 
evidence exists to suggest that heat alone may induce this reaction. In addition to 
the work of Hvistendahl et al., 94 analysis of acylcarnitines by desorption chemical 
ionization74 (pyrolysis in a chemical ionization source) identified trimethylamine as 
the major ion product with additional ions indicative of the lactone fragmentation 
(c f. Section 2.4.2). 
Refinement and control of the cyclization reaction was the starting point for the 
development of the derivatization. The lability of acylcarnitines towards Hofmann 
elimination (Scheme 8) and hydrolysis (Scheme 4) is known and needed to be 
respected. For this reason, strongly basic and/or aqueous reaction conditions were 
avoided. Also, careful control of heat was required to avoid decomposition of the 
formed derivative. This made necessary a bench reaction rather than one carried out 
in situ or on-column. An on-column reaction would not be appropriate anyway 
since cold on-column injection is generally regarded as the optimal technique to 
obtain precise quantification and good sensitivity when using GC/MS. 
The successful conversion of acylcamitines to the corresponding lactones (Scheme 
7) has enabled application of capillary GC and GGMS. 108 The lactones do not 
possess the highly polar, zwitterionic nature of the parent compounds and are 
suitably volatile for use of the previously inappropriate analytical techniques of GC 
and GC/MS. Initial investigations with a model acylcarnitine standard were used to 
identify appropriate derivatization conditions. The model compound continued to 
be useful in many subsequent studies as a suitable internal standard. Once the 
proposed derivatization had been validated with naturally occurring acylcarnitine 
standards, spiked urine experiments were conducted. 
The complex nature of a biological matrix places great demands on the selectivity of 
any analytical procedure for clinical investigations. It was found necessary to 
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extract the acylcarnitines from urine prior to derivatization and analysis. The most 
suitable technique employed ion-exchange resins and enabled selective isolation of 
the carnitine compounds. 
The developed analytical method has been applied to many clinical urine samples. 
Results from the study of urine from patients with defective fatty acid and amino 
acid metabolism are reported. Unambiguous identification of endogenous 
acylcamitines in such samples was observed using GCIMS. Similarly, carnitine 
ester metabolites were identified in urine from children undergoing certain 
therapeutic treatments. In this role, the technique enabled investigation of the 
metabolism of two acidic drugs; 3-phenyipropionic acid and 3-propylvaleric acid. 
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CHAPTER 2 
DEVELOPMENT. OF A METHOD BASED ON 
GAS CHROMATOGRAPHY 
RESULTS AND DISCUSSION 
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2.1 INTRODUCTION 
A limited range of acylcarnidnes is commercially available: acetyl-, octanoyl- and 
palmitoylcarnitine, all in the form of their HQ salts. A larger range of these 
camitine esters would be required for confirmatory purposes, if a developed 
analytical method were to be applied to clinical investigations. Therefore, it was 
thought important to be able to synthesise a range of acylcarnitines (2) of varying 
R group. These should include acylcarnitines previously identified and/or 
suspected in the metabolic disorders of interest. For example, hexanoyl- and 
octanoylcamitine in cases of medium-chain acyl-CoA dehydrogenase deficiency and 
isovalerylcarnitine in cases of isovaleric acidemia. Identification of such 
metabolites in biological fluids would be characteristic of the respective diseases. 
Also of initial interest was the synthesis of a "model acylcamidne" suitable for 
testing the derivatization reaction (Scheme 7). Monitoring the cyclization of a 
naturally occurring, acylcarnitine standard such as octanoylcarnitine presents some 
analytical problems. The ideal technique would be to use GC and GGMS to detect 
any conversion to the volatile lactose product. However, there exists the possibility 
of the cyclization occurring in the hot injector zone of the GC or even the GC 
column or the hot ion source of the mass spectrometer. 94 That is, the analytical 
procedure itself may interfere with the process under observation. To prevent such 
interference, a chromatographic method was needed that did not involve heating of 
the analytes. As a convenient and rapid method of monitoring reactions, TLC is 
well established in synthesis work. However, most naturally occurring 
acylcarnidnes, lacking any significant chromophoric properties, would require the 
use of developing reagents to monitor any reaction by TLC. Rather than investigate 
the viability of developing reagents, 109 it was decided to synthesise an unnatural 
acylcarnitine containing a UV absorbing functionality to facilitate ease of detection. 
Such a compound, whilst being easy to detect must behave in the same way as the 
natural acylcarnitines of primary interest, under the analysis conditions. For this 
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reason, 4"phenylbutanoylcarnitine [2, R= C3H6C6H5] was synthesised, in which, 
the UV active phenyl group was sufficiently remote from the cyclization site so as 
not to affect the derivatization process. 
The successful cyclization of this model acylcamitine would result in a 4- 
phenylbutanoyl-containing y-butyrolactone compound [3, R= C3H6C6H5]. The 
independent synthesis of this acyloxylactone from a non-carnitine origin, would be 
useful in checking for the successful conversion from acylcarnitine to volatile 
lactone (Scheme 7). The infrared (IR), mass, NMR and UV spectra of this product 
[3, R= C3H6C6H5], along with its TLC behaviour, could be used to confirm, or 
otherwise, the successful development of appropriate derivatization conditions. 
This was regarded as a more effective strategy than alternatively subjecting natural 
acylcamitines to various reaction conditions and attempting to analyse the products. 
The identification of appropriate derivatization conditions was necessary before 
application to acylcarnitines in biological fluids could be attempted. In addition, 
coping with the biological matrix would be essential to biochemical investigations. 
Extraction of the acylcarnitines from urine or blood prior to analysis has been 
necessary for other analytical approaches. The likelihood of interference by the 
biological matrix on the derivatization step, suggested that extraction of the analyte 
would also be required in this study. 
Successful extraction and derivatization of naturally occurring acylcarnitines from 
urine would enable the application of GC and GC/MS analyses. In order to gain 
the full benefits of selectivity, sensitivity and structural identification from these 
techniques, attention must be given to optimization of operating conditions and 
parameters. Correct choice of capillary column, injection technique, gas flows and 
temperature programming are fundamental to achieving suitable GC resolution of 
the sample components. This may require detailed attention when similar 
compounds (e. g. isomers) are being chromatographed. The mass spectral data 
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derived from an analyte are equally, if not more, dependent on operating 
parameters. Electron ionization (EI) and chemical ionization (CI) MS techniques 
are capable of producing completely different but often complementary analytical 
information. Utilizing the versatility of these techniques was regarded as important 
to realizing the objectives of the project. 
2.2 SYNTHESIS OF ACYLCARNITINES (2) 
Various syntheses of acylcamitines have been reportedi 10,111 but all are based on 
the condensation of carnitine hydrochloride with an appropriate acid chloride, as 
shown in Scheme 9. The methods of Ziegler et al. I I1 and variations on the 
procedures were employed exclusively in the studies reported here. All syntheses 
were performed with D, L-carnidne hydrochloride. The formation of racemic 
acylcarnitines, as their HC1 salts, was regarded as suitable for the purposes 
required. It should be noted, however, that only L-carnitine occurs naturally. 
Experience of the synthesis procedure was initially gained with known 
acylcarnitines and particularly those which could be analytically checked against 
authentic commercial samples. Acetyl-, octanoyl- and palmitoylcarnitine were 
prepared and analysed on this basis. The synthesis techniques were then applied to 
the preparation of 4-phenylbutanoylcarnitine (2, R= (CH2)3C6H5), 
hexanoylcarnitine (2, R= (CHjCH3) and 3-phenylpropionylcarnitine (2, R= 
(CHC6HS). Ziegler et a1.111 describe three synthetic methods for acylcarnitines 
of differing chain length, from acetylcarnitine to palmitoylcarnitine. Depending on 
the carnitine ester required, one of the following methods of preparation was used. 
The phenyl-containing acylcarnitines were prepared by Method C. 
Method A: Acetylcamitine was formed from the reaction of acetyl chloride with 
carnitine hydrochloride in acetic acid (Section 6.3.1). The product 
was obtained as a white crystalline solid in good yield after 
recrystallization from propan-2-ol. 
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Scheme 9 
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Method B: Acylcarnitines with an acyl chain up to six carbon atoms in length 
were also prepared in the absence of a conventional reaction solvent 
(Section 6.3.2). The appropriate acid chloride was prepared in situ 
by the action of freshly distilled thionyl chloride on the 
corresponding free acid. Carnitine hydrochloride, being soluble in 
the acid/thionyl chloride mixture, was added to form the appropriate 
acylcarnitine. The product was purified by recrystallization from 
propan-2-ol. 
Method G The solubility of carnitine hydrochloride in the fatty acid/thionyl 
chloride mixture decreases with increased chain length of the acid. 
When acids of carbon atom chain lengths greater than six are 
encountered, carnitine is insoluble in the reaction mixture and hence 
it becomes necessary to use an appropriate solvent. In accordance 
with previous workers, 111 trichloroacetic acid was used as the 
solvent for such reactions. This procedure was used to synthesise 
acylcarnidnes with seven to sixteen carbon atoms in the acyl chain. 
Other than the use of a solvent, the preparation of these carnitine 
esters was as for Method B above (Section 6.3.3). 
Care was required to ensure the preparations were performed in a dry atmosphere. 
Reactions under dry nitrogen were investigated but apparatus connected to CaCl2 
drying tubes proved adequate. Higher yields of acylcarnitines were obtained when 
freshly distilled thionyl chloride was used. Trichloroacetic acid was recrystallized 
from ethanol-free chloroform prior to use as the camitine solvent. 
The yields obtained for the syntheses varied from poor (28% for 3- 
phenylpropionylcarnitine), to good (81% for palmitoylcarnitine). Since sufficient 
product was usually obtained for the analytical purposes required, investigations 
into the reason(s) for the varying yields were not undertaken. 
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After reaction of the relevant acid chloride with carnitine, the crude acylcarnitine 
product was precipitated, with unreacted carnitine, by the addition of dry ether 
(Na-dried) to the reaction mixture (see for example, Section 6.3.2). This procedure 
sometimes caused problems. It was found that the ether should be introduced 
dropwise until precipitation had started to avoid the product forming as an oil. If an 
oil was produced it was difficult to obtain the pure acylcarnitine in an appreciable 
yield. 
The recrystallization of the acylcarnitine product from hot propan-2-o1 also required 
careful attention. Excessive heating of the alcohollcarnitine ester mixture could 
cause 1-methylethyl (isopropyl) esterification of the carnitine, acid function. This 
was observed in the case of the 3-phenylpropionylcamitine preparation (Section 
6.3.3). The positive-ion FABMS spectrum showed a peak at 42 daltons above that 
for the expected intact acylcarnitine ion. That is, the ion at m/Z 336 was attributed to 
[M + CH(CH3)2]+ whilst the base peak in the spectrum was observed at m/z 294, 
[M + H]+, where: 
OCOCH2CH2Ph 
M= Me3NCH2CHCH2000 
That is, M represents the acylcarnitine zwitterion. It is proposed that esterification 
of the free carboxyl of M, by the action of propan-2-ol, gave the m/Z 336 ion. This 
was supported by the 1H NMR spectrum, in which the integral ratios were not 
consistent with pure 3-phenylpropionylcarnitine and a doublet occurred at 1.2 ppm 
that could be assigned to the methyl protons of the isopropyl ester group. 
48 
The IR spectra (nujol mull) of the synthesised acylcarnitines were predictably 
similar. They all showed two carbonyl stretching bands, although in the case of 3- 
phenylpropionylcarnitine and hexanoylcamidne these were present as one 
unresolved, broad absorption band at 1730 cm-1. In the other cases stretching 
bands at 1710-1720 (acid) and 1730-1740 cnr' (ester) were observed (see 
Appendix, IR 2). This compared with the single carbonyl stretching band of 
carnitine itself which occurred in the IR spectrum at 1720 cm'1 (acid), as detailed in 
the Appendix (see IR 1). 
Similarities were also observed in the 90 MHz 1H NMR spectra of the synthesised 
acylcarnitines. All of them gave a complex multiplet signal at 5.4-5.5 ppm due to 
the single methine proton of the carnitine unit and a singlet at 3.1 ppm due to the 
nine methyl protons of the quaternary ammonium group. C-2 protons (a to the 
carboxyl group) gave a broad doublet at -- 2.7 ppm and C-4 protons gave a 
distorted doublet at - 3.6 ppm. All of these chemical shift values matched those 
reported by Millington er al. 95 Other signals for protons of the acyl chain were 
consistent with the proposed structures (see Appendix, 1H NMR 2). 
Occasionally some unreacted carnitine was identified as a contaminant of the 
synthesised acylcarnitine by the presence of a muldplet at 4.2 ppm. This signal is 
due to a methine proton in an a-position to the hydroxy function of carnitine as 
opposed to the ester function of an acylcarnitine. The 1H NMR spectrum of 
synthesised 3-phenylpropionylcamitine was complicated by contamination with the 
isopropyl ester of the required acylcarnitine and unreacted carnitine (Section 6.3.3). 
Integral ratios which were inconsistent with the pure acylcarnitine, and'foreign' 
signals at 4.2 ppm (multiplet due to carnitine methine proton) and 1.2 ppm (doublet 
due to methyl protons of the isopropyl ester functionality) were evident in this 
spectrum. 
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The chemical shift values of the 13C NMR spectra for the acylcarnitines proved 
interesting, in that they did not fit the open-chain structure as well as might have 
been expected. This observation was also noted for free carnitine. Taking free 
carnitine as an example, TABLE 1 summarizes the 13C NMR signals observed and 
the predicted chemical shift values of the open-chain structure. Also included in 
TABLE 1 are the hypothetical, chemical shift values predicted for the folded 
structural conformation shown, where the ionic interaction between the carboxyl 
and quaternary ammonium groups, effectively constitutes a bond. It may be 
concluded from TABLE 1, that the observed signals were more consistent with the 
predicted signals for a folded camitine structure than for an open-chain confirmation 
(e. g. structure 1). Minkler et al. 83 have previously suggested acylcarnitines, in 
solution, have a folded structure and suggested it was the close proximity of the 
carboxyl group to the quaternary ammonium group, which made esterification of 
the former difficult in derivatization attempts. The results presented here, support 
the proposed structural configuration and indicate that acylcarnitines, in solution, 
are ideally arranged to facilitate the cyclization reaction (Scheme 7), required for the 
purposes of this project. 
FABMS was a particularly useful technique for analysing the synthesised 
acylcarnidnes, without derivatization. The relative molecular mass was invariably 
easy to assign through a prominent [M + H]+ ion, where M represents the intact 
acylcarnitine zwitterion, as described earlier. The positive-ion FAB spectra 
obtained corresponded with those of others. 95 Postulated structures for the major 
ions observed and proposed fragmentation pathways are summarized in Scheme 
10. In common with other workers, 95 an ion at m/Z [M +H+ 14]+ was observed 
with all synthesised acylcamitines and was attributed to intermolecular methylation 
of the camitine carboxyl function. Free carnitine has been reported to undergo 
extensive intermolecular methylation in secondary ion mass spectrometry 
(SIMS)112 and a similar process is predicted for acylcarnidnes in glycerol under 
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Carbon 
Nuclei 
Observed Chemical 
Shifts 
/m 
Predicted Chemical Shifts 
/ppm 
AR ITI AR ITI AR ITI E 
(in D20) (Open-chain (Folded Structure) 
Structure) 
CO2H 176 
C2 43 51 47 
C3 72 76 71 
C4 65 50 67 
(CH3)3N 57 
TABLE 1: 13Carbon NMR Data For Free Carnitine 
+ /CH ` OH 
Me3N CH 
-p CH2 
II 
Folded structural conformation showing 
ionic interaction between the anionic 
carboxyl group and the cationic 
quaternary ammonium group 
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FAB conditions. Cluster ions, corresponding to [2(M + H) - H]+, were observed 
in some spectra but the abundance of these ions was dependent on the concentration 
of acylcarnitine in the glycerol matrix. The relative abundances of the major FAB 
ions also varied to some extent with sample loading and was therefore also assumed 
to be dependent on the concentration in glycerol. 
An ion at m/Z 162 was observed in all acylcarnitine positive-ion FAB spectra and 
was assigned the structure of free camitine. This ion probably occurs as a 
combination of rearrangement accompanying fragmentation of the acylcarnitine and 
contamination of the sample with unreacted carnitine from synthesis. 
The negative-ion FAB spectra of the acylcarnitines also indicated the molecular 
mass with ions at m/Z [M + Cl]- and [M +H+ 2C1]-. Other common fragments in 
the negative-ion spectra are summarized in Scheme 11. FABMS was also used to 
confirm the identity of six synthesised acylcarnitines provided as a gift from the 
laboratory of Dr Graham A Mills (Southampton General Hospital). Samples of 
propionylcarnitine (2, R= C2H5), 2-methylbutyrylcarnitine (2, R= 
CH(CH3)CH2CH3), valerylcarnitine (2, R= (CH2)3CH3), isovalerylcarnitine (2, 
R= CH2CH(CH3)2), heptanoylcarnitine (2, R= (CH2)5CH3), and 
valproylcarnitine (2, R= CH(CH2CH2CH3)2) were provided. In accordance with 
previous FABMS analyses of synthesised acylcarnitines, the positive-ion and 
negative-ion spectra of the above compounds supported the proposed structures. 
2.3 SYNTHESIS OF STANDARD -y-BUTYROLACTONE 
COMPOUNDS (3) 
The synthesis of acyl-containing lactones, 3, was important to the development of 
the derivatization. They provided an unambiguous check of successful, or 
otherwise, acylcarnidne cyclizations. Initially, only 4-phenylbutanoyl-containing 
lactone (3, R= (CH2)3C6H5) was prepared, to help monitor the cyclization of the 
model acylcarnitine (2, R= (CH2)3C6H5), as in Scheme 7. As the project 
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progressed however, a requirement for standards to match derivatized natural . 
acylcarnidnes arose. The availability of these compounds was also helpful when 
optimizing analytical conditions, especially GC and GC/MS for examination of 
derivatized acylcarnitines. Analysis of authentic samples of acyl-containing 
lactones allowed the chromatographic characteristics and mass spectral 
fragmentations of these expected acylcarnitine derivatives to be elucidated. 
The preparation of the standard lactone compounds was based on the synthesis of 
ß-hydroxy-y-butyrolactone (4) followed by reaction with the corresponding acid 
chloride (Scheme 12). 
Several synthetic pathways have been used to prepare compound (4). 113-115 The 
simplicity of the method reported by Henrot et a1., 113 starting from malic acid and 
shown in Scheme 13, favoured its application (Section 6.3.4). 
Malic acid (8) was acylated with acetyl chloride to produce the cyclic anhydride (7). 
The action of methanol, under neutral conditions, on (7) formed the diester-acid 
compound (6). The selectivity of the reaction is postulated to arise from attack of 
the methanol nucleophile only on the more hindered carbonyl group. That there 
was selectivity to this process was supported by the quantitative yield of (6). The 
proposed explanation for this reaction is the formation of a second five-membered 
ring in the intermediate species, prior to opening to the diester (6), as in Scheme 14 
(where the nucleophile shown is MeO- for simplicity). A loose association with the 
acetyl group of (7) may also guide the in-coming nucleophile to the hindered 
carbonyl function. Analytical 1H NMR and IR spectra recorded for both (7) and 
(6) were consistent with the proposed structures and in good agreement with the 
data reported by others. 113 The selective reduction of the ester groups of (6), 
initially proved difficult. Care had to be taken to ensure the 2-methylpropan-2-ol 
(1BuOH) solvent was dry. Success was only achieved when the reaction time 
quoted in the literature, 113 2hr, was increased to 20 hr. This effectively formed the 
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dihydroxy-acid compound (5), which spontaneously cyclized to the ß-hydroxy-y- 
lactone (4). There was no evidence to suggest that over-reduction had taken place, 
i. e. NaBH4 did not open the formed lactone to a triol compound (i. e., butan-1,2,4- 
triol). The crude lactone product obtained was purified by silica gel column 
chromatography. 
The resulting pure sample of (4) was analysed by IR and 1H NMR spectroscopy. 
The IR spectrum showed a typical OH stretching band in the region 3700-3100 
cm-1 and a carbonyl stretch at 1770 cm-1. All absorbance signals, in the IR range, 
were also consistent with data published for an alternative method of synthesis., 14 
The 1H NMR spectrum also supported the structure of the hydroxylactone and was 
consistent with data published for compound (4). 
Four standard acyl-containing y-butyrolactone compounds were synthesised and all 
were formed from the reaction of (4) with the corresponding acid chloride as in 
Scheme 12 (Section 6.3.5). For instance, an authentic sample of the UV 
absorbing, acyloxylactone compound [3, R= (CH2)3C6H5], was prepared using 
4-phenylbutanoyl chloride. The acid chloride was formed in situ by the action of 
thionyl chloride with 4-phenylbutanoic acid. It was thought that the condensation 
of the hydroxylactone (4) with the acid chloride would be aided by the presence of 
a base such as triethylamine, but this proved unnecessary. Monitoring the reaction 
by TLC was difficult. Whilst the acyloxylactone could be visualized on a silica 
TLC plate, under UV radiation, the Rf value was almost identical to that of 
phenylbutanoic acid. The origin of the interfering acid was either unreacted starting 
material or decomposition of the lactone product (see Section 2.4.1). The 
separation of the two components on silica was minimal in all solvent systems 
investigated and this predictably complicated column chromatography purification. 
The problem was overcome by washing the crude product with saturated NaHCO3 
solution which removed the acid. It was then possible to isolate the required 
product, on a column of silica gel, removing any unreacted starting materials. 
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The IR spectrum of the model derivative (3, R= (CHZ)3C6H5), showed carbonyl 
stretching bands of the lactone at 1790 cm"1 and that of the ester function at 1740 
curl. This characteristic pattern in the carbonyl region was found to be typical of 
the acyloxylactones and subsequently proved useful during the development of the 
acylcarnitine derivatization reaction (Section 2.4). Similarly, particular features of 
the 1H NMR spectrum of this compound became recognized as indicative of lactone 
formation. A very diagnostic signal pattern at 5.4 ppm due to one proton, was used 
in the development stages as a simple check for acylcamitine cyclization. The 
signal occurred as a distinctive multipler, (see Appendix, 1H NMR 3) and was 
assigned to the single methine proton of the lactone ring. The splitting pattern 
arises from coupling with the two pairs of non-equivalent methylene protons of the 
ring. Theoretically. this should result in four doublets and indeed, using a 90 MHz 
instrument, the signal was not fully resolved but appeared as a distorted octet. 
Synthesis of the acetyl-, oetanoyl- and palmitoyl-containing lactones was similar to 
that described for the model derivative above. In the case of the 
palmitoyloxylactone, the final product was a solid. Purification was achieved by 
recrystallization from diethyl ether rather than the column chromatography 
procedure used for the 4-phenylbutanoyl-, acetyl- and octanoyl-containing lactones. 
Satisfactory analytical data were obtained for all the y-butyrolactone compounds 
prepared, using 13C and IH NMR, IR and EI mass spectroscopy. The two 
carbonyl absorption bands in the IR spectrum and the ring, methine proton, 
multiplet signal in the JH NMR spectrum, were common to all the lactone 
compounds synthesised. 
2.4 DERIVATIZATION CONDITIONS 
2.4.1 Effect Of Heat On Octanoylcarnitine Hydrochloride 
Prior to the systematic investigations with the aromatic model acylcarnitine, a 
separate and simple investigation was conducted into the possibility of heat causing 
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the cyclization of acylcamitines. An experiment was performed (Section 6.3.6) 
whereby an ethanolic solution of octanoylcamitine hydrochloride was gradually 
heated in the septum inlet of a mass spectrometer. Any volatalized species formed 
in the inlet passed into the ion source of the mass spectrometer where the gaseous 
molecules were subject to electron ionization (EI). Subsequently, EI mass spectra 
were recorded for compounds originating from the ethanolic acylcarnitine mixture. 
The objective was to identify ions diagnostic of liberated trimethylamine (m/z 59) 
and possibly of any octanoyloxylactone (mIi 228) formed by heating. The 
experiment was similar to the work of others using desorption chemical ionization74 
when the CI mass spectrum of trimethylamine was noted during the analysis of 
acylcarnitines. 
On injecting a solution of octanoylcarnitine HCl in ethanol into the septum inlet, 
only the mass spectrum of the solvent was evident. The majority of the ethanol was 
allowed to evaporate before gradually heating the inlet. As the temperature slowly 
increased, residual ethanol continued to evaporate. No other significant ions were 
noted until an inlet temperature of 160° C was reached. At this stage mass spectra 
characteristic of octanoic acid were recorded, indicating decomposition of the 
acylcarnitinc. 
No evidence was obtained to suggest that cydization had occurred. The experiment 
was stopped on observation of decomposition products. 
It is speculated that active sites on the walls of the inlet chamber may have catalysed 
the ester pyrolysis process (Scheme 15). Esters are thermally quite stable, 
however, when heated to more than 400°C they are known to decompose into a 
carboxylic acid and an alkene. 116 Evidence exists that the pyrolysis may occur at 
lower temperatures when the produced alkene bond forms in conjugation with a 
carbonyl function, 117 as would be the case for an acylcarnitine (see Scheme 15). 
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Therefore, it is reasonable to propose that an ester pyrolysis reaction on the walls of 
the inlet chamber, at 160°C, resulted in the detected octanoic acid. 
Over the temperature range applied, small amounts of trimethylamine may have 
been released and gone undetected. Summed spectra at a temperature below that 
which induced decomposition may have produced evidence of cyclization. The 
presence of the acylcarnitine as the HCl salt may also have prevented lactone 
formation. The reaction requires a deprotonated carboxyl group to effect the 
necessary nucleophilic attack. Whilst the experiment was unsuccessful in 
identifying lactone formation, it indicated a temperature limit over which 
decomposition may be likely. This was taken into account in subsequent 
derivatization attempts. 
2.4.2 Development of a Controlled Derivatization 
The availability of fully characterized 4-phenylbutanoylcarnitine and the 4 
phenylbutanoyloxy-y-butyrolactone (3, R= C3H6C6H5) was beneficial to 
development of the derivatization. These model compounds enabled the convenient 
monitoring of reactions by TLC and confirmation of derivatization products by IR, 
NMR, GC and MS techniques. At the simplest level, they provided valuable 
information on physical state, solubility, stability and suitability of various work-up 
procedures. When interpreting analytical data, familiarity with the behaviour of the 
model compounds allowed rapid checks on reaction products. The first successful 
conversion of an acylcamitine into a volatile acyl-containing y. butyrolactone was 
observed and confirmed using these compounds. Initial investigations were 
concerned with identifying a suitable solvent for the reaction. 13C NMR data on 
carnitine and acylca nitines suggested that they have a folded structural confirmation 
in solution (Section 2.2). This is likely to favour the cyclization reaction (Scheme 
7). The same information is not available for acylcarnitines in the solid state. There 
exists the possibility of intermolecular ion associations in the solid. For instance, 
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the carboxyl group of one acylcamitine molecule may interact electrostatically with 
the quaternary ammonium group of another. Such interactions would probably 
inhibit intramolecular cyclization since the carboxylate function of the carnitine 
backbone would no longer be in the vicinity of the required electrophilic site. This 
may be a further reason for the unsuccessful cyclization of octanoylcamitine in the 
heated septum inlet of the mass specetrometer (Section 2.4.1). 
Considering the mechanism of the required reaction (Scheme 7, i. e. nucleophilic 
attack of the carboxylate group, in which charge is reduced in the transition state), a 
non-nucleophilic, aprodc solvent was thought appropriate. Heating acylcarnitines 
in an alcohol solvent has already been shown to cause esterification of the carboxyl 
group (Section 2.2). Other properties which were considered important in solvent 
choice were: availability, toxicity, volatility and ease of drying. Four solvents were 
investigated for application to cyclization of acylcarnitines; tetrahydrofuran (THF), 
ethylacetate (EtOAc), NN-dimethylformamide (DMF) and acetonitrile (CH3CN). 
Experiments employing THE and EtOAc did not produce evidence of cyclization. 
The negative results may be due to the inability of these media to dissolve the highly 
polar carnitine compounds. Heterogenous reactions were attempted with varying 
reaction times and temperatures (up to reflux). The use of ultrasound is reported to 
be applicable to some heterogenous reactions with dramatic improvements in 
product yield and reaction time. t 18 However, simple experiments employing an 
ultrasound source indicated that the technique did not facilitate the proposed 
derivatization of acylcarnitines (Section 6.7) 
2.42(a) Reactions in N, N-Dimethylformamide (Section 63.8) 
Dry DMF was a hopeful candidate as a suitable reaction solvent from an early stage 
in the project. The relatively high boiling point (bp. 153 °C) provided a large 
reaction temperature range, and its ability to dissolve acylcarnitines was considered 
advantageous. Previous work (Section 2.4.1) suggested the reflux temperature of 
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DMF may induce decomposition of carnitine esters. This was recognized in the 
design of each experiment and reaction temperatures were not allowed to exceed 
130 °C. The concentration of acylcarnitine (4"phenylbutanoylcarnitine) in reaction 
mixtures was also kept low. High concentrations may lead to intermolecular 
reactions and polymer formation. Acylcarnitine levels between 0.1 and 5% were 
subject to varying reaction conditions. 
Simply heating a 0.1% solution of 4-phenylbutanoyl-carnitine in DMF at 100 °C 
overnight resulted in a reaction product which eluted on a TLC plate to the same 
extent as the 4-phenylbutanoyloxy-butyrolactone. TLC analysis of the reaction 
mixture was complicated by the streaking effect of DMF on the silica plates used. 
This effect was minimized by heating the spotted TLC plates in an oven to 
evaporate the reaction solvent, prior to chromatography. The lactone product was 
heavily contaminated with unidentified by-products and 4-phenylbutanoic acid. At 
this stage, the free acid could not be distinguished as originating from ester 
hydrolysis of the acylcamidne or from over-reaction of the lactone. The reaction 
mixture assumed a dark brown colour within 3 hours of initiating heating. The 
formation of by-products detracted from the suitability of DMF as a solvent. 
Adjusting reaction time and temperature did not improve the derivatization yield to a 
useful degree. 
The addition of base to the reaction mixture was tried, in an attempt to improve the 
derivatization yield. The intention was to neutralize the acid from the HCI salt of 
the acylcamitine. A free carboxylate group is required if an acylcarnidne molecule 
is to cyclize to the corresponding y. butyrolactone as in Scheme 7. Any successful 
cyclizations will generate trimethylamine (NMe3) in addition to the lactone. Whilst 
NMe3 is a gas, any amine entrained in the reaction mixture may contribute to the 
neutralization process. 
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The application of inorganic bases was investigated with reactions in DMF. 
Sodium hydroxide, potassium hydroxide and calcium hydroxide were utilized in 
separate experiments. Excess base was avoided in all cases because of the known 
lability of quaternary ammonium salts to undergo Hofmann elimination (Scheme 8). 
Excess base may also cause ester hydrolysis (Scheme 4) and therefore quantities 
equimolar to the acylcamidne were not exceeded. None of the bases were soluble 
in DMF. Results of these investigations indicated no improvement over previous 
attempts. In any event, DMF is not regarded as a good solvent for GC because of 
its poor GC chromatography characteristics (Le. unsuitable tailing solvent peak 
with non-polar GC columns). 
2.42(b) Reactions in Acetonitrile (Section 639) 
The model acylcarnitine, and the naturally occurring acylcarnitines available, were 
all soluble in CH3CN. This agrees with the work of others when CH3CN was 
used as a solvent for the preparation of acylcarnitine derivatives for HPLC 
analysis. 83 
A refluxing solution of 4-phenylbutanoylcamitine (0.1%) produced the required 
lactone derivative, detected by TLC, within 20 hrs. Further examination of reaction 
products was simpler than for reaction in DMF because CH3CN was easily. 
removed (bp. 80 °C). 1H NMR and IR analysis confirmed the presence of the 4 
phenylbutanoyloxy y-butyrolactone (3, R= (CH2)3C6H5). Acetonitrile solutions 
remained colourless throughout the reflux period, unlike heated DMF mixtures. 
This indication of fewer side-reactions in CH3CN was supported by analytical data 
on the respective products. The main contaminants of the required derivative were 
unreacted acylcarnitine and some free acid (i. e. 4-phenylbutanoic acid). 
The addition of inorganic bases, as with DMF reactions, was unsuccessful in 
affecting the yield of derivative in CH3CN mixtures. However, on the basis of 
relative GC peak areas, the use of a non-nucleophilic organic base, triethylamine, 
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produced a significant improvement in acylcsrnitine cyclization. A solution of 4- 
phenylbutanoylcarnitine as its HCl salt in CH3CN, refluxed overnight with a molar 
equivalent of triethylamine, gave a good yield of the corresponding lactone 
derivative. The improvement was repeated in the derivatization of acetyl-, octanoyl- 
and palmitoylcarnitine. Products were confirmed by comparison of analytical data 
(IH NMR, IR, EI-MS) with that of synthesised lactone standards (Sections 2.3, 
6.3.5). 
The success of triethylamine may be attributed to its solubility in CH3CN, unique 
amongst the bases tried. Interaction of base with HCI in the same phase 
{i. e. CH3CN) appears to encourage the formation of the free carboxylate anion 
necessary for cyclization. Triethylamine hydrochloride, the by-product from the 
process, is insoluble in CH3CN and therefore probably takes no further part in the 
derivatization. Determinations of the yield of each derivative using GC with 
standard solution of the respective acyl-containing lactone, were performed after 
modification and improvement of the method so far described. 
2.4.3 Application Of Derivatization To Physiological Quantities Of 
Standard Acylcarnitines 
When less than 1 mg of any individual acylcarnitine was cyclized, by the method 
above, the corresponding lactone product was not detectable. A technique for 
analysing physiological levels of acylcarnitines with low urine sample availability 
(typically 1 ml) should detect µg quantities. The problem of free acid production 
also needed to be addressed. This reaction side-product was regarded as potential 
analyte, lost because of unsuitable reaction conditions. Heating a solution of 
standard octanoyl lactone (4, R= (CH2)6CH3) in CH3CN was found to produce 
octanoic acid within 30 mies. This confirmed the potential of the derivatization 
conditions to cause pyrolysis of the required lactone compounds (Scheme 16). 
Alternatively, the free acid may originate directly from the acylcarnitine (Scheme 
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15). In either case these reactions reduce the amount of derivative analyte and may 
limit the sensitivity of the method. Efforts were thus directed towards modifying 
the existing reaction to meet the requirements of clinical analysis. 
Lower reaction temperatures with varying reactions times did not improve y- 
butyrolactone yields. Higher reaction temperatures (i. e. > 80 °C) demanded a 
sealed reaction vessel. The ReactiVial (Figure 3) is designed for such applications. 
After introducing the reaction mixture, the vial is sealed with a teflon lined septum 
(teflon side down). Air sensitive reagents may be injected through the septum or 
samples withdrawn without opening the apparatus. Heat can be applied to the 
ReactiVial from a waterbath, sandbath or a reaction block. The latter consists of a 
block of aluminium drilled with holes slightly larger than the outside diameter of the 
ReactiViaL The aluminium block is placed in a heating unit which thermostatically 
maintains the aluminium, ReactiVial and reaction mixture at a constant temperature 
from ambient to 200 °G Early attempts at derivadzing acylcarnitines in ReactiVials 
were based on the successful reactions achieved previously with conventional 
apparatus (i. e. round bottomed flask, condenser, and drying tube). Milligram 
quantities of the acylcamitines in CH3CN with Et3N, heated in the sealed vessel at 
80 °C overnight, produced only small amounts of the corresponding acid. 
However, no lactone derivatives were detected by IR or 1H NMR spectroscopy. 
Further investigations with smaller quantities of acylcarnitines and sensitive 
capillary GC analysis of the products, identified the ReactiVial as an excellent 
reaction vessel. Providing a total acylcarnitine content of around I mg was not 
exceeded, good derivatization yields could be achieved using a Iml ReactiVial (see 
later). The cyclization of quantities of acylcarnitines greater than 1 mg however, 
was best achieved with the open apparatus system used in initial investigations. In 
such a system, the trims hylamine, liberated on cyclization, may escape from the 
apparatus. This was not so with a scaled vessel and it was noticed, when opening 
ReactiVials in which derivatization had been successful, that a strong pungent smell. 
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of NMe3 was released. The 1 ml ReactiVial also limits the amount of CH3CN 
solvent used in the derivatization process. Concentrations above I mg ml-1 of 
acylcarnitine may inhibit the required cyclization reaction. Intermolecular 
electrostatic interactions between the carboxylate and quaternary ammonium 
functions of the acylcamitine molecules in concentrated solutions, is likely to 
suppress the required intramolecular reaction (Scheme 7). Effectively, the volume 
of the reaction vessel dictates the total amount of acylcarnitine which may be 
cyclized. A1 ml ReactiVial was found suitable for all clinical urine applications. 
Total acylc amitine content of such samples rarely exceeds 0.5 mg m1-1 and 
therefore good derivatization yields could be expected when 1 ml or less of the 
urine was analysed. 
After trying a number of alternative bases to triethylamine, a more hindered, tertiary 
amine, NN-diisopropylethylamine, was found to improve slightly the yield of 
derivatives. Other workers have also found this base appropriate for neutralizing 
the dissociated HCl (i. e. when acylcarnitines are present as theirHC1 salts). 83 If it 
is assumed that the base is only performing a neutralizing function then an 
equimolar amount, with respect to the total acylcarnitines present, should represent 
optimum conditions. Experimentally, it was discovered that varying the amount of 
base between 50 and 150% equimolar had no detrimental effect on the reaction. 
This lack of dependence on the amount of base (probably a result of the cyclization 
generating its own base, trimethylamine) is obviously important to the. analysis of 
unknown quantities of acylcarnitines, and supported further development of the 
analytical method. 
Higher temperatures over shorter reaction times (compared to those used 
previously) worked well with ReactiVial reactions. Temperatures above 140 °C 
however, often resulted in ruptured septa and loss of sample, due to the high 
internal pressures generated. Over many experiments the optimum conditions were 
found to be 125 °C for 35 minutes. 
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Derivatization yields were determined by capillary GC using cold on-column 
injection (Section 6.3.10). Yields for the conversion of acetylcarnitine, 
octanoylcamitine and palmitoylcarnitine into the corresponding acyloxylactones 
were evaluated by comparing the FID response for the derivatives with the response 
for known quantities of authentic lactone standards. Table 2 summarizes the results 
obtained. The experiment gave an indication of derivatization yields. The 
acceptable yields (all in excess of 70%) encouraged further development and 
application of the method. Results did not account for acylcarnitine impurities and 
detector response over the tmole range was assumed to be linear. A full 
quantitative evaluation is envisaged for future work (Chapter 5). 
Whilst there appears to be scope for improving the cyclization yields (particularly 
the octanoyl-camitine derivatization), yields approaching 100% may not be 
necessary. A high yield is beneficial in preserving the sensitivity of the method, but 
if a lower yield provides a detectable signal, reproducibility of the method becomes 
more important for quantitative analysis. Providing a signal can be monitored, a 
reproducible yield of the derivative allows quantification with standard samples. 
Besides, further investigation with standard solutions of acylcamitines was deemed 
to have limited usefulness. When it comes to analysing these compounds in the 
presence of a biological matrix, the effect of other urinary components on the 
derivatization was expected to be detrimental and unlikely to be assessed by 
utilizing standard solutions. The effects of the urine matrix required attention 
before meaningful quantitative experiments could be conducted (Section 2.5). 
The ReactiVial reaction conditions were found suitable for the full range of 
acylcamitines available. Capillary GC analysis of a mixture of 11 derivatized 
acylcarnitines produced a chromatogram, shown in Figure 4, with 11 fully resolved 
peaks. Palmitoylcarnitine was not included in the mixture as such a hydrophobic 
acylcarnitine was not expected to be found in urine samples. However, this long- 
chain acylcamitine was derivatized and the acyloxylactone product analysed by GC 
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and GGMS, in a separate mixture of carnitine esters, 108 demonstrating the 
application of the technique to a wide range of acylcarnitine analytes. The identity 
of each peak was confirmed by separate derivatizations of individual acylcarnidnes 
and GGMS, using electron ionization (EI) and chemical ionization (Cl). In three 
cases (acetyl-, octanoyl- and 4-phenylbutanoyl-containing) the cyclized 
acylcamidnes were also compared with the independently synthesised lactones 
(Section 2.3), confirming that the required derivatization had occurred. 
Operating parameters for the GC and GCJMS (Section 2.5) were such that lactone 
derivatives of isomeric compounds (e. g. valerylcamitinefisovalerylcamitine and 
valproylcarnitine/octanoylcamitine) were sufficiently separated by the 
chromatography, to distinguish each in terms of retention time. The EI mass 
spectra for isomeric derivatives were difficult to differentiate, and therefore the 
chromatographic separation was essential for unambiguous identification. The 
ability to distinguish isomers easily was an important advantage of the GC/MS 
method over alternative HPLGMS and MS/MS techniques. 
2.4.4 On-Column Derivatization 
The early application of GC to the analysis of mixtures from attempted 
derivatiiation reactions suggested that the hot injector port could cause the 
cyclization. Before this was appreciated, false interpretations of the yield of a 
number of "on-the-bench" derivatizations were made. Investigations showed that 
comparable peaks to early bench derivatizations could be achieved by the direct 
injection of acylcarnirine. CH3CN solutions using an appropriate injector 
temperature and glass port liner. 
Above a temperature of 130 °C cyclization in the injector was found possible. 
Increasing the injector temperature to 200 °C produced the optimum lactone signal 
for octanoylcarnitine. Reproducibility however, was poor and the efficiency of the 
cyclization diminished as involadle residues built up on the walls of the glass liner 
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after iepeated injections. Periodic cleaning of the liner and replacement of its 
silanized glass wool packing helped, but cyclization yield from one cleaning 
procedure to another was very variable. Despite the very poor reproducibility of the 
method, it did find application as a quick check procedure in the development of 
ion-exchange extraction of acylcarnitines from various matrices (Section 2.5.3). 
The experiments conducted into on-column derivatization confirmed earlier 
suspicions that the lack of control over the cyclization is a problem. Whilst such a 
technique would simplify analysis, a pre-column derivatization chamber which 
could cope with a build up of involatile material and perform reproducible 
cyclizations is difficult to envisage. Even if such apparatus could be developed it is 
unlikely that it would be applicable to physiological levels of acylcamitines without 
prior isolation from the biological matrix. In addition, it is generally thought that 
for sensitive and quantitative GC analyses, the best injection method is the cold on- 
column technique. Clearly, this cold injector is not compatible with effecting a 
thermal reaction. 
2.5 HANDLING THE BIOLOGICAL MATRIX 
2.5.1 Why Extract? 
Since the beginning of the project it was known that the successful development of 
a GC/MS method for acylcarnidne analysis would involve dealing with complex 
biological matrices. Major urine components include high concentration. of urea, 
potassium and sodium salts. Organic acids are also encountered in urine, especially 
from patients with disorders of fatty acid metabolism (Section 1.1.2). Some 
existing techniques, notably FABMS and FABMS/MS, require minimum sample 
preparation, whilst others employ a variety of isolation procedures including 
solvent extraction, ion pair precipitation, paper chromatography, ion-exchange 
purification and purification on small silica columns. 
76 
The development of any derivatization must account for all components present in 
the reaction mixture. This includes constituents of the matrix if the required analyte 
has not been isolated. It should be remembered that even if matrix components do 
not react with the dcrivatizing reagent, or under the derivatization conditions, they 
may act to suppress (or less often, facilitate) the required reaction. The cyclization 
reaction developed in this project was expected to be prone to suppression and 
interference effects of matrices such as urine. It has already been shown with 
standards that the derivatization required careful control of conditions to optimize 
yields. Assuming acylcamitines could be derivatized in the presence of the urine 
matrix, analysis by GC and GC/MS would be complicated by volatile urinary 
compounds interfering with qualitative and quantitative evaluations. Urine samples 
from patients with (3-oxidation disorders would contain levels of organic acids, the 
signals from which would swamp any responses for derivatized acylcarnitines, 
when analysed by GC and GC/MS. Conventional cold on-column injection 
techniques could not be applied either. The buildup of involatile material at the 
head of the column would rapidly reduce the efficiency of modern capillary GC 
columns. 
A requirement for some form of sample purification was confirmed by freeze 
drying an aliquot of urine spiked with octanoylcarnitine and then attempting to 
derivatize the acylcarnitine as previous (Section 6.3.11). GC analysis was not able 
to detect octanoyl-containing y-butyrolactone (3, R= C7HI5), above the high 
background. As expected, numerous peaks were observed in the resultant 
chromatogram, including many broad peaks typical of semi-volatile components. 
At this stage, it was not determined whether the derivatization had failed or the 
acyloxylactone peak was swamped by other dominant urine components eluting 
from the GC column. Irrespective of this however, the procedure was wholly 
unsatisfactory for unambiguous analysis and so efforts were made to extract 
acylcarnitines from the urine matrix. 
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2.5.2 Solvent Extraction 
Extraction of urinary acylcarnidnes has been achieved using various water 
immiscible solvents. The medium-chain length carnitine esters can be extracted 
with a chloroform m ethanol119 mixture or butan-l-ol, 109 but ion-exchange 
chromatography is required for short-chain acylcarnitines, 120 such as 
acetylcarnitine and propionylcarnidne. Both solvent extraction procedures were 
applied to spiked urine samples. After evaporation of the solvent the oily residue 
was subject to the developed dcrivatization conditions (Section 6.3.12). 
Subsequent GC analysis failed to identify the derivatized acylcarnidnes. Either the 
purification procedures were unsuccessful in extracting the carnitine esters or the 
techniques were not specific and additional urinary compounds contaminated the 
acylcarnitine fraction and prevented cyclization. 
Whilst the results were obtained before the derivatization conditions had been 
optimized, they did indicate that alternative purification procedures should be 
investigated. Other workers analysing urinary acylcarnitines by techniques such as 
HPLC, 91 HPLC/MS, 105 and 1H NMR spectroscopy favour ion-exchange resins 
for extraction of the analyte prior to analysis. 
2.5.3 Ion-Exchange Purification 
The ionic nature of acylcamitines makes them amenable to ion-exchange 
techniques. Under acidic conditions with the carboxyl group protonated, camitine 
and its esters are cationic species. As such, they will pass through a column of 
anionic-exchange resin but may bind to a suitable cationic-exchange resin. 
Acylcamitines bound to a cationic resin may be eluted by displacement with another 
cation of greater affinity for the resin. That is, by the use of appropriate ion- 
exchange resins, elution procedures and fraction collection, urinary acylcarnitines 
can be purified. In practice it is not feasible to isolate completely the acylcarnitines 
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from all other matrix components. That is, absolute selectivity to acylcarnitines was 
not achieved. This is because a suitable extraction method needs to be applicable to 
a range of acylcarnidnes across which there is some variation in affinity for a resin. 
Within this affinity range there are some urine components (e. g. some amino acids 
and dipeptides) that have the same ion-exchange elution characteristics as 
acylcarnitines and hence that are also extracted. The intention was to develop a 
sample pretreatment which would purify the acylcarnitines to a degree which would 
enable (i) successful dcrivatization to the cyclic analogues, and (ii) a relatively 
"clean" chromatogram to be obtained (i. e. peaks due to cyclized acylcarnitines 
should not be obscured by other urinary components). 
The simplest ion-exchange method investigated was the use of a small column of 
anionic resin (Section 6.3.13). Two ionic forms of the resin were tried; chloride 
and formate. The resin was expected to bind most of the anionic species in urine 
including the organic acids. Under neutral conditions the acylcantidnes were 
expected to act as zwitterionic, overall neutral, species and pass through the column 
unretained. The folded structure of acylcarnitines in solution (Section 2.2), might 
be expected to prevent association of the carboxyl group with the fixed cationic 
function of the resin. Strong acidic conditions ensure a free passage for carnitine 
and its esters as cations, but they also protonate the organic acids preventing their 
binding and reducing the selectivity of the purification process. 
Attempts to recover acylcamitines from water were successful and derivatization to 
GC amenable derivatives was observed, indicating good recoveries of around 80% 
with the resin in its formate form. Acceptable purification of spiked urine samples 
with only an anionic resin was not achieved however. Much of the urine matrix 
passed through the purification process resulting in a complex GC chromatogram 
and fouling of the head of the capillary column when on-column injection was 
used. Peaks were assigned to octanoyl- and palmitoyl-containing lactones but these 
represented low recoveries (<20%) and were not confirmed by GGMS. Similar 
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results were obtained with the chloride form resin although in these attempts even 
less of the derivatives were detected when analysing the spiked urine sample. 
Chloride ions have a higher selectivity for the anionic resin used and therefore it is 
less likely that the acylcamitines would displace the resin counterions and thus be 
retained. More likely, the reduced specificity of the clean-up procedure allows 
more urine components to contaminate the aeylcarnitine fraction and subsequently 
suppress the derivatization. 
Cationic-exchange resins were expected to provide a more selective extraction 
procedure. Acylcarnitines may be bound to the resin and anionic, neutral and 
weakly bound cationic species washed from the column. The acylcarnitines are 
then eluted by equilibrating the column with cations of relatively high affinity for 
the resin, displacing the carnitine esters 90 The modified methods of others91 were 
applied to spiked urine samples and aqueous solutions of acylcarnitines (Section 
6.3.14). After extraction, water was removed by lyophilization before 
derivatization and GC analysis. 
The use of cationic resin in the pyridinium form, eluting with pyridinium acetate 
(Section 6.3.15(i)) was unsuccessful in determining acylcarnitines in spiked urine 
samples. Several attempts were made at this purification procedure examining the 
various column fractions, after lyophilization, with the hot-injection port GC 
method described (Section 2.4.4). Acylcarnitines could not be detected in any 
fraction. It was proposed that the extraction was still not sufficiently specific to the 
acylcamitines and/or they had not been eluted from the column. 
Results from the extraction of the aqueous solutions using ammonium hydroxide 
(O. SM) to elute the acylcarnitines off the resin in its pyridinium form were more 
positive (Section 6.3.15 (1i)). Analysis of the anioniclneutral washings did not 
detect any unretained acylcarnitines (as required), but elution with NH4OH did 
reveal acetylcamitine and octanoylcarnitine content in the first two 5 ml fractions. 
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CLINICAL URINE (0.5 ml) 
SPIKE WI'T'H INTERNAL STANDARD 
ANIONIC ION EXCHANGE RESIN 
PURIFICATION 
CATIONIC ION EXCHANGE RESIN 
PURIFICATION 
LYOPHILIZE 
Acetonitrile + base 
DERIVATIZE 30 mim at 120°C 
EVAPORATE ACETONITRILE AND 
DISSOLVE RESIDUE IN ETHYL 
ACETATE (0.2 ml) 
FILTER 
GC AND/OR GC/MS ANALYSIS 
Figure 5. Acylcarnitine extraction and derivatization procedure 
for clinical urine samples 
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Estimates of 60% recovery in the first cationic fraction and a further 10-15% in the 
second were made using split injection GC (Section 6.3.22). 
The success with aqueous solutions could not be repeated with spiked urine 
samples (Section 6.3.15). Lactone derivatives were detected but the estimated 
recoveries were only around 20%. In these samples the analysis of the 
anionic/neutral washing was impractical because of the many urinary components 
complicating the examination. Therefore the possibility of acylcarnitine complexing 
with other species, reducing the cationic nature and preventing binding, was not 
discounted. 
At this stage in the development, an extraction procedure for urinary acylcamitines 
was reported by Millington and co-workers. 102 It involved the combination of 
anionic- and cationic-exchange purification steps. The process was applied to 
spiked urine samples with only the mesh size of the resins varying from the 
published method (Section 6.3.16). It has also been found that the use of the 
cationic resin in the formate form produces similar results. An aliquot of urine was 
first passed through an anionic resin, the acylcamitines being unretained. 
Acidification of the anionic column effluent ensured that the carboxyl groups of any 
carnitine compounds were fully protonated before binding to a small column of 
cationic resin. Acylcarnitines were eluted with ammonium hydroxide solution (1M 
in 20% aqueous ethanol). Water and base needed to be removed as soon as 
possible because of the lability of acylcarnitines towards hydrolysis'and Hoffman 
elimination under aqueous base conditions. Freeze-drying was found to be the 
most expedient method of removing both. This method, when combined with the 
derivatization procedure and GC or GGMS analysis (Figure 5), was the most 
successful applied to date. 
After the derivatization step the CH304 solvent was removed by evaporation in a 
steam of nitrogen and the residue triturated with ethyl acetate (EtOAc). The EtOAc 
82 
was then filtered prior to GC analysis. This procedure avoided the small amounts 
of unreacted acylcarnitines or other insoluble material being injected onto the GC 
column. However, care had to be taken when evaporating the CH3CN. Prolonged 
evaporation resulted in loss of the lower boiling point derivatives notably, acetyl- 
and propionyl-containing acyloxylactones. This effect was minimized by only 
evaporating to a damp residue before reconstituting in EtOAc. 
Recoveries of acetylcamitine and octanoylcarnitine from water and urine, using the 
double ion-exchange method above, were estimated by GC analysis of the resulting 
derivatives (Section 6.3.17). The FID responses for the extracted and derivatized 
acylcamitines were compared with those for a matrix-free sample of the 
corresponding standard acylcarnitines which was not subject to ion-exchange 
purification but was dcrivadzed under identical conditions. The results (Table 3) 
indicate that good recoveries may be obtained for acylcarnitines in water. They 
compare favourably with the results of others (60% recovery for 
octanoylcarnitine)105 using alternative ion-exchange purification procedures. 
However, the results suggest poor recovery efficiences for acylcarnitines from 
urine. Since urine is currently the most important matrix for acylcamitine 
evaluation, this area required further investigation. 
Recovery efficiencies were determined for a range of carnitine esters added to four 
infant control urines (Section 6.3.18). The control samples were obtained from 
infants without disorders of fatty acid oxidation and were expected to be typical of 
"normal urine" from patients of the age range which would be encountered with 
disease-state urines (Chapter 3). Results from these urines, spiked with a range of 
acylcamitines (0.2 mg of each acylcamitine per ml of urine) are summarized in 
Table 4. 
Recovery figures were based on the average extraction across the acylcarnitine 
range investigated. For a given urine sample the percentage recovery for different 
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Matrix Acylcarnitine % Recovery 
WATER 
Acetylcarnitine 77 
Octanoylcarnitine 85 
URINE 
Acetylcarnitine 33 
Octanoylcarnitine 38 
TABLE 3: Apparent Extraction Efficiencies for the Ion-Exchange 
Purification Procedure 
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acylcarnitines was constant. For instance, the apparent average recovery for urine 
C2, was 57% for the four acylcarnitines. The consistency was not observed 
between urine samples however. Recoveries from Cl were the lowest at 31% and 
the highest from C4 at 83%. The results confirm the requirement for an 
acylcarnitine internal standard in any quantitative determinations. Ratioing the 
responses within a single sample to that of say 4-phenylbutanoylcarnitine (as the 
corresponding y-butyrolactone derivative) allows comparisons between samples. 
As Table 4 shows, for each acylcamitine the response ratio was constant from 
sample to sample. In the case of isovalerylcarnitine for example, the response ratio 
to the internal standard, 4"phenylbutanoylcarnitine, was 1.4 for all four urines 
examined. 
Whilst the use of an acylcarnitine internal standard overcame the apparent variation 
in recoveries from urine and hence would allow quantitative analysis, it did not 
explain why the variation arose. Two possible causes were favoured. The 
acylcarnitines may not behave as expected during the extraction step due to some 
complexation process with other urinary components. This may result in loss of 
analyte during either the anionic- or cationic- exchange procedures. Alternatively, 
urine components other than acylcamitines extracted by the sample pretreatment 
may be hindering the derivatization. Therefore an experiment was conducted 
(Section 6.3.19) whereby a urine sample spiked with isovalerylcarnidne and 
octanoylcarnitine was extracted and analysed as previously. The results were 
compared with those from the same urine sample spiked after extraction. Within 
experimental error, the FID detector responses for the corresponding derivatives 
were the same for the pre- and post-extraction spiking tests. If the acylcarnidnes 
were being extracted to a different extent in the presence of urine, then the 
derivative concentrations in the final sample would be higher for the post-extraction 
spiking experiment than for the pre-extracted. Therefore, the results indicated that 
the variations observed between urine samples were not due to differing recoveries, 
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but may be assigned to a varying derivatization yield. This is probably because of 
one or more undesirable components coming through the work-up and interfering 
with the cyclization. 
That urine components other than acylcarnitines did get through the extraction 
procedure was supported by observing differing amounts of solid materials present 
after the freeze-drying step, immediately before derivatization. Solid material was 
also encountered after the cyclization reaction and evaporation of the acetonitrile. 
The residue was insoluble in ethyl acetate and was filtered off by passing through a 
Millipore filter unit prior to GC analysis. 
Urea was suspected as a major contaminant and this was confirmed by GC/MS. 
The presence of urea was not obvious from the GC results because of the poor 
sensitivity of the FID to compounds which do not contain C-H bonds. Using 
GC/MS with EI however, the urea produced a very large broad peak in the total ion 
current chromatogram (see TIC traces later, e. g. Figure 7). 
Under EI conditions the urea was easily detected and characterized by ions with m/z 
60 (M+") and 44 (H2NC=O+). In all urine samples analysed by GGMS a large 
overloaded peak was attributed to urea and this caused problems when co-eluting 
with the more volatile acylcamitine derivatives of interest (Section 3.2.2). Attempts 
were made to remove this unwanted compound by enzymatic digestion with urease. 
Urine samples were treated with unease tablets before and after the extraction 
process. In both instances however, the urea was not completely removed and 
continued to cause problems when analysing for acetyl and propionylcarnitine, by 
co-eluting from the GC column with the derivatives of interest. The removal of 
urea warrants further investigation, possibly with pure urease rather than the tablet 
form. 
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2.5.4 Use of Bond Elut CERTIFY Columns 
These "ready to use" cartridge-type units are gaining popularity in the area of 
biological fluid analysis. They present a convenient and rapid method of extracting 
many compounds of interest from urine. Their flexibility arises from a mixed-bed 
ion-exchange resin (cationic- and anionic-exchange resins), which on sample 
application, binds most charged species (i. e. cations and anions). Extraction 
selectivity is then obtained by careful choice of eluting solvents and control of pH. 
Established methods exist for extracting drugs of abuse from urine for GC and 
GC/MS analysis. Modifications of these methods were applied to acylcarnitine 
extractions (Section 6.3.20). Unfortunately the elution systems investigated were 
not successful and since an acceptable ion-exchange procedure (Figure 5, and 
Section 2.5.3) had been identified, further attempts were not made using Bond Elut 
CERTIFY columns. Further work with these units is recommended since they are 
already common in clinical screening laboratories and potentially represent a simpler 
extraction procedure than the double ion-exchange procedure reported here and 
subsequently applied to metabolic investigations (Chapter 3). 
2.6 GC AND GC/MS: CONDITIONS AND TECHNIQUES 
APPLIED TO ANALYSIS OF ACYLCARNITINE DERIVATIVES 
The main objective of the project was to be able to analyse acylcarnitines by 
methods involving GC. Therefore, during method development, frequent attempts 
were made to apply techniques such as packed-column and capillary GC, 
GGFourier transform infrared (GC/FITR) and capillary GC/MS to reaction 
products. GGFTIR was of very limited success because high sample loading was 
required on wide-bore capillary columns to gain sufficient sensitivity for additional 
IR information over the chromatography retention time. This is unsuitable for 
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clinical urine samples when detection of acylcarnitines at physiological levels 
demands high sensitivity on limited sample volume. Sensitivity problems were also 
encountered with packed-column GC. Both on-column and vaporizing injection 
techniques were investigated but only decomposition products from the derivatives 
could be detected. This was probably due to active sites within the column and/or 
the injector port region. Whilst packed-columns are capable of handling high 
analyte amounts before overloaded peaks result, the disadvantages of active sites, 
stationary phase bleeding, low temperature limits, poor resolution and a lack of 
consistency between columns in their ability to separate a mixture, has severely 
limited their application. Modern vitreous silica capillary GC columns have largely 
superseded packed columns. Capillary columns are superior in separating 
efficiency, durability, consistency between columns and they are much simpler to 
interface to a mass spectrometer. The GC and GC/MS analyses reported here were 
all performed with wall-coated open tubular (WCOT), vitreous silica, capillary 
columns. 
The columns used for GC and GC/MS applications were those with a non-polar 
stationary phase, mainly the BP5 type (5% diphenyl dimethyl siloxane) from SGE. 
These columns have an immobilized stationary phase, chemically bonded to the 
silica walls of the column and heavy cross-linking within the phase. This allows 
for greater film thickness, temperature limits and gas flows. A range of separations 
is possible using different film thicknesses rather than the conventional approach of 
using different polarity columns. 
For GC analysis with FID detection, a 0.32 mm i. d., 25 m, BP5 column with a 
0.5 pm film thickness was generally employed. This allowed for suitable flexibility 
in sample loading and provided the required efficiency when helium was used as 
the carrier gas. A linear carrier gas flow around 30-40 cm/s was used in accordance 
with Van Dccmter curves, to maintain good efficiency. Helium was employed 
rather than hydrogen in order to be consistent with GGMS analyses. 
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For use in GC/MS apparatus, a narrower bore capillary was required. The 
interface accepted a 0.25 mm, BP5 column and phase thicknesses of 0.25 and 0.5 
µm were used. The thinner film thickness enabled higher efficiency separations but 
required lower sample loadings to avoid overloaded peaks. 
Correct choice of GC injection technique was found to be very important for the 
analysis of derivatized acylcamitines. The sample introduction techniques used are 
worth further description so that the results obtained with the respective injection 
methods can be fully interpreted. 
2.6.1 Vaporizing Injection GC121 
Vaporizing a sample in an injection chamber or port before chromatography was the 
first method of sample introduction to be developed for capillary GC. Split and 
splitless injection are established as the classical means of introducing analytes into 
the GC column. Despite several recognized disadvantages and limitations they are 
still by far the most common injection techniques. The vaporizing injection 
methods were employed during this project as well as the alternative on-column 
injection techniques. 
In doing so, different operating conditions were required to optimize selectivity and 
sensitivity depending on the sample introduction technique. An account will thus 
follow on how and why the conditions employed were identified as suitable for GC 
analysis of volatile acylcarnitine derivatives. 
2.6.1.1 Split Injection 
During split injection the vaporized samples is divided into two unequal parts. A 
small proportion is carried into the column by the flow of carrier gas, whereas the 
major part is vented through a split exit. Between 0.3 and 20% (depending on the 
split ratio) of the injected sample enters the column and is chromatographed. The 
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splitting process ensures that sample vapour is carried onto the column for only a 
short period of time. This transfer time determines the width of the solute bands 
and should be sufficiently short to result in sharp eluting peaks. 
The major problem with split injection is the poor reproducibility encountered 
between injections. This was initially thought to arise from the composition of that 
part of the sample which enters the column being different from the original sample 
(discrimination). Whilst this effect does exist and has been demonstrated with 
some elegant experiments with high boiling point alkanes, 121 many early 
difficulties arose from selective ejection of different solutes out of the syringe 
needle. Appropriate syringe design and handling techniques can improve 
reproducibility but discrimination cannot be eliminated. For meaningful quantitative 
results with split injection, internal standards are essential. 
The design of the syringe is important in ensuring a narrow bandwidth of sample 
on the head of the column. Plunger-in-barrel syringes ensure rapid expulsion of 
sample when the plunger is depressed. This is important to avoid evaporation of 
samplclsolvent in the needle leading to discrimination. Wire-in-needle type 
syringes tend to expel the sample more slowly and discrimination effects are more 
noticeable. 
Syringe handling techniques can also have remarkable effects on resulting peak 
shapes and resolution. For all split injections performed during this project, the hot 
needle technique was employed. The required volume of sample is drawn up in the 
syringe, then the outside of the needle wiped clean. Next, a plug of air is drawn up 
until all of the sample is visible in the barrel of the syringe. On inserting the needle 
into the injector, a pause of a few seconds allows the needle to heat to the 
temperature of the injection port. Depressing the plunger ensures sample is rapidly 
expelled from the needle by the combined action of the plunger with the effect of 
boiling solvent in the needle. This is in contrast to filled- and cold-needle 
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techniques where the sample evaporates as the needle is heated and before the 
plunger is depressed, leading to discrimination against high boiling point 
components and band-broadening. 
Split injection is an inherently insensitive technique because the majority of the 
sample is vented to waste prior to chromatography. Although high resolution and 
sharp peaks are relatively easy to achieve, if sample concentration is low (i. e. less 
than 100 ppm) alternative techniques are required in which more of the analyte 
enters the column. During development of the derivatization conditions, split 
injection was suitable when reactions with relatively large quantities of standard 
acylcarnitines were being investigated (i. e. greater than 0.1 mg). However, once 
the best derivaization conditions had been identified and interest turned to applying 
the reaction to physiological levels of acylcarnitines and clinical urine samples, 
sensitivity became a problem with split injection. Splitless and on-column injection 
techniques became necessary. 
2.6.1.2 Splitless Injection 
The splitless injection technique is based on using a split injector with the split valve 
closed. The column is the only exit for the sample vapour from the vaporizing 
chamber during the injection. After a preset period the split exit is opened to purge 
the injector and chromatographic separation begins. Since virtually all of the 
sample material is carried onto the column, splitless injection achieves a higher 
sensitivity than split injection. Suitable solute concentrations vary from 0.1 to 50 
ppm when an FD) is used. 
Most of the chromatography difficulties associated with splitless injection can be 
attributed to band effects, due to the large amount of sample entering the column 
compared to split injection. The sample transfer (at optimum carrier gas flow rate 
for chromatography) from the vaporizing chamber to the column takes several tens 
of seconds to complete. This creates excessively broad initial bands and if steps are 
92 
not taken to correct this effect, unacceptably broad peaks will result. The 
chromatographer must employ one of two known techniques to reconcentrate the 
initial bands before or at the start of separation. Both "cold trapping" and "solvent 
effect" act to block the first section of the sample vapour on the head of the column, 
until the last of the material has been transferred from the vaporizing chamber. The 
techniques have been described fully elsewhere121 but essentially temporary 
retardation may be achieved by lowering the GC oven temperature below the elution 
temperature of the solutes (cold trapping effect) or by an increase in film thickness 
of the stationary phase using the sample solvent as liquid phase (solvent effect). 
For reproducible results and quantitative evaluations using splitless injection, such 
reconcentration techniques must be employed. This is a distinct deficiency of 
splitless injection as it may require a skilled chromatographer with substantial 
experience to achieve optimum separation and sentivitiy. 
Like split injection, splitless injection suffers from selective expulsion of sample out 
of the syringe needle. When splitless injection was used in this project the hot 
needle method was used to minimize discrimination. 
Whilst the injection technique allows sensitive analyses, as compared to split 
injection, care is still required not to inject too large an amount of sample in the 
hope of gaining extra sensitity. The maximum sample quantity which may be 
injected is dependent on a number of factors including the vaporizing chamber 
volume. A situation must not be allowed to arise whereby the sample vapours 
expand backwards out of the injector port and down the gas lines. There is no 
method for acurately calculating the maximum tolerable sample volume and hence 
this must be determined experimentally, if the chromatographer wishes to work at 
the limit of sensitity. Typically, 1 tl volumes were used whenever splitless 
injection was applied to derivatized acylcamitine investigations. 
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An advantage of splitless injection is the ability to handle "dirty" samples and it has 
thus found many applications in trace analysis. Involatile material (providing it is 
expelled form the syringe needle) remains on the walls of the injector liner which 
may be periodically removed and cleaned. This may extend the life of the column 
especially when compared to analysing similar samples by on-column injection 
techniques. 
Splitless injection was often used in GC/MS applications during this project. It 
became apparent that an injector temperature limit had to be imposed to avoid ester 
pyrolysis (Scheme 16) of y-butyrolactone compounds in the vaporizing chamber. 
Table 5 summarizes the results from an investigation (Section 6.3.21) into the effect 
of injector temperature on the analysis of derivatized octanoylcarnitine. At low 
injector temperatures (e. g. 150 °C) sample transfer out of the vaporizer chamber 
was poor. So much so, that the peak for the derivative was only just detected as a 
broad signal of low peak height. An injector temperature increase to 230 °C 
improved the size of the signal and its peak shape. This temperature was regarded 
as optimum for the analysis of the octanoyl-containing acyloxylactone and became 
the standard setting for all acylcarnitine determinations which used vaporizing 
injection GC techniques. Raising the temperature above 230 °C caused substantial 
pyrolysis of the derivatives with the associated detection of products of this 
decomposition (Scheme 16). This process was unfavourable in mixture analysis as 
the liberated fatty acids may have retention times very similar or identical to those of 
other peaks of interest. Therefore, even though injector temperatures of 250 and 
280 °C produced excellent peak shapes for the derivative, such conditions were best 
avoided for unambiguous acylcarnitine analysis. High injector temperatures may be 
required if the primary interest of the analyst is in the long-chain acylcarnitines, 
however. For instance, an injector temperature of 230 °C was not suitable for the 
splitless injection analysis of palmitoylcamitine. The high boiling point of the 
acyloxylactone derivative of this compound results in poor transfer out of the 
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Injector 
Temperature PC 
Peak Height 
Ratio 
(3: RCOOH)* 
Peak Shape 
(3 and RCOOH)* 
Peak Height 
(3)* /mm 
150 - POOR 3 
230 8.7 MEDIUM 350 
250 2.0 GOOD 390 
280 0.6 GOOD 8 
TABLE 5: Effect of injector temp. on GC behaviour of cyclized 
octanoylcarnitine 
'Peak heights and shapes refer to compounds in the following decomposition 
reaction: 
C-O 
aH 
3 
co 
+ 
RCOOH 
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vaporizing chamber and therefore a poor peak shape. Such cases warrant high 
injection temperatures or, as preferred for GC analysis of all acylcamitine 
derivatives, on-column injection. 
2.6.2 Cold On-Column Injection GC122 
On-column injection techniques are generally regarded as unrivalled for precise 
quantification and good sensitivity. As the name suggests, the sample is injected 
directly into the head of the column prior to vaporization. A cooling circuit around 
the head of the column ensures sample initially enters the column as a liquid. 
Carrier gas then transports the sample plug into the heated portion of the column 
where vaporization and separation occurs. Careful control of the oven temperature 
is used to reconcentrate the solute bands and enable high efficiency separations. 120 
Cold on-column injection was particularly useful. in this project for the analysis of 
lactones derived from acylcarnitines. As observed with vaporizing injection 
methods, the lactone compounds were susceptible to decomposition on hot 
surfaces. Cold on-column injection was found to cope with this thermal lability and 
it became the method of choice for analysing acylcamitine derivatives by GC and 
GC/MS. 
Using standard solutions of synthesised acyloxylactone compounds, a linear 
relationship between concentration and peak area was observed. For example, 
over the range 1- 90 nmol, the correlation coefficient was 0.996 (nine points). The 
detection limit of the lactone compounds was concluded to be in the sub-nmol range 
but was not determined accurately. Accurate determinations await full evaluation of 
selectivity and recovery efficiency of extraction procedures for urine which will 
ultimately dictate the detection limits in biomedical application. At this stage 
however, detection limits for standards below the nmol level were regarded as 
suitable for attempting the determination of physiological levels of acylcarnitines in 
clinical samples. 
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Efforts were taken to minimize non-volatile components which are not "trapped- 
out" by on-column injection and eventually lead to deterioration of column 
performance by accumulating on the first few centimetres of the column. When 
analysing urine samples, only those which had been taken through the full 
extraction procedure (Figure 5) were subject to on-column injection. Despite this, 
the first 30 cm of column were periodically removed when the chromatography 
became noticeable affected. 
Temperature programming parameters were deduced empirically to obtain complete 
resolution of eleven, standard, derivatized acylcarnitines as shown in Figure 4. 
These conditions were then applied to extracted and derivatized clinical urine 
samples. This enabled preliminary investigation of many urine samples from 
infants with defective fatty acid and amino acid metabolism (Chapter 3). Further 
confirmation and identification of components was achieved using capillary GC/MS 
with on-column injection or splitless injection with a vaporizer chamber maximum 
temperature of 230 °C. 
2.6.3 GCIMS Investigations 
The benefits of structural information on peaks eluting from the GC was 
appreciated and was often deemed necessary when examining complex mixtures. 
This often occurred with clinical urine samples despite the multistep sample 
pretreatment (Figure 6). To date, only the qualitative abilities of GC/MS have been 
exploited. Sufficient sensitivity was available in the full-scan mode for initial 
investigations of clinical urine samples. Further sensitivity and quantification is 
envisaged with the use of selected ion monitoring (SIM), (Section 3.2.4). 
Interfacing the GC with the mass spectrometer was achieved by direct insertion of 
the capillary column into the ion source. Ionization and separation efficiency were 
not too adversely affected with this arrangement. The temperature of the interface 
section between the GC oven and the mass spectrometer ion source was maintained_ 
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Figure 6. GC analysis of urine from a child with MCADD 
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at 10 °C above the final programmed GC temperature. This maintained transfer of 
analytes through the column and did not induce any observable on-column 
decomposition. 
Two ionization methods were used: electron ionization (EI) and chemical ionization 
(Cn. EI was the most utilized method and produced characteristic fragmentation of 
the acyloxylactone compounds. However, EI rarely produced molecular ions with 
the compounds of interest but CI produced complementary data. 
The EI mass spectra were very consistent throughout the acylcarnitine range 
investigated. Fragmentations of the acyl chain were used to distinguish the 
different derivatives. Major ions observed and proposed fragmentation pathways 
are summarized in Scheme 17. The EI mass spectra of acetyl-, octanoyl-, 
palmitoyl- and 4-phenylbutanoyl-containing derivatives were identical to the 
corresponding synthesised lactone compounds (Sections 2.3 and 6.5) and examples 
are included in the Appendix. 
Characteristic ions immediately identified as originating from the acyloxylactone 
compounds include the signal at m/s = 85. This ion was often present as the base 
peak in the mass spectrum of the derivatives. The peak may be attributed to 
cleavage of the whole acyl chain, leaving the charge on the lactone ring residue. It 
is interesting to note that in the case of short-chain acylcarnitines, notably 
acetylcarnitine and propionylcarnitine, this process is not so significant and so does 
not yield a base peak at m/s 85. In these cases formation of the unsaturated lactone 
ring residue accounts for the most abundant ion at m/= 84. This process does occur 
with acylcarnitines of longer chain length but to a decreasing extent with increasing 
chain length. 
Another common ion in the EI spectra was that occurring at m/z 144. This product 
of a McLafferty rearrangement was formed when the acyl chain contained four 
carbons or more. In the case of 4phenylbutanoyl-containing lactone (3, R= 
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Loss of CH3, CH2CH3, CH2CH2CH3 etc. 
(depending on chain length) 
+" 
OH 
O 
O 
(m! z 144) 
CO 
IZI-ý--0 
(m! z 85) 
R CO 
[M-101]+ 
+" 
Oý 
(mlz 84) 
Scheme 17 
100 
R 
CH2CH2CH2Ph) the ion at ml.. 144 accounted for the base peak in the mass 
spectrum. The aromaticity of this compound, in common with the derivative of 3- 
phenylpropionylcarnitine, stabilized their molecular ions, producing larger M+- 
peaks. 
The identification of lactones from acylcarnitines by GC/MS analysis of extracted 
and derivatized urine samples benefited by a knowledge of the known 
fragmentation patterns of the standard acyloxylactones. In particular, the use of 
mass chromatograms proved very effective for locating peaks of interest. By using 
the data system to plot the variation of ion abundance at a specific m/Z value with 
time, detection of several acylcamitines was made from otherwise complex total ion 
current (TIC) chromatograms. In Figure 7, mass chromatograms at m/Z values of 
84,85 and 144 are shown alongside the TIC trace, typical of a clinical urine 
analysis. Acylcamidne presence was supported by coincident peaks in both mass 
chromatograms. For example, the peak eluting at scan number 544 is due to 
hexanoylcarnitine and may have been missed on the basis of the TIC trace alone. 
Further evidence was given by the retention time and mass spectrum of this peak 
which matched the authentic standard hexanoylcarnitine (although the mass 
spectrum showed additional ions due to co-eluting material). Similarly mass 
chromatograms at m/= 84 were invaluable for identifying acetylcarnitineand 
propionylcarnitine because of the co-elution of these components with an 
overloaded urea peak (Section 3.2.2). 
Most of the lactones from physiological acylcarnitines in urine were readily 
recognized from their EI mass spectra by comparison with reference mass spectra 
from derivatized standards. However, in the case of isomers, the EI spectra were 
often similar. Figure 8 shows the EI positive-ion spectra of derivatized octanoyl- 
and valproylcarnitine. The similarities between the spectra mean that more 
information is required to distinguish isomers unambiguously. The task is made 
easy by comparing the GC retention times with standard octanoyl and 
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valproylcamitine, thus demonstrating a major advantage over MS/MS techniques. 
Other than differentiating isomers in mixtures, the comparison with reference 
spectra was usually sufficient for positive identification of acylcarnitine derivatives. 
If reference spectra had not been available, the EI spectra could have been 
interpreted but may have been difficult to assign because of the very small, or often 
absent, molecular ion peak. Determining the molecular mass was best achieved 
using CI conditions, then the accumulated data from both EI and CI spectra could 
be used to identify the lactone compound. 
Chemical ionization was performed using ammonia or methane as reactant gas. 
This milder form of ionization was effective in forming quasi-molecular ions 
especially with CHS reactant gas ions. Results obtained with ammonia indicated 
that protonated molecular ions and ammonium adduct ions QM + NH4]) were 
formed. Using methane as reactant gas gave good Cl spectra (Appendix). The 
protonated molecular ion was always evident and was usually the base peak. 
Relative molecular masses of the lactones were immediately evident from these 
spectra. From the investigations conducted into CIMS of acylcamitine derivatives, 
it was concluded that the technique provided useful complementary data on the 
acyloxylactone compounds. It is recommended that CI is employed if the EIMS 
and retention time of a peak is not sufficient for unambiguous assignment. 
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CHAPTER 3 
APPLICATION OF THE ACYLCARNITINE DERIVATIZATION: 
RESULTS AND DISCUSSION 
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3.1 INTRODUCTION 
Once the derivatization and analysis methods had been shown to work successfully 
on urine spiked with acylcarnitines, the procedure was applied to clinical samples. 
During the course of the project many urine samples were kindly provided by three 
hospitals with paediatric departments and/or interests: Sheffield Childrens Hospital, 
Southampton General Hospital and Höpitaux de Lyon. Samples were usually sent 
by post in standard 5-10 ml biological sample tubes. They were stored frozen prior 
to despatch and on arrival were immediately refrozen and stored at -30 °C. 
Creatinine concentrations were often determinedI23 before the samples left the 
hospital. For acylcarnitine evaluation, individual urine samples (2-5 ml) were 
thawed at room temperature, then an analysis aliquot (0.5 ml) removed and the 
remainder refrozen and stored. Repeat analyses on a given urine suggested that this 
procedure had no effect on urinary acyIcamitine content and its evaluation. 
Since the application to clinical urine samples was a continuous process over much 
of the project, early attempts did not employ optimum extraction and derivatization 
conditions. Therefore, initial applications (e. g. cases of MCADD108) gave complex 
chromatograms compared to later analyses (e. g. Figure 6 as compared to 
Figure 10). Care must be taken when comparing analyses and, because of the on- 
going development, quantitative sample comparisons were only estimated. 
However, the technique has been used to identify trends in urinary acylcarnitine 
concentrations (see later) and current data suggest the method can be developed into 
a fully quantitative analysis (Chapter 5). 
The majority of work carried out on clinical samples has concerned well- 
characterized diseases which are known to result in excretion of elevated amounts 
of acylcarnitines in the urine. The welt-characterized nature of the disease state was 
especially important for early applications, when the technique needed to be proved 
as a suitable method of investigating metabolic disorders. Therefore, in cases of 
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MCADD, octanoylcarnitine and hexanoylcamitine were expected to be present and 
initial efforts were made in detecting only these carnitine esters. Similarly, 
isovalerylcarnitine is known to be excreted in cases of isovaleric acidemia, as is 
propionoylcarnitine in propionic acidemia, and thus the experimental approach was 
centred around these expected metabolites. With the use of GC/MS and increasing 
experience of the analysis, however, it soon became possible to detect not only the 
major acylcarnitines, but also some minor and some unexpected ones as well. 
These observations have continued to prove interesting, enabling speculation of the 
metabolism (or defective metabolism) of some endogenous and two exogenous 
compounds. 4-Phenylbutanoylcarnitine (2, R= (CH2)3Ph), originally employed 
as a model acylcarnitine for development of the derivatization (Chapter 2), 
continued to be useful as a suitable internal standard and indicator of cyclization. 
This acylcamitine is not known to occur naturally, nor has it been reported in the 
metabolism of any exogenous compounds to date. In most analyses of clinical 
urine samples, a known amount of the synthesised phenyl-containing acylcarnitine 
was added to the urine before extraction and derivatization. Subsequent GC and 
GC(MS analysis then identified the 4-phenylbutanoyl-containing lactone 
(3, R= (CH2)3Ph), if the sample pretreatment was successful. From previous 
investigations (Section 2.3.3), it may be assumed that other, physiological, 
acylcarnitines behave similarly to (2, R= (CH2)3Ph) and so the presence of 
(3, R= (CH2)3Ph) after derivatization should be accompanied by other y- 
butyrolactones if urinary carnitine esters occur in the original sample at levels above 
the limit of detection. Comparison of respective signals (Section 6.3.19) can give 
an indication of acylcarnitine levels. 
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3.2 INVESTIGATIONS OF DEFECTIVE LIPID AND 
BRANCHED-CHAIN AMINO ACID METABOLISM. 
3.2.1 Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) 
Several inherited defects of fatty acid oxidation have been recognized during the last 
decade. A deficiency of mitochondrial, medium-chain acyl-CoA dehydrogenase 
(MCAD) is one such disorder. MCADD has recently drawn considerable attention 
because of its relatively high incidence (compared to other fatty acid oxidation 
defects), high mortality, non-specific symptoms and the difficulty of diagnosing it. 
The genetic deficiency of MCAD was first described by K0lvraa et al. 124 in 1982 
and since then, approximately 100 cases have been reported in the literature. 20 In a 
survey conducted in the Sheffield area of England, Bennet et al. 125 have recently 
reported that the incidence of pathological dicarboxylic aciduria (indicative of 
MCADD) was 1 in 5000 live births. Although further studies to confirm the origin 
of the dicarboxylic aciduria, are necessary, the evidence does suggest that MCADD 
is one of the most common inborn errors of metabolism. For example, it is 
probably more prevalent than phenylketonuria (PKU), a genetic defect in 
phenylalanine metabolism for which babies are routinely tested. 52 Patients with 
MCADD are unable to utilize fatty acids for energy or ketone production and hence 
suffer energy depletion when glycogen stores are low or exhausted. The resulting 
hypoketotic hypoglycaemia is often life threatening. Typical clinical symptons of 
MCADD include intolerance to fasting, episodic vomiting, lethargy and episodes of 
coma. These are usually accompanied by medium-chain dicarboxylic acidura. 
Dicarboxylic acids are by products of an alternative fatty acid oxidation pathway, 
microsomal co-1 oxidation, which becomes stressed as miochondrial (i-oxidation is 
curtailed. An episode of MCADD may occur abruptly in apparently healthy 
children, with a mortality rate, within the first two years of life, of 59% with the 
first episode. 53 Unfortunately, the typical symptoms mentioned above are not 
always evident (or sufficiently characteristic) and this has led to considerable 
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confusion during diagnosis. Initially, patients with MCADD were reported to have 
Reye's syndromet26-128 and further studies have indicted that in some cases 
MCADD has been misdiagnosed as sudden infant death syndrome (SIDS). 129-131 
Strictly, the term SIDS should be reserved for sudden unexplained deaths (cot 
deaths). There is a growing agreement that fatal cases of defective oxidation 
diseases including MCADD may be catagorized as sudden unexpected death 
syndrome (SUDS). 
A deficiency of the MCAD enzyme causes a block in the metabolism of long-chain 
acyl-CoA species, as indicated in Scheme 18. Characteristic urinary hydroxyacids, 
dicarboxylic acids and glycine conjugates, arising from the alternative metabolic 
processes are also recognized for this disorder. Clinical diagnosis of MCADD, in 
the hospital environment at least, relies on detection of these alternative metabolic 
products to support the clinical symptoms. GC/MS, after TMS derivatization, is 
often employed to determine the organic acids present in the urine. Suberylglycine 
and hexanoylglycine, absent in the urine of healthy patients, are typical metabolites 
excreted by infants with MCADD. These compounds are often regarded as 
diagnostic of MCADD. However, the usefulness of this approach in asymptomatic 
patients has not been fully evaluated. The glycine conjugates are usually 
accompanied by elevated medium-chain dicarboxylic acid concentrations, 132 and 
phenylpropanoylglycine may also be present (see Section 3.2.1). An experienced 
analyst, familiar with MCADD cases and the GGMS data they present, should be 
able to identify the disorder with an acceptable degree of confidence. However, 
there remains a potential shortcoming of this approach, in that the analyst is not 
monitoring the actual defective metabolic process. Could it be that the glycine 
conjugates and elevated dicarboxylic acids may arise from another metabolism 
disorder, independent of MCADD? 
In order to investigate the defective metabolic process itself (i. e. mitochondrial 13. 
oxidation), it is necessary to perform enzymatic assays of MCAD activity in patient 
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Scheme 18. Degradation of long-chain (LC) fatty acids by mitochondrial 
ß-oxidation. MCAD deficiency results in accumulation of 
medium-chain (MC)-acyl-CoA. which are excreted as 
MC-acylcarnitines when adequate L-carnitine is available. 
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cells2O or at least analyse the carnitine esters; products from the detoxification 
process of carnitine (Chapter 1). All current methods for assaying MCAD are 
cumbersome, taking several weeks to produce results and only a few laboratories 
provide the service worldwide. The difficulties associated with current 
acylcarnitine analyses have been discussed (Section 1.2), but the development of an 
alternative, rapid, simple and accurate method would be useful to some 
investigative studies of MCADD. 
As indicated in Figure 10 certain acylcarnitines may be expected in the urine of 
patients with MCADD. Octanoylcamitine and hexanoylcarnitine are usually the 
most prevalent but studies using FABMS and FABMS/MS have identified others. 
The application of the derivatization/GC and GCIMS method, developed in this 
project, initially aimed to detect the major acylcarnitines with the future objective of 
also confirming, or otherwise, the presence of octenoyl-, decanoyl- and 
decenoylcamitine, in urine from patients with MCADD. 
Urine samples from eleven patients with MCADD were analysed using the 
developed GC and GC/MS methods. Several samples were available from some 
patients, allowing interpretation of urinary acylcarnitine status at different stages of 
the disease. Urine from an MCADD patient undergoing L-carnitine 
supplementation was obtained, as were regular samples over the first four-week 
postpartum period of a baby with MCADD. 
Early attempts at using the developed method to analyse for endogenous 
acylcarnitines in clinical samples involved application to urine from two babies with 
MCADD. Figure 6 shows the gas chromatogram obtained after subjecting 0.5 ml 
of urine from one of the infants to the double ion-exchange purification procedure 
and derivatization conditions. 108 The peak eluting at 12.68 min had the same 
retention time as the lactone derivative of octanoylcarnitine. Confirmation of this 
result was obtained by GCIMS analysis of the same sample. Figure 9, `shows the 
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total ion current trace and the mass spectrum of the peak at scan number 798 (which 
also corresponded, in retention time, under GC/MS conditions, to the 
octanoylcarnitine derivative). A comparison with the EI mass spectrum of the 
authentic octanoyl-containing acyloxylactone (Appendix, MS 6) clearly confirms 
the identification of octanoylcarnirine in the clinical sample. Using mass 
chromatograms at m1: 85 and 144 and examining the relevant mass spectra, a 
further three lactones from acylcarnitines were identified. This first clinical urine 
sample had been spiked with synthesised 4-phenylbutanoyl-containing y- 
butyrolactone (3, R= (CH2)3Ph), after derivatization, as the first step towards 
assessing the suitability of 4-phenylbutanoylcarnitine (2, R= (CH2)3Ph) as an 
internal standard. The lactone was detected as a peak eluting at scan 1019 in the 
TIC trace (Figure 9) and having a corresponding mass spectrum. Another expected 
lactone compound was the derivative of hexanoylcarnitine found at scan 648, using 
mass chromatograms. This technique also identified mass spectra consistent with 
the lactone from 3-phenyipropanoylcamitine (2, R= (CH2)2Ph), originally an 
unexpected metabolite but subsequently explained (Section 3.3.1). 
The results from this first MCADD sample validated the application of the 
developed method to acylcarnitine determinations in biochemical studies. The 
appearance of apeak for the aromatic lactone (2, R= (CH3)3Ph) in an appropriate, 
uncluttered part of the chromatogram, with a convenient retention time (i. e. not 
excessively long), supported the use of 4-phenylbutanoylcarnitine as an internal 
standard for future quantitative analyses. As expected from the results of analysing 
standards, the technique was sensitive enough to detect the characteristic major 
urinary acylcarnitines of MCADD, thus prompting further application. 
The general conclusion, drawn from the analysis of the MCADD sample and 
several normal urine samples, was that the disease state samples contained elevated 
quantities of acylcarnitines. Other than a very small repsonse for acetylcarnitine, 
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carnidne esters were not detected in urine from normal patients. Improvements 
leading to a lower limit of detection may subsequently allow analysis of the low 
acylcarnitine levels (i. e. sub-nmol) excreted by normal, healthy persons (see 
Section 3.2.2). With the exception of one MCADD sample (Table 6, Patient 2), the 
GC and GCJMS methods identified acylcarnidnes in all urine samples from patients 
with the disorder. Table 6 summarizes the results of acylcarnitine detection in 
eleven urine samples from nine patients with MCADD, collected at varying stages 
of the disease. Acylcarnitine concentrations, where quoted, were estimated from 
the relative FID response for the corresponding derivative with that for the lactone 
from the internal standard. As expected, octanoylcarnitine and hexanoylcarnitine 
were prominant metabolites detected in the analysis of MCADD samples. 
However, the estimated concentrations for both the major carnitine esters varied 
significantly between samples. Some urines when analysed by the developed 
method gave poor detector responses for the expected acylcarnitines. This was 
especially noticeable for samples collected during a crisis stage of the disorder. 
Failure to observe high concentrations of endogenous acylcarnitines in early 
applications of the technique, was attributed to a non-optimized extraction and 
derivatization procedure. However, as the project progressed, a pattern emerged 
whereby urine collected during or shortly after an episode of acute clinical 
symptoms (crisis condition), presented lower concentrations of carnitine 
compounds (even below the I. o. d. ) compared with samples collected during the 
basal stage of the disease. The same observation was made with other disorders of 
mitochondrial ß-oxidation, i. e. propionic acidemia and isovaleric acidemia (see 
later). 
Without precise information on the stage of the disease, relative time of sampling, 
therapeutic treatment, creatinine determinations and sample treatment and storage 
procedures, it is only possible to speculate on explanations for the trend in 
acylcarnitine excretion detailed above. One explanation concerns the overall 
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reduction in accumulating acyl-CoA groups may occur, thus leading to decreased ' 
acylcamitine excretion. Further work, including time course studies over the crisis 
phases of MCADD, seems advisable to determine the reason(s) for the fluctuating 
levels of carnitine esters in the urine of patients with the disorder. 
The urine from one patient, diagnosed MCADD (Table 6; patient 8) gave interesting 
GC and GC/MS results in that isovalerylcarnitine was detected along with 
octanoylcamitine. Isovalerylcarnitine was not observed in any other MCADD urine 
and was originally thought to be specific to another metabolic disorder, isovaleric 
acidemia (Section 3.2.3. ). Whilst octanoylcamitine (characteristic of MCADD) was 
present, hexanoylcarnitine was not detected. Also worthy of attention was the large 
FID response for acetylcarnitine which was confirmed by GGMS. The patient was 
diagnosed as MCADD on the basis of the urinary organic acid profile and decreased 
octanoate oxidation in fibroblasts. However, a phenylpropionic acid load did not 
result in detectable urinary phenylpropionylglycine (see Section 3.3) and the 
electron transfer flavoprotein (1fF) assay20 of the MCAD was normal, both results 
atypical of MCADD. The detection by GC/MS of excreted isovalerylcarnitine as 
well as octanoylcarnitine, coupled with the inconclusive results from the established 
clinical tests, suggests that the patient may be suffering from a multiple acyl-CoA 
dehydrogenase (MAD) deficiency as diagnosed for a patient reported by Kidouchi 
et al. 88 Such a disorder would be expected to give unexpected and original organic 
acid and acylcamitine profiles due to complex permutations of multiple enzyme 
deficiencies. Other urinary components could not be positively identified due to 
limited mass spectral information obtained with this sample. Improvements to the 
sensitivity of the GCIMS method and analysis of further samples from patient 8 
may produce valuable results to help fully elucidate the metabolic disorder in this 
infant and others with MAD deficiency. 
The highest concentrations of the typical MCADD acylcarnitines, were found in the 
urine of patient 9, collected during a basal period of the disorder. In contrast to 
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this, the urine from the same patient, during a crisis stage of MCADD, had one of 
the lowest concentrations of octanoylcarnitine and no hexanoylcamitine was 
detected. * Using GC/MS and mass chormatograms (Section 2.4.3), two additional 
compounds with typical EIMS characteristics of acylcarnitines were identified 
(notably responses at mlz 85 and 144). The retention times of both these 
components did not correspond to any of the standard acylcarnitine derivatives 
available, but it was predicted that they respresent oct-2-enoylcamitine 
(2, R= CH=CH(CH2)4CH3) and decanoylcarnitine (2, R= (CH2)gCH3) 
previously identified by FABMS/MS and HPLGMS in other MCADD urines. 102 
Good quality mass spectra could not be obtained on the minute levels of these 
components and therefore confirmation awaits synthesis of the standard 
acylcarnitines 
The derivatization of physiological acylcarnitines to acyloxylactones was applied to 
urine from two patients receiving an oral L-carnitine load of 50 mg/kg body weight. 
One was a two month old neonate with a normal fatty acid metabolism. The second 
was a similar aged baby with diagnosed MCADD. Pre-load samples from both 
infants were collected at the same time of day (09.00 hr) and subject to the 
extraction, derivatization and GC/MS analysis (see Figure 5). Post-load urine 
samples were collected from the normal and the MCADD baby, 4 hr and 2.5 hr 
It has recently been revealed that patient 9 was receiving L-carnitine on a therapeutic basis at the 
time the "basal urine" sample was collected. The crisis sample was collected when the patient was 
admitted with symptoms of MCADD and not receiving L-carnitine. This may explain, in this 
patient at least, the observation of greater acylcarnitine excretion in 'basal' than in crisis samples. 
+ Oct 2-enoylcamitine and decanoylcamitine have recently been synthesised and retention rimes and 
ELMS of the respective derivatives confirm their presence in the urine of patient 9. The synthesis 
and analysis of these compounds was performed by Dr RJ Morrow, The Open University. 
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respectively, after the L-carnitine administration. These samples were also analysed 
using the developed GGMS method. 
For the normal infant, the carnitine load resulted in a signal which corresponded to 
acetylcarnitine. Also evident by GGMS, was a broad peak which gave a mass 
spectrum consistent with ß-hydroxy-ybutyrolactone. This could be assigned to 
carnitine, cyclized as the acylcarnitines are derivatized. Under the GC conditions 
imposed, the camitine peak eluted shortly before the lactone from acetylcarnitine 
and had a broad shape due to unfavourable interaction of the free hydroxy group 
with the stationary phase of the column. The analysis of this post-load sample, 
from the infant with normal ß-oxidation metabolism, did not detect octanoyl- or 
hexanoylcamitine. These results supported those from the previous application of 
FABMS/MS by others, who also found that acetylcarnitine was the only urinary 
acylcarnitine to increase in the normal subject upon carnitine supplementation. 
Analysis of the urine samples from the MCADD patient were performed as for 
those from the normal baby. In this case, the urine collected after the carnitine load 
gave significant signals for acetyl-, hexanoyl- and octanoylcamitine. Acylcarnitine 
levels were not determined but those detected in the post-load sample were not 
evident in the pre-load sample. The broad peak for cyclized camitine was also 
observed in the post-load urine of this patient. Previous FABMS/MS analysis of 
these urine samples also showed an increase in octanoyl- and hexanoylcamidne 
after carnitine administration, validating the GC/MS results reported here. 
The results of this short study on L-carnitine loading suggest that it may be a 
suitable method of gaining biochemical information from patients with suspected 
fatty acid oxidation defects. Administration of L-carnitine is tolerated by infants 
and has been used as a therapeutic treatment of MCADD, although its efficacy in 
this role is variable. 134 L-Camitine loading may be particularly useful in 
investigating the metabolism of suspected MCADD patients, who are currently not 
119 
excreting detectable amounts of urinary acylcarnitines. It represents a technique for 
maximizing biochemical information for confirmatory purposes. As such, it may 
be applied to other metabolic defects which involve accumulation of acyl groups in 
the mitochondrion. 
The organic aciduria which accompanies acylcarnitine excretion in cases of 
MCADD was studied, over the first four weeks of life for a baby with the disease, 
by Walker et a1.135 Urine samples from the same patient, over the same time 
period, were obtained and analysed by the GC and GGMS methods developed in 
this project. Aliquots of the same samples were also analysed independently by 
Millington and co-workers using FABMS/MS. 
The male baby was born normally at 37 weeks gestation, weighing 3440 g. He 
was the second child of unrelated parents whose first child had died unexpectedly at 
15 months. MCADD was suspected in the first child, on the basis of gross fatty 
infiltrations of the liver and biochemical investigations of the vitreous humour. 136 
The second child appeared healthy but urinary organic acid analysis by GCJMS 
indicated that he too had MCADD. Urine samples were collected at intervals from 4 
hours after birth. Hexanoylglycine and suberylglycine were detected in all samples. 
The study concluded that (i) the organic aciduria evolved with time, (ii) the levels of 
hexanoylglycine and suberylglyeine progressed rapidly to peak on the second day 
of life and then subsided rapidly, (iii) other characteristic metabolites (i. e. 
hydroxyacids and dicarboxylic acids) showed a similar trend, and (iv) on the 
second day the full range of organic acids reported in MCADDP except 
phenylpropionylglycine, was observed. 
The results from subjecting the urine samples to the extraction, derivatization and 
analysis procedure depicted in Figure 5 are presented graphically in 
Figure 11. Acylcarnitine concentrations were estimated from CC chromatograms, 
comparing FED signals for the respective derivatives with that for the internal 
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Figure 11. GC/MS determination of four organic acids excreted 
by a patient with MCADD during the first week of life 
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standard. Figure 10 shows a typical GC trace obtained during the time course 
study. It represents the analysis of the urine obtained from the child at 41 hr after 
birth. The lactones of acetylcarnitine (4.65 min. ), hexanoylcarnitine (9.84 min), 
octanoylcarnitine (12.38 min) and the internal standard (15.78 min) are all evident 
in this trace. All proposed acyloxylactone peaks were confirmed by GCIMS, 
matching authentic standard samples (Appendix MSI, MS4, MS6 and MS8). The 
excretion of acylcarnitines is represented graphically in Figure 12. As usual, in 
cases of MCADD, octanoylcarnitine was the major acylcarnitine excreted. 
However, the concentration of this metabolite varied from undetectable to 470 
nmoles ml-1 over the time period investigated. Acetylcarnitine and 
hexanoylcarnitine were also detected with maximum concentrations estimated at 170 
and 60 nmoles ml-1 respectively. In common with the results for organic acid 
analyses (Figure 11) the maximum acylcarnitine excretions occurred between 40 
and 60 hr of age. The general trend in urinary carnitine ester concentrations 
obtained here was also superimposable on the excretion pattern for other diagnostic 
MCADD metabolites. In all cases the rapid increase in metabolite concentrations is 
followed by a sharp fall, at around 50 hr after birth. A slight rise in 
hexanoylcarnitine and octanoylcarnitine at approximately 110 hr was also observed 
and this was also detected by D. S. Millington (Duke University) using the 
established FABMS/MS method102 (see below). 
Millington and coworkers, using FABMS/MS, 102 were able to detect the major 
acylcarnitines along with butanoyl-, octenoyl-, adipyl-, suberyl- and 
sebacylcamitine in the same set of samples. The detection limit of the technique 
was 1 nmol ml-1, thus allowing analysis of acylcarnitines not detected by the 
current full-scan GCIMS method. However, the FABMS/MS technique does not 
produce unambiguous full-scan spectra of the analytes. The method involves 
detecting the precursors of a common fragment ion (m/r 99), consisting 
predominantly of acylcamitine molecular cations. A degree of ambiguity arises 
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Figure 12. Estimations by GC/MS of acylcamitines excreted by a 
patient with MCADD during the first week of life 
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because urinary components, other than acylcamintes, could fragment and give 
detectable m/= 99 ions under the FABMS/MS conditions imposed. This was 
supported by many peaks, other than those attributed to acylcamitines, in the parent 
ion scan spectra (i. e. false positives). Secondly, isomers would give the same 
response, so inhibiting their differentiation. 
Only approximate acylcamidne levels were determined by FABMS/MS 
(unpublished results). Inappropriate internal standard spiking (2H3-acetylcarnitine 
and octanoyl-2H3-camitine) resulted in a signal which could not be accurately 
compared with the signals for the physiological acylcarnitines. Despite this, the 
estimated concentrations were in good agreement with those from the GC and 
GC/MS method. The trend in acylcamitine excretion, over the first week of life 
was also confirmed by the FABMS/MS estimations (Figure 13). Therefore, all 
results substantiate the original observations of Walker et al. 135 in that the metabolic 
disturbance progressed to a peak then rapidly subsided, during the second day after 
birth. 
Similar studies on other babies with MCADD are required to determine if the 
metabolic events noted in this case are characteristic of the disease. The use of the 
GCIMS method, developed in this project, would be ideal for acylcamitine 
determinations in such a study. Further sensitivity could be achieved, at the 
expense of full-scan mass spectral information, by employing selected ion 
monitoring (SIM). This may allow detection of the minor acylcarnitines as in the 
FABMS/MS method reported above. 
If the trend in metabolite excretion is common to cases of MCADD then this is very 
significant to diagnosis of the disease. Walker et al. 137 report another 
symptomless newborn baby with MCADD for which, by chance, the first urine 
collected was at 43 hr of age. Analysis of the organic acids using GGMS identified 
the full range of characteristic MCADD metabolites, except for phenylpropionyl- 
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Figure 13. FABMS/MS estimations of metabolites excreted by a 
patient with MCADD during the first week of life 
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glycine. Metabolite excretion in this baby may also have been approaching a 
maximum at 2 days of age, since subsequent analyses of urine collected at 18 days 
after birth, revealed only a trace of hexanoylglycine using GC/MS. The organic 
acid profiles for both infants with MCADD were compared with acid excretion in 
59 unaffected babies ages 0- 72 hr, and confirmed the elevated metabolite 
concentrations when the disease was present. 
Detection of acylcamitines by derivatization and GC/MS of the resultant 
acyloxylactones was successful over the peak excretion period. However, 
diagnostic carnitine esters were not detected after the first week of age in this case 
and hence the infant may have passed as normal on the basis of urine screening 
after the first week of life. These observations are in contrast to many previous 
analyses of basal condition MCADD urines (see Table 6), which are usually 
characterized by readily detected amounts of octanoyl- and hexanoylcamitine. A 
comprehensive understanding of the MCADD disorder demands further studies 
which discover why, how and when metabolite excretion varies. 
3.2.2 Propionic Acidemia 
Propionic acidemia, a disorder of organic acid metabolism, results from defective 
propionyl-CoA-carboxylase. The disease is characterized by accumulation and 
urinary excretion of propionylglycine, 3-hydroxypropionate and methylcitrate. Roe 
et a1.138 and Chalmers et a1.139 also observed greater amounts of acylcarnitines in 
the urine of patients with this disorder compared to normal subjects. An increase in 
propionylcarnitine was particularly striking. Most of the metabolites excreted share 
a common precursor, propionyl-CoA. This compound and its metabolites are 
known to have several detrimental consequences on normal metabolism. These 
include inhibition of the tricarboxylic acid (TCA) cycle, 140,141 gluconeogenesis, 142 
pyruvate dehydrogenase complex143 and the glycine cleavage system. 144 The long 
term use of supplementary L"carnitine together with dietary restrictions has been 
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recommended for control of the disease. 138 L-Carnitine administration provides a 
mechanism whereby otherwise accumulating propionyl groups are removed for 
urinary excretion thus (i) replenishing mitochondrial, free CoA, (ii) maintaining 
normal ATP production, and (iii) providing sufficient L-camitine for the patients' 
metabolic requirements. 
Propionylcarnitine has been detected in the urine of patients with propionic acidemia 
by several methods, including FABMS, 95 thermospray LC/MS, 104 desorption 
CIMS78 and LC. 87 1H NMR spectroscopy has also been used, after administration 
of an L-carnitine load, to a propionic acidemia case thus elevating the excreted 
propionylcarnitine to such a degree that the metabolite could be detected by this 
relatively insensitive technique. 72 In this project, derivatization to the 
corresponding acyloxylactone with GC and GGMS analysis was applied to urine 
samples from two patients with propionic acidemia. 
Two samples from each patient were available for analysis. In all four urines, 
propionylcarnitine was detected. Figure 14 shows a typical gas chromatogram 
from a sample which was extracted, derivatized and analysed by GC as depicted in 
Figure 5. The major peak at 5.90 min corresponded, in retention time, to the 
lactone from propionylcarnitine. GC/MS confirmed the component was the lactone 
from propionylcamitine (see Appendix: MS2 for standard) but the spectrum was 
complicated by co-eluting urea. Urea interference was a recurring problem in the 
GGMS analysis of propionic acidemia samples. GC analysis was not particularly 
affected by the presence of urea because of the insensitivity of the FID to urea. 
Detection problems with GC/MS were largely overcome by the use of mass 
chromatograms. Plotting the variation in ion abundance of the base peak of the 
lactone of propionylcarnitine, m/, 84, gave a sharp peak deconvoluted from the 
broad and otherwise interfering signal of urea in the TIC trace. However, the 
interference still has to be taken into account when interpreting the mass spectrum 
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Figure 14. Analysis of urine from a child with propionic acidemia 
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of the peak. Alternatively enhanced data may be obtained by using subtraction 
procedures to remove the mass spectrum of urea from the spectra of interest. 
Before extraction, the urines were spiked with phenylbutanoylcarnitine as in the 
MCADD investigations. Approximate levels of propionylcarnitine were estimated 
from the relative signals from the resulting lactone compounds. As with cases of 
MCADD, acylcarnitine excretion appeared to vary markedly in propionic acidemia. 
For both patients, propionylcarnitine concentration was estimated to be in the low 
nmol ml-l level in one sample and approaching pmol ml-1 in the other. Such 
variations seem to have been poorly investigated, other than the comparative results 
from L-camitine loading tests. 138 Detailed studies which take into consideration 
aspects such as sample collection periods and disease condition, are required to 
determine the reasons for the fluctuating acylcarnitine levels. 
The results obtained from the investigation of the limited number of propionic 
acidemia samples support the observations of others. Propionylcarnitine does 
appear to be a major urinary metabolite, characteristic of the disease. The high 
concentration of the acylcamitine detected in some samples indicates that the 
disorder may lead to secondary carnitine deficiency. As such, L-carnitine 
supplements and control of dietary fat intake are essential to maintaining a healthy 
metabolic status. The application of the developed acylcarnitine analysis method to 
these samples also demonstrated that the technique may be used to investigate fatty 
acid metabolism in disorders other than MCADD. The procedure was identical to 
that used in the MCADD investigations but the combination of high resolution gas 
chromatography with full scan ELMS data allowed unambiguous acylcarnitine 
determinations. 
3.2.3 Isovaleric Acidemia 
As shown by Millington et a1., 145 stable isotope experiments and FABMS analysis 
prove that isovalerylcarnitine is derived from a defective leucine metabolism in 
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patients with isovaleric acidemia. In the degradation of leucine (Figure 15) a 
mitochondrial process is employed whereby a-ketoisohexanoic acid passes through 
the inner mitochondiial membrane and is converted to isovaleryl-CoA. In patients 
with isovaleric acidemia, further metabolic breakdown is inhibited by deficiency of 
isovaleryl-CoA dehydrogenase. Carnitine acts in its familiar detoxification role, to 
remove the potentially toxic accumulation of isovaleryl groups and excrete them as 
isovalerylcarnitine (2, R= CH2CH(CH3)2) in the urine. Other urinary metabolites 
of isovaleric acidemia include isovalerylglycine and 3-hydroxyisovalerate. 
Carnitine deficiency and the subsequent effects on fatty acid metabolism have been 
reported in cases of the disorder. 146 In common with other inherited defects of 
mitochondrial ß-oxidation L-camidne supplementation has been recommended as 
efficacious treatment of patients with isovaleric acidemia. I47 
Urine samples from three patients with the disorder were subject to the extraction, 
lactonization and GC and GC/MS analysis depicted in Figure 5 with the results 
summarized in Table 7. A typical gas chromatogram resulting from the analysis of 
one of the samples is shown in Figure 16. The major peak in the chromatogram, 
eluting at 7.82 min, had an identical retentention time to standard, derivatized 
isovalerylcarnitine. GC/MS analysis of the same peak gave the EI mass spectrum 
shown in Figure 17. The spectrum shows a base peak ion at mis 85, characteristic 
of the medium-chain acyloxylactone compounds. A comparison with the EI mass 
spectrum of standard, derivatized isovalerylcarnitine (Appendix MS3) confirmed 
the presence of the acylcarnitine in the urine sample analysed. The metabolite was 
readily detected in all the samples from patients with diagnosed isovaleric acidemia. 
Relatively high concentrations of the endogenous acylcaraitine were detected in 
these samples, compared to other metabolic disorders investigated in the project. 
The largest estimated concentration (about 4 µmol ml-1) was determined for the 
sample from patient 3. collected during a stable stage of the disorder. As 
2 
2ý previously encountered with MCADD cases (Section 3.1.1), acylcarnitine excretion 
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Figure 15. Mitochondrial steps of leucine metabolism leading to 
isovalerylcarnitine formation. 
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at a crisis stage was significantly reduced in this patient. However, the observation 
should be contrasted with the results for patient 2, which suggest higher excretion 
during crisis conditions. Further studies are required to make deductions on the 
relevance of the varying pattern of isovalerylcamitine excretion. 
Application of the developed method to urine from patients with isovaleric acidemia 
further supported the value of the technique for investigating metabolic disorders. 
However, care should be taken if quantitative evaluations are required. The high 
concentrations of acylcarnitines encountered in urine from patients with isovaleric 
acidemia (see Table 7) may approach the limitation of the derivatization method 
used here. As discussed in Section 2.4.3, high acylcarnitine concentrations in the 
ReactiVial may supress the cyclization process, due to intermolecular interactions. 
Smaller volumes of urine, i. e. less than 0.5 ml, should be analysed or a larger 
reaction vessel employed. 
3.2.4 Other Applications And General Observations 
The GGMS method was applied to some other inherited metabolic diseases with 
less conclusive results. For example, urine from one patient with methylmalonic 
acidemia was subject to the method. The disorder has previously been 
characterized by urinary excretion of propionyl- and acetylcarnitine. 138 The 
GGMS method described here (Figure 5) did not identify propionylcamitine 
although a small amount of acetylcarnitine was evident. The technique has been 
successfully applied to physiological quantities of propionylcarnitine in cases of 
propionic acidemia and therefore there is no obvious reason why it should not be 
applicable to methylmalonic acidemia diagnosis. Further attempts with such urine 
samples are envisaged for future work. Likewise, application to urine from patients 
with 0-ketothiolase deficiency is anticipated. Millington et al. 103 identified 
tiglylcamitine (2, R= C(CH3)=CHCH3) in the urine of a patient with ß- 
ketothiolase deficiency by thermospray mass spectrometry (LGMS) and resolved it 
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from the biological isomer, 3-methylcrotonoylcamitine (2, R= CH=C(CH3)2). 
The one application of the lactonization method to urine from a patient diagnosed 
with this disorder of ß-oxidation did not identify any acylcarnitines. The method 
has proven to work with other branched-chain acylcarnitines (isovalerylcarnitine 
and valproylcarnitine) and unsaturated acylcarnitines (octenoylcamitine) and 
therefore tiglylcarnitine should be amenable to the developed technique. The 
fluctuating concentrations of excreted acylcarnitines encountered throughout the 
analysis of clinical samples may have been responsible for these negative results. If 
the urine samples were collected during a low acylcarnitine-excretion period of the 
disease, the disease-specific acylcarnitines may occur at a concentation below the 
detection limit of the technique. Improving the extraction procedure in terms of 
recovery and selectivity may be required for such applications. Alternatively or 
additionally, the use of a more sensitive mass spectrometric assay for extracted and 
derivatized acylcarnidnes may enable detection of the lower physiological levels 
encountered in some disease state urines and may even allow determinations of 
normal urine acylcarnitine levels. Using the mass spectrometer in selected ion 
monitoring (S1M) mode is one method of gaining substantial sensitivity over full 
scanning. For SIM, the mass spectrometer is tuned to detect one or a small number 
of ions expected in the mass spectrum of the analyte of interest. Since the 
instrument does not spend valuable analysis time collecting data on background and 
ions of no relevance to the analyte, detection sensitivity may be improved by a 
factor of up to 1000. The technique is especially effective in improving sensitivity 
of capillary GCIMS analyses. The width of fully resolved GC peaks is typically 
1-2 s and therefore a mass spectrometer scanning the mass range 20-800 in 1 
second may only collect data on a given peak during one scan. In that one scan 
there may be very few ions originating from the compound that gives the 
chromatogram peak. The combined ion current of those few ions determines the 
sensitivity of the technique and is represented by the total ion current (TIC) 
chromatogram . In the application of SIM to the analysis of the acyloxylactone 
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compounds the instrument may be tuned to focus only the common ions at m/Z 84, 
85 and 144 expected from the analytes of interest under EI conditions. 
Alternatively, using CI, the expected quasi-molecular ions may be selectively 
monitored for suspected acylcarnitines, depending on the disease being 
investigated. 
One urine sample from a patient with glutaric aciduria type 1 was analysed using the 
GC/MS technique. The disease is caused by a defect in the oxidation of glutaryl- 
CoA and possibly glutaconyl-CoA which are intermediates in the catabolism of 
tryptophan, lysine and hydroxylysine. Analysis of urinary organic acids reveals 
glutaric, glutaconic and 3-hydroxyglutaric acids as the major diagnostic metabolites. 
Recently, using HPLC, 87 glutarylcarnitine has also been detected in the urine of 
infants with the disease. The analysis of other dicarboxylic acid conjugates of 
camitine in neonatal urine is also attracting interest. 
Methylmalonyl-, glutaryl-, adipyl-, suberyl- and sebacylcarnitine have all been 
detected using FABMS/MS and LGMS. 102 The relevance of these metabolites to 
essential metabolic processes has not been fully evaluated, a situation which would 
benefit from a sensitive and simple assay such as the one developed in this project. 
The attempt to detect glutarylcarnitine in the urine from a glutaric aciduria type 1 
patient was unsuccessful. A gas chromatographic peak of cyclized glutarylcarnitine 
may be expected to be broad and unsuitable for quantification because of 
unfavourable stationary phase interactions with the remaining free carboxyl group. 
No such signal, nor any other which could be assigned to an acylcarnitine, was 
detected by GC or GC/MS. There are several other possible explanations for this 
result including: (i) glutarylcamitine was not present in detectable quantities in this 
sample; (ii) the metabolite was not extracted using the ion-exchange method 
developed for the simple acylcarnitines of monocarboxylic acids; and (iii) camitine 
-esters with additional carboxyl functions in the side chain do not cyclise under the 
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derivatization conditions. It is difficult to eliminate any one of these potential 
explanations without further attempts with well characterized clinical samples and/or 
with standard glutarylcarnitine. The purification procedure, as it stands, does 
appear suspect in its application to such acylcarnitines. The extraction was 
designed and modified to be as specific as possible for isolating conventional 
acyicarnitines. The likely change in ion-exchange behaviour caused by an 
additional acid group in the analyte may mean that the extraction procedure is 
inappropriate for the carnitine esters of dicarboxylic acids. A loss of the analyte 
may occur at either of the ion-exchange steps but the first anionic-exchange stage 
seems most likely to be the problem. Under the anionic-exchange resin conditions, 
acylcamitines containing a carboxyl function in the side chain can carry a net 
negative charge unlike the overall neutral nature of conventional carnitine esters. As 
such, glutarylcarnitine and other dicarboxylic acid carnitine esters may remain on 
the anionic-exchange resin column. Careful control of pH and possible reliance on 
only cationic resins may provide a suitable alternative purification procedure. 
Derivatization of glutarylcarnitine by conversion to the respective acyloxy-y- 
butyrolactone (3, R= (CH2)3COOH) is not expected to be as difficult as might 
initially be envisaged. Only the carboxyl group of the carnitine backbone should 
participate in the cyclization reaction since an analogous mechanism involving the 
side-chain carboxyl group would, theoretically, lead to a seven-membered ring. A 
five-membered ring, like the butyrolactones derived from conventional 
acylcarnitines, will form much more rapidly than a seven-membered ring. In fact, 
the lactonization of Br(CH2)n000- species is known to occur at least 100 times 
faster when n=3 (i. e. to give a 5-membered ring) than with any other value of 
n. 148 Thus any problems which occur in the application of the GC/MS method to 
carnitine esters of dicarboxylic acids, should only concern the free carboxyl group 
still present in the side chain of the derivative. Standard trimethylsilylation (TMS 
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derivatization) of this group may be required in order to achieve sharp GC peaks 
suitable for quantification. 
In addition to acyloxylactones, some other compounds were regularly encountered 
in both the GC and GC/MS analysis of urine samples subject to the extraction and 
derivatization procedure depicted in Figure 5. A broad peak, eluting towards the 
end of a standard GC analysis (over 15 min) was almost always observed. The 
mass spectrum of this peak was characteristic of a phthalate plasticiser with an 
abundant ion at m/Z 149. This artifact probably arises from the ReactiVial 
derivatization step. The rubber septa used to seal the reaction vessels did have a 
teflon side, but the high pressures generated inside the ReactiVial may allow solvent 
vapour to come into contact with the soft rubber before condensing back into the 
reaction mixture. After derivatization, samples were stored in 2 ml glass sample 
vials with teflon-lined septa and screw top caps. Other, conventional precautions 
were taken when handling solvents for example, to avoid contamination. The 
presence of GC plasticizer peaks was not a problem in the studies conducted in this 
project since they eluted substantially later than any peaks due to derivatized 
acylcarnitines. 
Another peak, more difficult to explain, was observed in almost every neonatal 
urine examined, from both normal and disease states. It occurred as a broad peak, 
requiring a GC oven temperature above 230 °C to elute it from a BP5 capillary 
column. The peak never interfered with the signal for any acylcarnitine of interest. 
EI mass spectra for this component were reproducible and a typical spectrum is 
shown in Figure 18. 
The spectrum is obviously very different from the now familiar spectra of the 
acyloxylactone compounds and could not be interpreted as originating from any 
acylcamitine. The simple nature of the derivatization procedure and the lack of 
reagents involved, indicates that the compound is a component of urine, or is 
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derived from a component of urine. Such material must behave similarly to 
acylcarnitines in order for it to be extracted by the ion-exchange purification method 
and hence reach the derivatization and anlaysis stages. A base peak at m/Z 70 is 
highly indicative of an amino acid, prolyl group (9), and suggests a simple peptide 
or proline derivative. The presence of an amino-acid type substance would explain 
the material being extracted along with any acylcarnitines. The zwitterionic 
structure, containing an anionic carboxyl group and a cationic quaternary amine 
group, is common to amino acid and acylcarnitine molecules. Therefore, it was 
expected that any pepddic material present in the urine samples would be extracted 
using the ion-exchange purification procedure outlined in Figure 5. If the ion at m/Z 
210 is assigned to the molecular ion of the compound, the mass spectrum (Figure 
18) may be interpreted as one of the dipeptides, prolyl-isoleucine, prolyl-leucine, 
isoleucyl-proline or leucyl-proline, which has lost 18 daltons, i. e. loss of a 
molecule of water. That is, the spectrum suggests the presence of a cyclized 
dipeptide: a 2,5-diketopiperazine. In fact, the spectrum matched that of a previous 
ELMS analysis of cyclic Pro-Ile but not of cyclic Pro-Leu. 149 The peaks at m/= 86 
and 124 probably represent a rearrangement reaction within the fused ring structure 
as shown in Scheme 19, which has also been observed in the EIMS of other 2,5- 
diketopiperazines. 150 Occasionally another component with a mass spectrum 
which correlated with cyclic alanine-leucine or alanine-isoleucine was also observed 
(m/= 184 (M+"), 5%; 112,100%; 99,40%; 98,60%; 70,45%; 43,50%). This 
substance had a GC elution time of around 16.9 min and this could interfere with 
medium-chain acylcarnitine derivatives. However, the compound was not 
consistently encountered as with cyclic Pro-Ile in neonatal urine samples. The 
limited number of adult urine samples analysed did not contain the postulated 
diketopiperazine compounds found with the normal and disease state childrens' 
samples. 
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The detection of cyclic dipeptides may originate from urinary dipeptides extracted 
by the ion-exchange purification and then thermally cyclized, either during the 
derivatization process or during chromatography. However, commercial samples 
of Pro-Ile and Ala-Leu, when subject to the derivatization conditions and GC 
analysis did not produce peaks consistent with those attributed to the cyclic 
dipepddes in the clinical samples. Further work is required to confirm the identity 
of these components unambiguously (the sequence of the parent dipeptide is, of 
course, ' lost" once the diketopiperazine has formed) including synthesis of 
standard 2,5-diketopiperazines. 151 Such investigations seem worthwhile since the 
identification of urinary dipeptides may have important clinical value. It would also 
be of interest to investigate the origin of the dipeptides detected. 
3.3 INVESTIGATIONS OF THE METABOLISM OF SOME 
EXOGENOUS COMPOUNDS 
In recent years, certain drug treatments have been associated with reduced plasma 
and urinary carnitine levels. 105.152.153 Of these, secondary carnitine deficiency 
induced by valproic acid (3-propylvaleric acid or 3-propylpentanoic acid) 
adminstration to patients with epilepsy is most documented. Urinary excretion of 
valproylcamitine has been proposed as a mechanism for reducing carnitine levels to 
an extent that patients show clinical symptoms of hypocarnitineaemia. A similar 
process is suggested for the metabolism of the antibiotic, pivampicillin 
(pivaloyloxymethyl-ampicillin), increasing urinary loss of carnitine as 
pivaloylcarnitine (2, R= C(CH3)3). 154 
Oral loading with phenylpropionic acid (PPA or, properly, 3-phenylpropanoic acid) 
is now widely accepted as an in vivo screening/diagnostic procedure for patients 
with suspected MCADD. In normal subjects, phenylpropionic acid is produced 
naturally from phenylalanine by intestinal bacteria. This is then further metabolized 
to benzoate by the action of MCAD and excreted in the urine as hippurate. 
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Therefore, a deficiency of the dehydrogenase enzyme results in a nzitochondrial 
accumulation of phenylpropionyl-CoA. GGMS of urinary organic acid profiles 
often identifies phenylpropionylglycine, originating from endogenous 
phenylalanine. Administration of PPA attempts to accentuate this process for 
diagnostic purposes. 
The acylcarnitine analysis procedure reported here was applied to urine samples 
from patients undergoing treatment with phenylpropionic acid and valproic acid. 
The results are given in this secn. 
3.3.1 Acylcarnitine Determination of Urine Samples from Patients 
Administered Phenylpropionic Acid (PPA) 
100.0 
50. ß 
M/2 
Figure 19. Mass spectrum of phenylpropanoylcarnitine detected in the urine 
of a patient with MCADD 
U' 
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The very first MCADD urine analysed with the developed method identified the 
21 expected hexanoylcarnitine and octanoylcamitine (Section 3. L. 1). 1O8 Use of mass 
chromatograms, m/Z 85 and 144, indicated the occurrence of another component 
with the typical mass spectral characteristics of an acylcarnitine lactone derivative 
(Figure 19). Interpretation of the spectrum suggested the compound the 
acyloxylactone from 3-phenylpropanoylcarnitine. Subsequent synthesis of the 
standard acylcarnitine and mass spectrometric analysis of the corresponding lactone 
derivative (Appendix MS7) confirmed the presence of the aromatic camitine ester. 
The patient had not received a recent bolus of PPA and therefore the metabolite 
probably originated from incompletely metabolized phenylalanine, due to a 
deficiency of MCAD. 
Further studies of MCADD urines occassionally identified the derivative of 
phenylpropionylcamitine, estimated at low nmol ml-l levels. However, there was 
little consistency between samples with regard to this observation. Post-load urine 
samples from patients given PPA produced equally variable analytical results. 
Some samples gave substantial signals, by GC and GC/MS, for the lactone of 3- 
phenylpropanoylcarnitine, comparable with the octanoylcarnitine response, whilst 
in others, even after a PPA load, the aromatic acylcamitine was not detected. The 
results suggest that the carnitine detoxification process may not be the only pathway 
for 3-phenylpropionyl group removal, and in some MCADD patients alternative 
pathway(s) predominate. Conventional GC/MS organic acid profiles, which 
accompanied some of the urine samples, often identified hippurate, suggesting that 
the PPA may have been fully metabolized even with a limited and otherwise 
insufficient MCAD activity. Also, glycine may act to remove the toxic acyl groups 
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to such a degree that carnitine esters are not required, this being supported by 
detection of phenylpropionylglycine in some organic acid analyses. 
The identification of 3-phenylpropanoylcarnitine in a clinical urine sample was first 
reported using the method developed in this 108 The almost simultaneous 
identification of the same acylcarnitine, in one other patient with MCADD, using 
FABMS/MS, supports the observation reported here. 155 It is reasonable to 
propose that this metabolite derives from the detoxification role of carnitine 
previously encountered in (3-oxidation disorders. That is, a deficiency of MCAD 
may result in accumulation of 3-phenylpropanoyl-CoA species in the mitochondria 
and thus carnitine acts to alleviate this potentially critical situation by forming 
carnitine esters, to be excreted in the urine. The common practice of administering 
a PPA load to patients with MCADD, on the basis of the results obtained in this 
project, produced variable concentrations of the acylcarnitine metabolite. 
Controlled studies are required to determine if an acylcamitine excretion pattern is 
reproducible over the drug treatment period. It should be noted, however, that a 
PPA load to MCADD patients with critical symptoms of secondary carnitine 
deficiency should be avoided, as this represents a further mechanism for lowering 
the body carnitine pool. 
3.3.2 Acylcarnitine Determination in Urine Samples from Patients 
Administered Valproic Acid 
Valproic acid is a short-chain fatty acid widely used to treat epilepsy in paediatric 
practice. A daily dose, in the range 600 to 1200 mg, is frequently used to minimize 
convulsions in epileptic children. The metabolism of the drug in otherwise normal 
infants and in animals has been studied and is well documented. 156 In a small 
percentage of patients, however, hyperammonemia and a Reyc's-like syndrome 
have been reported. 157-159 Irreversible and even fatal liver injury has been reported 
with valproate therapy. It is suggested that the use of this anticonvulsant 
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may induce secondary carnitine deficiency in some patients thus leading to a 
Reye's-like syndrome, clinical condition. An inverse relationship between plasma 
carnitine levels and dosage of valproate has been reported. 153 The mechanism for 
carnitine reduction is thought to be due to increased urinary excretion of 
acyleamitines. However, a study of patients with normal mitochondria ß- 
oxidation, on valproate therapy and given an L-carnitine load, showed that 
acylcarnitine excretion increased slightly but the majority of the carnitine was 
excreted unesterified. The study also included analysis of excreted urinary 
acylcamitines from patients treated with pivampicillin and concomitant 
L-carnitine administration, which indicated that the drug readily esterified to 
carnitine and was excreted as pivaloylcarnitine. 152 Despite poor esterification of 
valproie acid to carnitine, Millington et a1.105 first identified valproylcarnitine 
(2, R= CH(CH2CH2CH3)2), as a drug metabolite in the urine of a patient on 
valproate therapy. FABMS, with linked scanning, was first used to identify the 
acylcarnitine but HPLC/MS, employing thermospray, was required to distinguish it 
from the biological isomer, octanoylcarnitine. Patients were not receiving carnitine 
supplementation during the study and valproylcarnitine levels were determined in 
the region of 10 nmol ml-1. The investigation also included assays of free carnitine 
and short- to medium-chain acylcarnitine totals using a radioenzymatic method. 67 
The results indicated that under 10% of the excreted acylcarnitine was accounted for 
by valproylcarnitine. It was concluded that, "valproylcarnitine was not the 
predominant acylcarnitine excreted by patients receiving valproate, " but no 
suggestion was made for the major acylcamitine(s). Acetyl-, propionyl- and 
isobutyrylcamitine were previously identified in the urine of patients receiving 
valproate. When carnitine supplementation was administered, the carnitine esters 
were detected by hydrolysis and GC analysis of the liberated fatty acids. 152 The 
ambiguous origin of the fatty acids (see Section 1.2) was of concern in these 
analyses. Also, the acylcarnitines identified were not specific to the valproic acid 
metabolism and may be simply a consequence of the carnitine load. 
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Kuhara et al. 160 reported an altered valproic acid metabolism in a patient with 
diagnosed Reye's syndrome and suggested the drug should not be used to treat 
seizures in patients with symptoms of the disorder. This has been extended to 
include infants with any of the defective mitochondrial ß-oxidation diseases. 
Therefore, the application of the acylcarnitine method reported here concerned urine 
samples from patients with normal fatty acid oxidation metabolism and receiving 
valproate therapy (i. e. unlike samples in which 3-phenylpropanoyl-carnitine was 
detected, (Section 3.2.1)). 
Urine samples from two patients on chronic vaiproate therapy were subject to the 
extraction, derivatization and GC and GCJMS analysis as previously described. 
The fast sample analysed gave the gas chromatogram shown in Figure 20. A peak 
consistent in retention time to the lactone from standard valproylcarnitine was 
observed at 10.89 min. Using GC/MS, the mass spectrum of this component was 
obtained. The low concentration resulted in a poor spectrum but it was 
characterized by relatively abundant ions at m/Z 57,85 and 157, consistent with 
valproyl-containing acyloxylactone (Appendix MS5). The major peak in the gas 
chromatogram of Figure 20 eluting at 12.10 min, was originally regarded as not 
being derived from an acylcarnitine, since its retention time did not correlate with 
any previous carnitine ester derivatives analysed. Using GC/MS, however, the 
component showed familiar fragment ions in its EI mass spectrum (Figure 21). 
The spectrum can be interpreted as consistent with the lactone from 3- 
oxovalproylcarnitine(2, R= CH(CH2CH2CH3)000H2CH3). 
It is proposed that the patient was excreting 3-oxovalproic acid esterified to 
carnitinc. Further confirmation awaits synthesis and analysis of 3- 
oxovalproylcarnitine (Chapter 5). 
The discovery of this novel metabolite of valproic acid is significant for the full 
elucidation of the metabolism of the drug. Analysis of the second urine sample 
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from a child receiving valproate therapy supported the results obtained with the first 
sample. In addition to signals assigned to derivatized valproyl- and 3- 
oxovalproylcarnitine, several other components with the characteristics of lactones 
derived from acylcarnitines were indicated by using mass chromatograms (m/Z 84, 
85 and 144). Full-scan mass spectra were not helpful because of the low 
concentration of these analytes. Application of the extraction and derivatization 
procedures to larger volumes of clinical urine sample (when available) may 
overcome the sensitivity problems and allow further interpretation of the 
metabolism of this and other acidic compounds. 
The presence of the proposed metabolite is supported by the observation of 
others156 that 3-oxovalproic acid (2-propyl-3-oxovaleric acid) is a major 
degradation product of valproate in man. The results of the investigations reported 
here suggest that carnitine plays a role in removing acidic drug metabolites from the 
body. Even in the case of subjects with a normal fatty acid metabolism, carnitine 
may be involved in buffering the stresses on mitochondrial f3-oxidation, imposed 
by exogenous compound administration. This observation may have further 
repercussions in evaluating the metabolism of other acidic drugs. The excretion of 
3-oxovalproylcarnitine represents another mechanism for reducing body carnitine 
levels, thus accounting for possible Reye's-like symptoms in patients receiving 
chronic valproate therapy. 
It is interesting to speculate as to why the metabolite discussed here has not been 
previously identified. The FABMS technique employed by Millington et a!. 105 
would be expected to identify a signal consistent with 3-oxovaiproylcarnitine, if it 
was present in the urine samples examined. One feasible explanation concerns the 
limited analytical information obtained from the FABMS method. Acylcamitines 
were identified by the mass of the intact molecular ion and the ability of this ion to 
loose 59 mass units (i. e. loss of NMe3). Other than this fragmentation, there is 
little evidence to distinguish acylcarnitines from other urinary components which 
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also loose 59 mass units under the mild FAB ionization conditions. The mass of 
the 3-oxo-valproylcarnitine ion is 302 daltons and whilst this ion most probably 
fragments by loss of 59 daltons, it may have been difficult to distinguish from 
nonanoylcarnitine and its isomers, which have the same nominal mass. The 
presence of the next higher homologue of an administered drug is very difficult to 
explain on the basis of established metabolic routes, but with the FABMS method, 
there is little additional analytical information available. Therefore, the signal may 
have been simply attributed to another urinary component which lost 59 daltons. 
Otherwise, the signal may have been recognized as originating from an acy1carnidne 
but the limited analytical information may have prevented further structure 
elucidation. This would explain the authors comment that valproylcarnitine was not 
the predominant acylcarnitine excreted in the limited number of cases examined. 105 
The situation illustrates the benefit of chromatography and EI full-scan mass spectra 
as obtained with the derivatization approach to acylcamitine analysis. 
A similar shortcoming of the analytical method may explain the results of Mills et 
al., 161 who, using FABMS/MS with parent ion scanning, report detection of 
nonanoylcarnitine and heptanoylcarnitine in the urine of a child with MCADD. 
Odd-carbon chain length acylcarnitines (above C-5, i. e. isovalerylcarnine) are 
unexpected and difficult to explain because of. the mechanism of fatty acid $3- 
oxidation (see Scheme 3). Therefore the proposed identification of 
nonanoylcarnitine as the second most abundant acylcarnitine metabolite in a case of 
MCADD requires further attention. Application of the GC/MS method may provide 
valuable additional information on such samples and with standards should 
unambiguously confirm or otherwise the FABMS/MS results. 
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CHAPTER 4 
CAPILLARY ZONE ELECTROPHORESIS AND ITS 
APPLICATION TO ACYLCARNITINE ANALYSIS 
154 
4.1 INTRODUCTION TO CZE TECHNIQUES 
Since the development of electrophoresis as the basis of an analytical technique in 
the late nineteenth century the methodology has remained essentially unchanged. In 
electrophoresis, charged molecules in solution migrate, upon the application of an 
electric field, towards the electrode of opposite charge. Early applications involved 
biomoleculest62 and it is in the area of biological chemistry that the technique has 
maintained its devotees. 163 Based on separation through a gel or liquid medium, 
electrophoresis has developed as both an analytical and preparative method. 
Capillary zone electrophoresis (CZE) was originally described as free solution 
electrophoresis in a capillary. 164 Hjerten demonstrated separations with the use of 
high electric field strengths in free solution electrophoresis using 3 mm W. 
capillaries in 1967.164 He also drew attention to the zone broadening effects due to 
thermally induced density gradients and described approaches to minimizing them 
for improved separation efficiency. However, it was the work of Mikkers et a1.165 
and Jorgenson and Lukacsl66 which initiated a steadily growing interest in the 
subject. This was followed by further publications by Jorgenson and 
Lukacs16 '168 and an important review of electrophoresis in capillary tubes by the 
same authors in 1983.169 They established the basic theory and practical 
experimental approaches and demonstrated the high separation efficiency possible 
with this technique. Over the past decade, the technique of CZE has found many 
applications with over 90% of publications on the method appearing in the last two 
yß, 170.171 At this stage in its development, it is possible to speculate that CZE 
will become a popular laboratory technique because of its potential to be applied to a 
wide variety of studies. Benefits include high resolution, simplicity, speed of 
analysis and versatility. Applications in areas such as recombinant protein quality 
control, purity evaluation of peptides and DNA fragments, checking biological 
degradation, pharmaceutical analysis, monitoring antibodies and studying bioactive 
peptides and many others have already been reported. The availability of 
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commercial instrumentation and the increasingly widespread use of CZE confirms 
the acceptance of the technique, especially in the life sciences, and should ensure 
further developments and applications. 
4.2 CZE THEORY AND METHODOLOGY 
The principle of CZE is shown schematically in Figure 22. The charged analyte or 
mixture containing charged molecules is introduced into a capillary containing an 
electrolyte solution. Under the influence of a high voltage, sample molecules 
differentially migrate through the capillary. Cationic species move towards the 
cathode whilst anionic molecules migrate towards the anode. However, the rate of 
migration is dependent on both charge and size of the analyte and therefore 
separation of ions is effected. This movement of ions is referred to as 
electrophoretic migration. 
In free-zone capillary electrophoresis, that is, when using an open capillary tube 
filled with electrolyte solution, separation occurs due to the combined action of 
electrophoretic migration and electroosmotic flow. Electroosmotic flow is one of the 
most distinguishing properties of capillary electrophoresis. It is caused by the 
formation of a static diffuse double layer on the inner walls of the silica capillary 
column. Fused-silica columns present internal walls which have a negative charge 
in solution as a result of their surface silanol groups becoming ionized. Counter- 
cations are attracted from bulk solution to the walls. Most of the cations are 
stagnant but some extend into the mobile "diffusive" layer. These cations migrate 
towards the cathode, "dragging' with them the solvent. This results in bulk 
movement of the electrolyte plus analyte molecules towards the cathode. The plug- 
like flow is said to have a flat velocity distribution across the capillary diameter, 
deviating only within a few nanometers of the capillary surface. A nearly flat flow 
profile allows high separation efficiencies to be realized. The effect of net mobility 
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Fused Silica Capillary 
+1 I- 
Figure 22. Schematic diagram of free-zone CZE; 
small arrows : electrophoretic migration of anions and cations 
large open arrow : bulk electroosmotic flow towards cathode 
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(i. e, elution of anionic, neutral and cationic species) means that all species 
eventually pass through the on-line detector. 
Altria and Simpson developed an elegant method of measuring the rate of 
electroosmotic flow. 17ZI73 They arranged an analytical microbalance to monitor 
the change in weight of one of the buffer reservoirs. This avoided problems with 
adsorption on the capillary walls of otherwise unretained marker compounds. Flow 
rate was found to be inversely proportional to ionic strength of the electrolyte and 
independent of column diameter. The effect of pH between 2 and 12 and applied 
voltage was also determined. Increases in both were found to increase 
electroosmotic flow rate linearly. 
Much work has been directed to manipulating the electroosmotic flow in order to 
optimize separations. In the simplest cases, this may involve simply adjusting 
applied voltages and/or pH. The addition of several chemicals to the electrolyte to 
alter the zeta potential of the double layer at the capillary wall has been investigated. 
The direction of flow can be reversed by addition of cationic surfactants. 172,174 
Addition of simple organic solvents can also influence electroosmotic flow 
dramatically. 175 Methanol decreases the bulk flow whilst acetonitrile causes an 
increase. Chemical derivatization of the capillary wall has also been investigated, to 
change the properties of the double layer. The interaction of phosphate with the 
silica surface has benefited some applications in that electroosmotic now is reduced 
and the surface is shielded from protein adsorption, allowing separation of proteins 
up to 77 kDa. 176 Electroosmotic flow may even be eliminated by silylating with (y- 
methacryloxypropyl)-trimethyloxysilane followed by cross-linking the surface- 
bound methacryl groups with polyacrylamide. l77 
Coated capillaries that eliminate electroosmotic flow are used in a technique termed 
isoelectric focusing, an extension from a gel-slab electrophoresis technique. The 
sample is injected into the capillary in a mixture of ampholytes. When the voltage is 
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applied, the ampholytes quickly form a stable, continuous and linear pH gradient 
across the length of the capillary. Charged sample molecules move through the 
gradient towards the electrode of opposite charge (i. e. electrophoretic migration). 
However, because of the pH gradient, the molecules reach a point where their net 
charge is zero and migration stops. This is known as the isoelectric point. As a 
substance moves out of its isoelectric point region, it encounters a different pH, 
acquires a charge and is forced by the electric field back to its isoelectric point. The 
process results in extremely sharp bands of sample molecules which are then swept 
past the detector by use of pressure. 
Mikkers et al. 165 demonstrated that high efficiency separations are best achieved by 
ensuring the sample concentration is only a small fraction of the buffer 
concentration. Otherwise, detrimental inhomogeneities in the electric field form 
across the capillary, because of concentration gradients induced by differential 
migration of different solutes. 
Applying a voltage of several kV across an electrolytic solution has the potential to 
generate considerable thermal energy through the Joule heating effect. Much of the 
early theoretical discussion concerned heat dissipation in relatively large inside 
diameter capillaries when an electric field was applied over such a column 
containing an electrolyte. Jorgenson and Lukacs166,169 demonstrated that narrower 
capillaries than those used by Mikkers et al. 165 were more effective in minimizing 
the effects of Joule heating. They also developed the key relationships between 
separation efficiency, voltage, column diameter, column length, solute 
concentration, and resolution. 
4.2.1 Sample Injection 
The combination of minimum band broadening on the column and the short 
analysis times possible with CZE produces an extreme constraint on sample 
introduction into the capillary. The samples must be injected in an on-column 
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fashion with minimum volume to preserve the high separation efficiency. There are 
several very simple approaches to sampling, which may or may not be suitable for 
the CZE investigation required. Most commercial instruments are capable of two or 
more different injection techniques, to cope with a variety of applications. The 
simplest methods of sample introduction are direct electrophoretic migration of the 
sample onto the column (electrokinetic injection) and hydrodynamic injection via 
generation of a pressure difference between inlet and outlet of the column. 
Electrokinetic injection is applicable to any charged species and involves placing an 
electrode, with the inlet to the capillary, into the sample. On applying a voltage, 
charged molecules start to migrate towards the electrode of opposite charge. 
Therefore if the outlet of the column is held at a negative potential with respect to 
the sample, cations will preferentially enter the column. In free-zone 
electrophoresis, neutrals and some anions will also be sampled because of the effect 
of electroosmotic bulk flow. Sample volume is determined by the applied voltage 
during injection and the duration of the potential whilst the inlet is in the sample. 
The discrimination towards species of a certain charge (i. e. it is equally applicable 
to anions if polarities are switched) may be useful as a crude analyte concentration 
procedure. For example, the technique may be useful for sampling acylcarnitines 
directly from urine. Carnitine compounds, under neutral or slightly acidic 
conditions, will be cationic and therefore should be selectivity sampled onto the 
capillary, minimizing possible interference by organic acids and other urinary 
components. However, the technique does not allow a representative sample to be 
analysed and therefore its application is limited. Huang er a1.178 showed that 
electrokinetic injection induces a bias proportional to the total mobility of each ion. 
The peaks can be corrected for differential mobilities by normalization with their 
retention time. 
Honda et al. 179 automated a syphoning sampler for CZE. A hydrostatic pressure 
gradient was generated by raising the inlet of the capillary, in the sample, above the 
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outlet reservoir. Sample volume was determined by relative heights of the inlet and 
outlet reservoirs and duration of the syphoning process. Automation of the 
technique involves mechanical complexity, although it is available on a commercial 
instrument, Sample viscosity is likely to affect the volume introduced onto the 
column and reproducibility between samples may be a problem. 
Other methods of using pressure to introduce material into a capillary include 
applying positive pressure on the sample vial, or negative pressure at the outlet of 
the capillary. Both methods are available on commercial instruments and have been 
used to investigate CZE analysis of acylcarnitines in this project. Both methods 
introduce a representative sample into the capillary, however, care has to be taken to 
ensure good seals on application of the pressure difference to avoid irreproducible 
injection volumes. The maximum length for the injected zone and the detection 
volume are dependent on efficiency, column length and retention time. 180 In 
practice, maximum efficiency for a particular separation requires an empirical 
approach investigating the effect of the many variables of CZE. 
4.2.2 Detection 
Irrespective of the injection method, once the sample is in the capillary, the inlet of 
the column is immersed in a reservoir of electrolyte and electrophoresis effected by 
application of a high voltage as in Figure 22. After separation, a detection system is 
required to produce peaks in an electropherogram. As with HPLC, UV-visible 
abosorbance detection is the most popular means of obtaining data from a CZE 
experiment. Due to the need for small detection volumes to preserve separation 
efficiency, UV detection is accomplished on-column, such that the path length is 
defined by the diameter of the capillary. This limits the sensitivity of absorbance 
methods, since sensitivity is proportional to path length. The development of UV 
light focusing devices has been critical in the design of commercial instrumentation. 
By stripping a small section of the polyimide coating off the capillary, the focused 
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UV light passes through the column to a photomultiplier. Foret and Bocek used 
fibre optics to adapt a standard HPLC UV detector for use with CZE. 182 A 
photodiode array for on-column UV detection in CZE has also been described. 183 
Laser light sources are finding application in CZE detection. The light from a laser 
is highly compatible with focusing onto a small capillary diameter. Helium 
cadmium lasers are the most popular, being relatively inexpensive and they emit 
light in the UV range (325 nm). 183-187 The more powerful argon ion lasers, have 
also found application. 188-190 A current disadvantage of lasers is the limited 
wavelengths available for use. Despite this, some impressive analyses have been 
performed. For example, Dovichi and co-workers used a1W Ar+ ion laser to 
detect derivatized amino acids in human urine with a separation efficiency 
equivalent to 200 000 plates and a detection limit of 50 atmol of analysed 
analyte. 191 The introduction of tuneable lasers is likely to find many further 
applications in CZE. 
Fluorescence detection is also applicable to CZE. An important advantage of 
fluorescence detection is the fact that it is usually much more sensitive than UV 
detection (depending on the quantumn yield for fluorescence of a given analyte). 
On-column detection is simply accomplished by focusing the excitation source onto 
the column and collecting the emission at an angle perpendicular to the incident 
light. The use of sensitive fluorescence detection has allowed analysis of DNS- and 
fluorsecamine-labelled products form tryptic digests of proteins. 192 The 
disadvantage of derivatization is often overcome by the advantages of increased 
sensitivity and selectivity. 
An alternative to derivatizadon of non-fluorescent compounds is the use of indirect 
detection. With this technique, the analyte displaces a chromophore uniformally 
present in the background electrolyte. Thus, in CZE, a charged chromophore can 
be used such that analyze ions of like charge will displace the chromophore, while 
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ions of opposite charge may ion-pair with it. This method allows detection of 
species which would otherwise be transparent to the detector, since the signal 
produced is independent of the chromophoric properties of the analyte. Foret et 
x. 193 used the technique to determine metabolic carboxylic acids in a background 
electrolyte containing benzoic or sorbic acid. A detection limit of 0.5 pmol was 
achieved from these weakly chromophoric analytes. 
ElectrochemicalI94 and radioisotopic 195 detectors have also found application, 
however, the technology has largely relied on minaturisation of HPLC detectors. 
One of the most exciting detection developments currently attracting attention is the 
combination of CZE with mass spectrometry. The introduction of atmospheric 
pressure ionization techniques has increased the compatibility of the two 
techniques. Such CLF., /MS methods avoid vacuum-induced-flow through the 
capillary. Smith et al. '96 have demonstrated the use bf an electrospray interface for 
CZEFMS. The interface makes electrical contact with the electrophoretic buffer via a 
thin film of silver deposited on the surface of the capillary. Electrospray ionization 
is performed by biasing the potential between the capillary outlet and the ion optics 
of the mass spectrometer inlet. The solvent in the spray produced in this manner is 
evaporated with hot N2 before the ions enter the mass analyser of a quadrupole 
instrument. The technique was applied to peptide, protein and quaternary 
ammonium salts. Total ion electropherograms had sensitivities comparable to those 
obtained with UV detection. Recent improvements of the electrospray interface for 
CZE/MS have allowed application of the technique to large biomolecules. 197 The 
formation of multiply charged molecular ions allowed analysis of proteins with 
molecular weights greater than 130 000 daltons, with a determination of MW to 50- 
100 ppm accuracy, on a sample injection of 0.1-10 pmol of the analyte. An 
extension of the technique by interfacing the CZE to a triple quadrupole mass 
spectrometer allows CZE/MS/MS experiments. 197,199 
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4.2.3 Micellar Electrokinetic Capillary Chromatography 
Although CZE is a highly efficient separation technique, the basic method is only 
applicable to charged compounds, because the separation principle is based on the 
difference in electrophoretic mobilities. Typically, in free-zone capillary 
electrophoresis, neutral molecules do not separate but travel as a single band at the 
speed of electroosmotic flow. Micellar electrokinetic capillary chromatography 
(MECC) is performed with the same equipment as CZE but employs the 
chromatographic principle of separation, i. e. partition between two phases. That is, 
the method permits the separation of uncharged or neutral analytes by the 
electrophoretic technique. 
The principle of MECC is shown schematically in Figure 23 (the double layer 
formed at the capillary wall and responsible for electroosmotie flow is not depicted. 
for simplicity). Charged surfactants are dissolved in the elecrrophoretie buffer to 
produce charged micelles. Sodium dodecyl sulphate (SDS) forms suitable micelles 
and is commonly used for MECC. The micelles are represented as the open circles 
in Figure 23, in which neutral analyte molecules (represented by x's) may be 
incorporated. When a high voltage is applied over the capillary, the negatively 
charged SDS micelles are attracted to the positive electrode. However, the 
electroosmotic flow, caused by the double layer at the capillary walls, effects bulk 
flow towards the cathode. Under neutral pH conditions, the electroosmotic now is 
greater than the electrophoretic velocity of the micelles. Separation of the neutral 
analyte molecules is thus determined by their relative affinities for the hydrophobic 
micelles. The separation occurs as a result of analyte molecules partitioning 
between the micelles and the surrounding electrolyte. Neutral molecules which 
have zero affinity for the micellar matrix remain in the aqueous bulk solution and 
therefore migrate through the capillary solely under the influence of the 
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0 to tR tC 
electroosmotic flow. However, molecules which do become incorporated into the 
micelles for any period of time will, overall, travel slower owing to the 
electrophoretic mobility of the negatively charged micelles. As such, the affinity of 
the neutral analyte molecules for the micelles determines their rate of migration 
through the column. A molecule which is totally incorporated from the time of 
injection will have the slowest migration time of any neutral species. 
A schematic representation of the migration of three typical zones and the 
corresponding chromatogramlelectropherogram are shown in Figure 24. The 
electroosmotic velocity Veo is assumed to be greater than the electrophoretic velocity 
of the micelles, Vm, in the opposite direction. All solutes injected at the anode end 
of the capillary, move through the column to the cathode, as in Figure 23. The 
band of water, or a tracer for water such as methanol, is, in conventional 
chromatography terms, unretained. It does not dissolve in the micelles, at any stage 
and therefore migrates through capillary at the fastest speed for a neutral molecule, 
Veo. (N. B. Non-incorporated cations will travel faster due to the combined effects 
of electroosmotic flow and electrophoretic mobility. ) At the other extreme, a tracer 
for the micelles which is totally incorporated in the hydrophobic micelle structure 
and is neutral, moves with the velocity (Veo-Vm). A neutral solute which is 
partially included is transported through the capillary at a velocity between the two 
extremes. The capacity factor (1') of the zones is given by: 
K" tR - to ......... equation (1) (I- tRltc) to 
and may be calculated from the retention times of a chromatogram such as that in 
Figure 27. In conventional chromatography, a capacity factor of infinity means that 
the solute would not be eluted because it would be totally retained by the stationary 
phase. In MECC, however, every solute is eluted in the retention time window 
between to and tc provided they are electrically neutral. 
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The first results of MECC were achieved using SDS micelles, 200 however, the use 
of other surfactants should find application. When cationic surfactants are used, the 
micelles migrate to the cathode but the electroosmotic flow is towards the anode. 
This is because the inner wall of the capillary becomes positively charged owing to 
adsorbed surfactant molecules and hence all solutes migrate towards the positive 
electrode, assuming eIectroosmotic flow is greater than the electrophoretic velocity 
of the micelles, 
4.3 APPLICATION TO ACYLCARNITINE ANALYSIS 
The charged nature of acylcamitines makes them potential analytes for free-zone 
capillary electrophoresis, without derivtization. If the carboxyl group of the 
carnitine backbone is protonated (i. e. at low pH values) the acylcarnitine will be 
cationic, due to the remaining positive charge on the quaternary ammonium group. 
The application of CZE techniques to analyse standard solutions of acylcamitines 
employed free-zone capillary electrophoresis. Solutions of individual acylcarnitines 
and mixtures of several carnitine esters were subject to various CZE conditions. 
Initial investigations were made during 'demonstration sessions' for four 
commercially available instruments. Different sample introduction and detection 
systems were evaluated in their application to acylcarnitine analysis. Experiments 
were also conducted to determine the effect of applied voltage, temperature, pH, 
column diameter and length, and acylcarnitine concentration (Section 6.3.23). An 
acidic pH was favoured in an attempt to protonate the carboxyl group of the 
carnitine backbone, presenting the acylcarnitine as a cationic species. Without 
protonation, carnitine compounds are neutral and therefore would not separate 
under free-zone electrophoresis conditions. Excessive acidification, however, may 
result in acid-catalysed hydrolysis of acylcarnitines, resulting in detection of 
carnitine as the only cationic species. Separation of peptides and amino acids has 
previously been achieved at pH 3-5,176 suggesting this may be an appropriate pH 
range for acylcarnitines, considering the basic similarity between the structures of , 
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carnitine and amino acids. A sodium phosphate/sodium borate buffer system was 
used as the electrolyte and to maintain the acidic conditions. 
The results obtained during initial investigations with free-zone capillary 
electrophoresis were difficult to interpret. When individual acylcarnitine solutions 
were analysed, a peak was usually observed in the resulting electrophoregram if the 
solute concentration of acylcarnitine was in excess of 5 mg ml-1. The migration 
time for the component which gave the UV detector response varied significantly, 
depending on the analysis conditions. Over the experiments performed, however, 
it was confirmed that separation of a mixture of acylcarnitines was not achieved to 
any useful degree. Depending on the CZE operating parameters, the migration time 
for each acylcamitine was very similar. The time taken for the camitine esters to 
elute from a capillary, under acidic conditions, suggested they were acting 
electrophoretically as cations since they migrated faster than the electroosmotic 
velocity, Veo (see Figure 24). Peak shape was generally very poor and could be 
attributed to the high sample loading required for UV detection of the weakly 
chromophoric analytes. Improved peak shapes were obtained with the phenyl- 
containing acylcarntines, when lower solute concentrations were analysed, having 
greater molar absorption coefficients in the UV region. Separation of 3- 
phenylpropanoyl-carnitine and 4-phenylbutanoylcarnitine could be achieved under 
some CZE conditions although the peaks detected were not fully resolved nor of the 
quality expected for CZE. It was concluded from the initial experimental 
investigations made to date that free-zone electrophoresis did not provide the 
separation efficiencies required for acylcamitine analysis. At the concentrations 
required for detection, the mass-to-charge ratios were not sufficiently different to 
result in resolved peaks. Reducing the acylcarnitine quantities introduced into the 
capillary may improve the separation process, however, alternative detection 
systems would be necessary for analysis of the weakly UV absorbing analytes. 
Chemical conversion of acylcarnitines to derivatives amenable to UV and/or 
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fluorescent detection may be effective for subsequent CZE analysis. Chemical' 
derivatization of acylcarnitines has previously been achieved for HPLC 
determinations83-85 and has been outlined in Section 1.2. The introduction of better 
chromophoric groups, compared to the existing carboxyl function, will allow lower 
concentrations of the analyte to be detected. This may avoid the overloading effect 
currently encountered and enable superior peak shapes to be obtained. Then, the 
characteristic high separation efficiency of CZE may be realized. 
Since free-zone capillary electrophoresis was not successful for acylcarnitine 
separation, micellar electroidnetic capillary chromatography (MECC) was 
investigated (Section 6.3.24). The principle was to effect separation by exploiting 
the partitioning of acylcarnitines between the aqueous electrolyte and sodium 
dodecyl sulphate (SDS) micelles. A pH 7 buffer electrolyte was used with the 
acylcarnitines present as zwitterionic, overall neutral, species. This is appropriate 
to MECC where electrophoretic migration applies to the negatively charged micelles 
rather than the analyte molecules themselves. Figure 25 shows an 
electrophoregram from the MECC analysis of a mixture of eleven acylearnitines. 
The peak assignments shown in Figure 25 were based on analysis of individual 
standard acylcarnitines under identical MECC operating conditions. These results 
represent initial investigations although initial variations of the MECC conditions 
(i. e. SDS concentration, temperature and applied voltage) did not improve the 
separations. The electrophoregram in Figure 25 is characterized by poor peak 
shapes for the non-aromatic acylcarnitines (eg. 9.12 and 11.45 min. ), attributed to 
saturation of the available micelles. Lowering the SDS concentration resulted in 
worse peak shapes, but higher concentrations of the micelles did not improve on 
those in Figure 25. Assuming MECC is performed at or above the critical micelle 
concentration (c. m. c. ), the concentration of SDS affects the elution time of the 
carnitine esters. An increase in SDS concentration causes an increase in the 
capacity factor (K) of each solute, since K represents a distribution coefficient 
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between the micelles and the aqueous electrolyte phase (see equation 1). 
Consequently, the higher the SDS concentration, the slower the elution within the 
retention time widow (i. e. between the elution times of non-incorporated 
component and a totally incorporated micellar component). Poor peak shapes may 
occur when high analyte concentrations are present in the capillary, because 
incorporation into the micelles will also be dependent on the concentration of the 
micelles available. This effect will contribute to broadening of peaks such as that 
observed for octanoylcamitine when SDS concentration was reduced. 
The elution order of the acylcarnitine mixture shown in Figure 25 may be 
interpreted in terms of affinity of the solutes for the non-aqueous micelles. 
0 
Octanoylcarnitine has the longest retention time (11.4 min) and this canbe 
explained by the relative hydrophobicity of the alkyl chain of this compound. The 
electrophoregram suggests that the longer the acyl-chain of the carnitine ester, the 
greater is the affinity for the micelle. The remaining peaks in the electrophjr4gram 
correspond to the other aeylcamitines in the mixture and to some unknown 
k1) 
components. For instance, the peak at 3.5$ min was thought to originate from a 
neutral or weakly cationic species since it elutes with or just before water, identified 
by the dip in the baseline. This and some of the other non-assigned peaks in the 
electrophoregram may represent impurities in the acylcarnitine samples. 
The initial experiments conducted into MECC suggest that such CZE techniques 
may be applicable to acylcarnitine analysis given successful development from these 
early investigations. Chemical derivatization of the analytes with strongly 
chromophoric groups (in common with free-zone CZE) is likely to improve the 
peak shapes of the non-aromatic acylcarnitines, since reduced levels may be 
detected, avoiding saturation of the micelles. The use of alternative micelle systems 
also needs to be investigated if optimum separations are to be achieved. 
Appropriate methods should then be applied to spiked urine samples to determine 
what, if any, sample purification is required. 
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The potential of CZE techniques to acylcamitine determinations makes it worth 
pursuing. In comparison to the GC/MS method, CZE offers some relative 
advantages if the techniques can be suitably developed. Determinations in the 
aqueous phase avoids the complications involved in transfer to an organic solvent 
required for GC applications. Sampling directly from the urine matrix, using 
electrokinetie injection may avoid or allow a simpler work-up procedure than that 
currently employed for the derivatization and GC/MS method. CZE techniques 
should also be applicable to acylcarnitines with any functionality in the side chain. 
Problems may be encountered in applying the ion-exchange purification and GC 
analysis procedure (Section 3.2.4) to carnitine esters of dicarboxylic acids. Such 
difficulties are not envisaged for CZE techniques. 
The disadvantages associated with CZE largely arise from the fact that the methods 
are still in the development stages. Commercial instruments have only recently 
become available and it is likely to take some time before CZE is an established 
technique in the clinical laboratory. The lack of structural information on eluting 
components is one which is common to all stand-alone chromatography techniques. 
Development of CZ. /MS is gaining momentum and should prove to be a very 
useful analytical technique for compounds such as acylcarnitines, although it is 
doubtful if this technique will become widely available to hospital laboratories in the 
imminent future. 
In the area of acylcamitine analysis, CZE techniques and their development are seen 
as a viable complement to the proven GC/MS method. The potential of CZE 
remains promising but considerable effort is required to build on the results 
reported here, to produce a method applicable to all physiological acylcarnitines in 
body fluid samples. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
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Throughout the period of this project, interest in the biological role of carnitine has 
maintained a flux of publications from research groups worldwide. The relevance 
to inherited metabolic diseases has continued to be the driving force behind such 
research. Acylcarnitine determinations in biological fluids are still regarded by 
many as important in elucidating the metabolic status and influencing therapeutic 
care. The derivatization method reported here has been shown to be appropriate for 
many such applications. As a result, several established groups involved in 
acylcarnitine determinations have shown an interest in the GC/MS procedure. This 
has resulted in fruitful collaborations from which the initial results are included in 
this thesis. It is hoped and expected that such contacts will continue in this 
developing area of clinical chemistry. 
As a method for identifying common physiological acylearnidnes, the derivatizadon 
and GC1MS method can now be included as an option alongside the other existing 
procedures and techniques (see Section 1.2). For the simplest analysis, the major 
analytical instrument need only be a conventional capillary gas chromatograph with 
flame ionization detection. Such apparatus along with the required reagents, ion- 
exchange resins and standard laboratory equipment allows detection of acylcarnitine 
derivatives from a sample of urine. This basic setup allows separation of a mixture 
of acylcarnitines, including structural isomers; however, identification relies on 
matching peak retention times with those of authentic standards. For unambiguous 
analysis, structural information on the components eluting from the GC column 
may be obtained by interfacing to a mass spectrometer. Several clinical research 
establishments and hospital laboratories have GCI'MS equipment and the 
introduction of affordable bench-top instruments makes the derivatization procedure 
an attractive proposition for simple and rapid determinations of urinary 
acylcarnitines. During this project, a bench-top GC(MS system has been used to 
identify acylcarnitine derivatives, detecting octanoyl-, hexanoyl- and 
phenylpropionylc arnitine in the urine of a patient with MCADD. 108 The availability 
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of an affordable acylcarnitine analysis procedure contrasts with the high expendituie 
and running costs of LC/MS and MS/MS techniques previously required for 
comparable determinations. It is believed that this factor, together with the success 
of the method demonstrated during the project, will lead to continued development 
of the procedure. 
Derivatization of acylcamitine standards in the absence of a biolgical matrix has 
indicated that the optimized conditions give an excellent yield of the butyrolactone 
compounds. Yields above 70% were regarded as acceptable during the 
development stages. Ultimately however, the required sensitivity is dictated by the 
analysis being attempted and this includes extraction efficiency, derivatization yield, 
handling losses and detector sensitivity. Therefore, when deciding if the method is 
sensitive enough for acylcamitine analysis of biological samples the complete 
analytical procedure has to be considered. For the future it is important to address 
those steps in the procedure having the worst effect on recovery (i. e. mitigate 
against low detection limits) and improve them for the good of the whole method. 
Defining the sensitivity required depends on the application intended. Initially it 
was envisaged that the derivatization method would be able to determine the 
characteristic acylcarnitines in the urine of patients with metabolic disorders such as 
MCADD and isovaleric acidemia and this has now been demonstrated to be so. 
However, minor acylcarnitines are now known to be excreted along with the major 
carnitine esters in some disorders (e. g. unsaturated octenoylcarnitine in MCADD). 
Such metabolites are beginning to be detected with the derivatization method and it 
is hoped that improvements will enable routine detection of such compounds, 
important for full elucidation of the metabolic defect. Significant improvements to 
sensitivity may even enable detection of acylcarnitines in the urine of normal infants 
and adults (thought to be excreted at the pmol level). 
The results from the studies conducted so far suggest that improvements to the 
extraction procedure, which may only recover about 30% of each acylcarnitine, 
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would lead to substantially better sensitivity and selectivity. It is likely that 
improved sensitivity will be dependent on greater selectivity towards acylcarnitines 
in biological samples. The results from the experiment described in Section 6.3.18 
(see Section 2.5.3) indicate that the constituents of the biological matrix, which are 
co-extracted with the acylcarnitines, reduce the yield of the derivatization step. 
Therefore an acylcamitine-specific extraction procedure should also lead to an 
improved derivatization step for physiological camitine compounds and hence 
greater sensitivity of the method. In practice, this may not be straightforward since 
the extraction procedure needs to be applicable to a range of acylcarnitines with 
different chemical properties. This problem may be further compounded when 
attempts are made to analyse acylcamitines with additional functional groups such 
as acid functionalities in the side-chain. By nature, the extraction procedure then 
has to cover metabolites with a wide range of polarities and ion-exchange resin 
behaviour. For instance, glutarylcamitine and even long-chain acylcamitines (i. e. 
above C12) are known' to have relatively high affinities for anionic-exchange 
resins, making the existing extraction procedure inappropriate. Further 
investigations of solvent extraction techniques may be required for such 
applications. 
The large amounts of urea known to be extracted with the acylcarnitines using the 
double ion-exchange method may be one of the urinary components influencing the 
derivatization process. This has not been fully evaluated to date although several 
unsuccessful attempts were made to degrade this compound enzymatically prior to 
derivatization (see Section 2.5.3). It is believed that this area is worthy of further 
attention especially since urea interferes with the chromatographic resolution of 
short-chain acylcarnitine derivatives. 
RJ. Morrow and M. E. Rose, unpublished results. 
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Improvements to the speed of analysis and hence sample turnover rate may also be 
envisaged. This aspect is particularly important to the interests of clinical screening 
laboratories where automated or partially automated sample pretreatment and 
analysis are commonplace. The current procedure requires a degree of manual skill 
to achieve optimum results. Sample turnover to an extent, is dependent upon 
freeze-drying facilities, analyst experience, and the performing of several ion- 
exchange procedures simultaneously. Analysing more than five samples per day 
will require alternative sample pretreatment procedures. Initial investigations with a 
one-step, mixed-bed, ion-exchange column have been tried (see Section 2.5.4) and 
further studies with such commercially available units may result in a quicker 
analysis. Ion-exchange membrane units may also be useful and are probably worth 
some initial trials. 
The gas chromatographic equipment and operating conditions have met all the 
requirements to date. Peak shapes for the acylcarnitine derivatives are excellent and 
the resolution of responses for all carnitine esters encountered have aided 
unambiguous assignments. The limit of detection of the GC step has proved 
adequate for trace analysis. Therefore, improvements to the chromatographic step 
are currently not necessary. However, with the technique being applied to an ever 
widening range of carnitine compounds, this may have to be reviewed in the future. 
Identification of the compounds eluting from the GC column will remain to be most 
effectively achieved by mass spectrometry, although rapidly advancing MS 
techniques may also lead to sensitivity improvements. For instance, ion trap 
instruments are gaining popularity due to their associated high sensitivity, 
compatability with gas chromatography, bench-top dimensions and low cost. Such 
an instrument may prove to be well suited to the analysis of derivatized 
acylcatnitines. 
The identification of urinary acylcamitines has been an encouraging success of this 
project and is currently attracting attention from other research groups. However, . 
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an emerging requirement is the availability of quantitative data on the identified 
metabolites. Such information is important to the deduction of clinical status and 
also to investigations of the acylcarnitine excretion process. Studies conducted in 
this project have helped to uncover some interesting variations in acylcarnitine 
excretion over a time period. Whilst these experiments were done on an estimation 
basis only, the findings warrant further exploration with truly quantitative analysis. 
The use of phenylbutanoylcamitine as a spiked internal standard has remained 
consistent throughout the analysis of clinical samples in this project. The aromatic 
acylcamitine fulfilled the basic requirements of an internal standard in that (i) it was 
extracted from the spiked raw urine and derivatized along with the analyte carnitine 
compounds thus allowing comparison of signals and estimation of quantities, (ii) it 
is not a naturally occurring metabolite, (iii) it is available as an easily synthesised 
compound (see Section 2.2), and (iiv) during chromatography its derivative eluted 
in a relatively uncluttered area of the chromatogram, resolved from other peaks but 
without an excessively long retention time. Other internal standards were not 
investigated although alternative non-physiological acylcarnitines such as 
heptanoylcamitine may be equally acceptable. 85 
When developing a quantitative analysis pure standard compounds are best used in 
the calibration process. Calibration mixtures of varying analyte concentrations and 
fixed internal standard concentration are made up and a calibration curve of the ratio 
of peak area versus analyte concentration is then constructed. Obtaining high purity 
standards may require further investigation of the acylcarnitine synthesis 
procedure. 111 Alternative methods of preparation and purification are available110 
and should be considered in attempts to produce the purest standard compounds. 
The other published methods of acylcarnitine preparation are also based on the 
condensation of the relevant acid chloride with carnitine but formation of the acid 
chloride, reaction solvents and work-up procedures vary from the methods of 
Ziegler et al. 111 used in this project to date. Purities in excess of 95% should be the 
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objective of future syntheses for quantitative purposes. Calibration curves should 
cover the concentration range of physiological acylcarnitines expected in the clinical 
samples to be analysed. Also, when using mass spectrometry as the detection 
system, it is generally recognized that selected ion monitoring (SIM) is the most 
effective means of obtaining good quantitative data. 201 As previously described, 
this can also decrease detection limits by a factor of 100-1000 and so this change at 
the mass spectrometric stage is most likely to be the single most efficacious means 
of improving detectability. When combined with an optimized extraction 
procedure, SIM may be applicable to acylcamitine excretion in patients with normal 
P-oxidation metabolism. 
For optimum quantification, the ideal internal standard and the substance to be 
quantified must behave identically during sample pretreatment, derivatization and 
work-up. This would ensure that incomplete extraction and/or derivatization would 
not influence the ratio of peak areas (analyte to internal standard) used in the 
construction of a calibration graph. It has been shown in this project that 
incomplete extraction and derivatization does occur with physiological 
acylcarnidnes and that the degree of incompleteness varies with different carnitine 
esters. Therefore, there lies a flaw in the use of a single acylcarnitine (i. e. 
phenylbutanoylcarnitine) as an internal standard for the quantification of other 
acylcamitincs. Isotopically labelled analogues of the substance(s) to be quantified 
are useful internal standards for mass spectral analyses. Such compounds are 
practically identical in chemical properties whilst being readily distinguished by 
their mass differences. The use of isotopically labelled acylcarnitines as internal 
standards for the quantification of physiological acylcarnitines by FABMS and 
FABMS/MS has been reported97"102 The same or similar approaches may be 
usefully employed with the derivatization and GC/MS technique. However, 
consideration must be given to the difference in ionization modes. For instance, 
under EI conditions it has been shown that the lactone derivatives readily fragment. 
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Selected ion monitoring of a major fragment ion such as that assigned to the 
lactone ring residue (m/Z = 85) should provide a sensitive assay of most 
acylcarnitines. To exploit this sensitivity in a quantitative analysis, the internal 
standard fragment ion must contain the label atom(s) since there will be little or no 
chromatographic separation between analogues. Therefore when using electron 
ionization the internal standard must be isotopically labelled on one of the carnitine 
backbone atoms, with the exception of the nitrogen atom or any carbon atom of the 
quaternary ammonium group since this is eliminated during the derivatization. 
If CI conditions are to be employed then the same internal standards as with EI may 
be used or alternatively, 13C, 180 and/or 2H labelling may be incorporated in the 
side-chain. The wider range of labelling sites with CI arises because this mild form 
of ionization results in minimum fragmentation and therefore SIM may be 
performed on the intact ion of each derivative (i. e. [M + H]+ ion). The potential 
disadvantage of using CI with SIM is that there is no fragment common to the 
majority of the acylcarnitine derivatives, unlike the situation with GC/EIMS. 
Therefore, the analyst may need to perform a full-scan investigation of the sample 
prior to SIM quantification in order to identify the acylcarnitines present and thus 
select the ion or ions to be monitored. Unlike the single ion monitoring possible by 
GCIEIMS, the sensitivity would be reduced by the need to focus on all [M + H]+ 
ions of derivatives known, or expected, to be present. 
The objective of an accurate quantitative assay in future developments of the 
derivatization method should not detract from the validity and importance of the 
quantitative results achieved so far. The trend in acylcarnitine excretion levels over 
the postpartum period of an MCADD patient demonstrated that the GCIMS method 
and an FABMS/MS investigation of the same samples yielded comparable results. 
Both techniques confirmed the original hypothesis based on urinary organic acid 
profiling. Such a discovery, if it is shown to be common to other infants with 
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MCADD will have important implications for future screening programmes and 
therapeutic treatment. Whilst there are difficulties in arranging time-course studies 
of body fluids for new-born babies in a hospital environment, the potential 
treatment and preventative care advances which may be derived should encourage 
such investigations. This may even be extended to other metabolic diseases since 
the results obtained in this project indicate that urinary concentrations of 
acylcarnitines are variable for patients with any of the recognized disorders. The 
general observation of higher acylcamitine levels being detected in basal condition 
urines as compared to those collected during or shortly after crisis needs to be 
addressed. Controlled studies (or as near as possible to controlled studies) should 
be performed whereby accurate and detailed sample inforrnation is available, so 
vital for correct interpretation of the analytical results. This will demand close and 
clear liaison between the analyst, clinician and any other persons involved with 
sample collection, storage, work-up and analysis. 
The derivatization and GGMS'technique has been shown to be effective in 
detecting the diagnostic acylcarnitine metabolites of MCADD, isovaleric acidemia 
and propionic acidemia. It is hoped that the method will also be successfully 
applied to some other 0-oxidation disorders which result in acylcarnitine excretion. 
Included in these diseases are those which gave negative results during the initial 
investigations conducted in this project. The analysis of two urine samples from a 
patient with methylnmalonic aciduria may have been expected to detect 
propionylcarnitine as observed by Roe et a1.138 The predicted metabolite was not 
observed and without detailed information on the sample it is only possible to 
speculate on the reason(s) for its absence or reason for going undetected (see 
Section 3.2.4). Further studies on urine from patients with methylmalonic aciduria 
are required before conclusions can be drawn on the suitability of the method to 
such samples. Another disease which is likely to yield urinary acylcarnitines, 
directly amenable to the existing derivatization method is ß-ketothiolase deficiency. 
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As the name suggests this disorder results in an insufficiency of a mitochondrial 
enzyme required for the ß-oxidation process (see Scheme 3). The disorder may 
result in the urinary excretion of tiglylcarnitine (2, R= C(CH3)=CHCH3) as 
observed by Millington et a1.102, I03 Despite the unsaturated function in the side 
chain of this acylcarnitine metabolite, the existing extraction and derivatization 
procedures should be amenable to such a compound. As with the cases of 
methylmalonic aciduria, further analysis of samples from patients with diagnosed 
f3-ketothiolase deficiency are recommended. 
Recently, an interest has developed in the metabolic role of some acylcarnitines 
which may not be directly amenable to the existing GCIMS method. Long-chain 
aeyl-CoA dehydrogenase deficiency (LCADD) is a disease analogous to MCADD 
with a metabolic block to 13-oxidation resulting in formation and excretion of long- 
chain acylcarnitines (C12-C20) rather than the medium-chain length acylcarnitines 
associated with MCADD. The cyclization of long-chain carnitine esters is not 
expected to cause difficulties, especially since palmitoylcarnitine (i. e. C16 acyl chain 
length has been shown to be amenable to the technique during the development 
stages of this project (see Chapter 2). 108 However the extraction of such long acyl- 
chain compounds from biological material may require a review of the existing ion- 
exchange procedure. Poor recoveries are expected from the resins and this . may 
necessitate the use of alternative pretreatment techniques. Solvent extraction 
methods have been reported for recovering carnitine esters from biological material 
including urine. Simple investigations may present a suitable solvent extraction 
procedure for long-chain acylcarnitines. 202 
In some recognized disorders, carnitine is known to conjugate with dicarboxylic 
acids. Conjugation by ester bond formation with one of the acid carboxyl groups 
leaves one free carboxyl group terminating the acyl chain of the carnitine ester. 
Glutaryl- (2, R= (CH2)3COOH), adipyl- (2, R= (CH2)4COOH), suberyl- (2, R 
(CH2)6COOH) and sebacylcarnitine (2, R= (CH2)gCOOH) are examples of 
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dicarboxylic acid acylcarnitines positively identified in metabolic profiles of urine 
from infants with perturbed fatty acid catabolism. 102 For instance, the disorder, 
glutaric aciduria type 1, is known to be accompanied by the urinary excretion of 
glutarylcarnitine. HPLC86 and FABMS/MS102 techniques have been applied to 
such samples, together with their associated disadvantages (see Section 1.2 ). It is 
intended to develop the existing derivatization technique to be amenable to such 
metabolites. However, in order to attain this objective, several potential problems 
in applying the analysis procedure to carnitine esters containing a carboxyl function 
in the side-chain need to be evaluated and, if necessary, modifications implemented 
so that the advantage of the GC/MS technique are maintained. The first 
consideration involves the appropriateness, or otherwise, of the extraction 
procedure. A second free carboxyl group in the acylcarnitine molecule is likely to 
markedly affect the affinity for the ion-exchange resins currently employed. An 
alternative elution procedure may be required. Once the analyte molecules have 
been shown to be effectively extracted, then the consequences of the side-chain 
carboxyl function on the cyclization process should be determined. As already 
mentioned (Section 3.2.4), the favourable formation of a five-membered ring by the 
action of the carnitine carboxyl group is likely to result in the required butyrolactone 
derivative rather than a product of an intramolecular reaction involving the side- 
chain carboxyl. Any such reaction leads to formation of a larger ring which is 
kinetically less favoured. Assuming that extraction and derivatization can be 
suitably achieved, there may remain a problem concerning the gas chromatographic 
properties of an analyte containing an organic acid function. A further, simple 
derivatization step such as trimethylsilylation (TMS) may be necessary to produce a 
volatile derivative of the original dicarboxylate ester of carnitine which is amenable 
to GC and GCIMS. 
Once the method is shown to be compatible with physiologically occurring 
acylcarnitines, the analyst will have a powerful tool for investigating defective 
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metabolisms presented by the recognized diseases of fatty acid catabolism and also 
uncharacterized ones such as Reyes Syndrome. Reyes-like symptoms have been 
reported previously 12943 without sufficient analytical information (largely due to 
the lack of a convenient analysis) to characterize conclusively the exact nature of the 
metabolic disorder. It is predicted that the derivatization method reported here, 
together with some "fine tuning" of the technique will be ideally suited to such 
studies, studies which may be conducted in many modern clinical laboratories. 
In addition to the identification of acylcarnitines produced from the metabolism of 
dietary fatty acids and amino acids, results from the initial investigations of some 
exogenous compounds have also proved interesting (see Section 3.3). The 
excretion of urinary phenylpropionyl-carnitine from MCADD patients has 
subsequently been confirmed by others, but it was the present derivatization and 
GC/MS technique which first positively identified the metabolite, originating from 
the administration of phenylpropionic acid (PPA). Considering the metabolism of 
fatty acids in patients with MCADD, the occurrence of phenylpropionylcarnitine is 
easily understood and may even have been expected. It is interesting to note, 
however, that this metabolite was not always present in the urine of MCADD 
patients even when a PPA load had been administered shortly before urine 
collection. Controlled time-course studies combined with analysis by the GC/MS 
method may give further indications as to how the excretion of 
phenylpropionylcarnitine varies. However, interpretation of the results must also 
take into account the PPA produced, naturally and independently of any exogenous 
administration, in the gut. 
The results of analysing the urine of patients receiving valproic acid treatment were 
less easy to explain. It is postulated that some patients being administered this 
anticonvulsant drug excrete acylcarnitines previously unreported. Analogous to the 
metabolism of PPA, valproylcarnitine may have been predicted as an excreted 
substance when a defective ß-oxidation condition was present. Indeed, Millington 
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et al. 105 have observed this metabolite using FABMS and thermospray LC/MS. 
Investigations in this project, using the derivatization method, also detected a 
component extracted from an appropriate urine sample which had acylcarnitine 
GGMS characteristics and a GC elution time identical to synthesised 
valproylcarnitine. However, the analysis also indicated a larger concentration of 
another acylcamitine derivative. The EI mass spectrum could not be assigned to 
any of the conventional acylcarnitines previously encountered. On the basis of the 
mass spectrum, it was postulated that the metabolite detected was 3- 
oxovalproylcarnitine. This assignment is supported by an earlier study of valproic 
acid metabolism in man which found 3-oxovalproic acid to be the major 
metabolite. 160 Confirmation of the GC/MS identification is required and, whilst 
chemical ionization studies may give further support to the assignment, 
unambiguous identification demands synthesis of the expected acylcarnidne. 
Synthesis of 3-oxovalproylcarnitine may not be as simple as previously 
encountered with the preparation of other acylcarnitines. A potential problem rests 
with the free acid, 2-propyl-3-oxovalerie acid, which is a j3-keto-acid, known for 
readily undergoing decarboxylation under heat. To minimise this reaction, very 
mild conditions will be needed for the formation of the required acid chloride (i. e. 
2-propyl-3-oxovaleryl chloride) and for the condensation of this species with 
carnitine. Here, the alternative methods of acylcarnitine preparation which do not 
require a heating process may be employed to good advantage. If this is 
unsuccessful, then a transesterification reaction may be appropriate (possibly using 
the ethyl ester of 2-propyl-3-oxovaleric acid) or a synthesis involving protection 
and deprotection of the ketone functionality. Whilst the synthesis may require 
considerable experimental investigation, it is currently regarded as important for the 
confirmation of the valproic acid metabolite. It would also be interesting to 
determine if other techniques such as FAB MS/MS can produce complementary 
results. The consequences of a positive identification of acylcarnitine metabolites in 
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patients with normal fatty acid catabolism may prove very important for complete 
elucidation of the metabolism of other exogenous compounds. For example, the 
breakdown of pivampicillin is thought to include acylcamitines154 and it proposed 
to confirm this and investigate other drugs which involve acidic metabolites, such 
as cannabis components. 
To date, the analysis of physiological acylcarnitines has only concerned those 
occurring in urine. Carnitine and its esters have also been found to accumulate in 
other body fluids and tissue including, plasma, muscle liver102 and vitreous 
humour. 136 It is intended to apply the GC(MS method to these other biological 
matrices. Initially this is expected to involve the analysis of samples spiked with 
known acylcarnitine quantities, as was the case with the urine samples. Successful 
developments would be followed by analysis of previously characterized samples, 
to verify the method prior to the application to uncharacterized body fluids or tissue. 
The analysis of biological material other than urine is likely to require modifications 
of the method in terms of the sample pretreatment. The partial purification of the 
various biological matrices may employ the existing methods of others for 
FABMS/MS analyses, relying on solvent extraction, ion exchange and/or reverse- 
phase C18 cartridges. 
Further studies regarding the GGMS detection of urinary components assigned to 
cyclic dipeptides also demands attention. The relevance of such compounds in the 
urine of infants is uncertain and they may be the products of a normal metabolism. 
Confirmation of the presence of cyclic proline-isoleucine and alanyl-leucine or 
alanyl-isoleucine shall require the synthesis of standards to compare the analytical 
data with that from the biological sample assignments. If the presence of dipeptides 
is verified then efforts are recommended to identify their origin and deduce their 
relevance on the metabolism. Such studies may be well suited to alternative 
techniques including capillary zone electrophoresis (CZE). 
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The use of CZE and the closely associated micellar electroldnetic capillary 
chromatography (MECC) is still regarded as a promising approach to analysing 
acylcarnitines in complex mixtures. The separation of a mixture of quaternary 
ammonium salts, 203 and the applications to peptidic material176 support this view. 
Initial investigations conducted in this project gave a good insight into the effects of 
varying the operational parameters. Acceptable separation and sensitivity was not 
achieved, however. This was attributed to the UV detector employed and the 
instrumental restraints imposed by the effective small UV cell volume. That is, to 
maintain separation efficiency the UV cell is simply a small portion of the silica 
capillary stripped of its polyimide coating. Acylcarnitines, having no strong 
chromophoric function are inherently insensitive to such a detection system. 
Consequently concentrations of carnitine compounds which can be detected tended 
to substantially overload the separation process. It is proposed that conversion to 
p-bromophenacylester derivatives, already employed for HPLC determinations, 83- 
85 will enable detection of the low acylcarnitine quantities necessary for effective 
CZE separations. Similarly, attempts to separate a mixture of eleven acylcarnitines 
by MECC using SDS micelles suffered from overloading effects. Again 
derivatization may facilitate improvements to such analyses. 
The potential advantages of capillary electrophoresis techniques warrant the 
continued development of a method for acylcarnitine analysis. Minimum sample 
pretreatment, Universal application to carnitinc esters (including those with side 
chain carboxyl functionalities), high efficiency separations and the ability to 
interface to a mass spectrometer are all expected to influence further developments. 
There is also the possibility of detecting compounds other than acylcarnitines. An 
interest in urinary dipeptides has previously been highlighted. The analysis of 
peptides using CZE techniques is widely reported by others and their findings 
should be of direct relevance to the study of any urinary dipeptides excreted by 
infants. In addition, urinary components purposely removed during the GGMS 
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sample pretreatment stages may be viable analytes for analysis along with the 
acylcarnitines. For example, successful developments with CZE techniques may 
allow the simultaneous analysis of acylcarnitines, organic acids and glycine 
conjugates all diagnostic metabolites of f3-oxidation disorders. Application to such 
a wide range of urinary components is not currently envisaged for the GC/MS 
method since the results indicate that specificity in extraction of the acylcarnitines is 
important for successful evaluations. A simple technique which could handle a 
wide range of compounds, as is theoretically possible with CZE, would be 
extremely useful for the metabolism studies discussed in this project. 
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CHAPTER 6 
EXPERIMENTAL 
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6.1 INSTRUMENTS 
Melting points were taken on a digital melting point apparatus, Electrothermal 
Engineering Limited. 
Infrared spectra were recorded on a Perkin Elmer 1310 IR Spectrophotometer. 
Samples were prepared as thin films or KBr discs. 
Nuclear magnetic resonance (NMR) spectra, 1H and 13C, were recorded on a Jeol 
FX 90 Q Fourier Transform NMR Spectrometer (90 MHz) by courtesy of Mr. G. 
Howell, (Open University, Milton Keynes). All 13C NMR spectra reported are 
noise-decoupled. 
Split and splitless injection, capillary gas-liquid chromatography (GC) with flame 
ionization detection (FID) was performed on a Perkin Elmer 8410 gas 
chromatograph. On-column injection, capillary GC was performed on a Carlo Erba 
Strumentazione, Series 4160 instrument, or a Carlo Erba Strumentazione HRGC 
5300 Mega Series Capillary Column GC, equipped with a MFC 500 programmable 
control unit and a FID 40 detector. All GC analyses employed 12 or 25 m SGE 
fused-silica, capillary GC columns with internal diameter 0.32 mm and film 
thickness 0.5 pm. Further details of operating conditions are reported in the 
corresponding sections (i. e. Sections 6.3.11 and 6.3.12). 
A VG 305 single-focussing mass spectrometer coupled to a VG DS 2050 data 
system, was used for one study (sec Section 6.3.7). 
Xenon FAB mass spectra were recorded on a VG 20-250 single quadrupole 
system, equipped with an IonTech saddle-type FAB gun operated at 7-8 KeV with 
a tube current of about I mA and controlled from a PDP-I 1 data operating system. 
Three instruments were used for GC/MS (i) A VG 20-250 quadrupole system 
coupled to a Hewlett-Packard Model 5890 gas chromatograph and controlled from a 
PDP-11 data operating system. An SGE GCI-3 on column injector was fitted to 
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the gas chromatograph to complement the existing split/splitless injection facility. 
(ii) A Finnigan-MAT INCOS 50 bench-top quadrupole instrument coupled to a 
Varian Model 3400 gas chromatograph equipped with a 25 m fused-silica SE54 
column and a splitless injector. (iii) A Hewlett Packard 5971A Mass Selective 
Detector bench-top quadrupole system employing split-splitless injection. Unless 
stated, all GC/MS analyses used SGE fused-silica columns as for the GC 
applications. With all instruments electron ionization (EI) was employed, with an 
electron energy of 70eV and an ion current of 100 µA. Investigations using 
chemical ionization (CI) were also effected with the HP 5971A MSD instrument, 
using methane as the Cl gas and the VG20-250 using ammonia. 
Studies requiring an ultrasound source (Section 6.3.8) employed an MSE Soniprep 
150 Ultrasonic Disintegrator equipped with a 9.5 mm diameter probe. 
Capillary zone electrophoreses (CZE) and micellar electrokinetic capillary 
chromatography (MECC) were performed with a Beckman P/ACE System 2000 
connected to an IBM PS/2 computer with windows-based control software. 
6.2 MATERIALS AND REAGENTS 
DL- Carnitine hydrochloride, thionyl chloride (gold label), acetyl chloride, hexanoic 
acid, palmitic acid, 3-phenylpropionic acid, 4-phenylbutanoic acid, triethylamine 
and NN-diisopropylethylamine were obtained from Aldrich and used without 
further treatment. Trichloroacetic acid (gold label) was also obtained from Aldrich 
but was recrystallized from ethanol-free chloroform before use. Malic acid, ethyl 
acetate (pistol grade) and acetonitrile (Distol grade) were obtained from Fisons; dry 
DMF, THF, other solvents and octanoic acid from BDH; and acetyl-, octanoyl-, 
and palmitoyl-DL-carnitine hydrochloride, and urease tablets from Sigma. Samples 
of propionyl-, 2-methylbutyryl-, isovaleryl-, valeryl-, heptanoyl- and valproyl-DL- 
carnitine hydrochloride were provided as a gift from the laboratory of Dr. G. A. 
Mills, Southampton General Hospital. " 
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Other standard chemicals and reagents used in this project were general laboratory 
reagent grade samples obtained from Aldrich or BDH. 
Reacti-Vials (1 ml volume) were obtained from Pierce; analytical-grade ion- 
exchange resins from Bio-Rad; and Gelman Acro LC13 0.45 µm filter units from 
biilliporc. 
6.3 EXPERIMENTAL PROCEDURES 
6.3.1 Synthesis of Acctylcarnicinc (2, R. = CH3) 
A mixture of acetic acid (10 ml) and acetyl chloride (0.8 g; 0.01 mole) was stirred 
for 2hr at 80 °C. DL-Carnitine hydrochloride (1 g, 0.005 mol) was added and the 
solution stirred at the same temperature fora further 2 hr. Excess acetic acid and 
acetyl chloride were removed by evaporation at low pressure. The residual orange 
oil was dissolved in hot propan-2-ol (5 ml) and the resulting solution was filtered to 
remove traces of unreacted carnitine. Acetone (20 ml) was added to the filtrate and 
the product allowed to crystallize from the solution overnight. The fine white 
crystals were filtered, washed with acetone and dried in an oven at 70 °C. A yield 
of 0.91 g (76%) was obtained, mp 208 °C (lit., tt1210 °C). 
IR: wavenumber 3300-2400 (acid O-H stretch), 1735 (ester C=0 stretch), 1710 
(acid C=O stretch), 1240 cm'1(O-C stretch). 
1H NMR ([2H6]-dimcthyl sulphoxide, 90 MHz): 8 2.0 (s, 3H, H3CCOO), 2.7 (d, 
2H, CH2000H), 3.1 [s, 9H, (CH3)3], 3.8 (d. 2H, NCH2), 5.4 ppm (m, 1H, 
cHOCO). 
FABMS +ve ion, glycerol matrix: m/: 204 ([M + H]+, 100%). FABMS -ve ion, 
glycerol matrix: m/ 238 QM + C11-, 18%). 
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632 Synthesis of Hezanoylcarnirinc (2, R= (CH2)4CH3) 
A mixture of hexanoic acid (5 ml) and freshly distilled thionyl chloride (1 g; 8.3 
mmol) was stirred for 3 hr at 80 °G DL-Carnidne hydrochloride (I g; 0.005 mole) 
was added and the solution stirred at the same temperature for a further 2 hr. After 
cooling, diethyl ether (50 ml) was added dropwise. Once the precipitate had fully 
formed, it was filtered, washed with diethyl ether and redissolved in hot propan-2- 
ol (10m1). Dry acetone (40 ml) was added to the propan-2-ol solution to precipitate 
unreacted camitine hydrochloride. After 3 hr, the slight precipitate which formed 
was filtered. Dry diethyl ether (100 ml, Na dried) was added to the filtrate and the 
product was allowed to precipitate overnight. The white precipitate was filtered, 
washed with diethyl ether and dried. A yield of 0.65 g (42%) was obtained, mp 
165 °C (lila 11160 °C). 
IR: wavenumber 3300-2500 (acid O-H stretch), 1730-1710 broad (ester C=O 
stretch, acid C-0 stretch), 1200 cm'1 (O-C stretch). 
1H NMR ([2H6J-dimethyl sulphoxide, 90 MHz): 8 0.9 (t, 3H, Chf3CH2), 1.1-1.7 
(m, 6H. CH3CH2CH2CK2)" 2.3(t, 2H. CH2CHi000), 2.7 (d, 2H, CH2COOH), 
3.1 Is, 9H, (CH3)31,3.8 (d, 2H, NCH2) 5.4 ppm (m, 1H, CHOCO). 
13C NMR ([2H4]-dimcthyl"sulphoxidc, 90 MHz): 813 (CH3CH2), 22 (CH3CH2), 
24 (CH3CHzCH2), 30 (CH2CH2000), 33 (CHZCH2000), 42 (CH2000H), 53 
(N(CH3)31.65 (CH2-NMc3), 67 (CHOCO), 170 (COOCH). 172 ppm (COOH). 
FABMS +vc ion, glycerol matrix: m/= 260 ([M + Hj+, 100%). FABMS -ve ion, 
glycerol matrix: J"/= 294 ((M + C11'. 100%). 
6.33. Synthesis of Ocwnoyl (2, R= (CH2)6CH3), 3-Phenylpropionyl 
(2, R= Cl12CH2Ph), 4"Phcnylburanoyl (2, R= CH2CH2CH2Ph) and 
Pabnitoylcarnüine (2, R- (CH2)14CH3)- 
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A mixture of the relevant organic acid (5 ml) and freshly distilled thionylchloride 
(0.6 g; 0.005 mol) was stirred for 3hr at 80 °C. DL-Carnitine hydrochloride (0.5 g; 
2.5 mmol) was dissolved in trichloroacetic acid (2.5 g) at 60 °C and added to the 
reaction mixture. The solution was stirred at 80 °C for 3.5 hr. After cooling, dry 
diethyl ether (100 nil, Na dried) was added, dropwise until precipitation began. 
After precipitation was complete, the white precipitate was filtered, washed with 
diethyl ether and redissolved in hot propan-2-ol (10 ml). This solution was filtered 
and dry diethyl ether (50 ml) added to the filtrate. The product was allowed to 
precipitate overnight, then filtered, washed with ether and dried. 
Octanoylgrnidne: A yield of 0.48 g (59%) was obtained mp 158 °C (lit. 111 160 °C). 
IR waventunber, 3300-2500 (acid O-H stretch), 1735 (ester C=0 stretch), 1715 
(acid C=O suetch), I I80 rnrl (0-C stretch). 
1H NMR ([2H6]-dimcthyl suiphoxidc, 90 MHz): S 0.9 (t, 3H, CH3CH2), 
1.1-1.7 (m, 10H, CH3. CH2CH2CH2CH2CH2), 2.3 (t, 2H, CH2000), 2.7 (d, 
2H, CH2000H), 3.1 Is, 9H, (C 3b], 3.8 (d, 2H, NCH2), 5.4 ppm (m, IH, 
CHOCO). 
13C NMR ([2H6]-dimethyl sulphoxide, 90 MHz): 5 14 (CH3CH2), 23-35 (five 
signals assigned to side chain methylene groups), 43 (CH2COOH), 53 [N(CH3)31, 
65 (CH2NMe3), 67 (C IOCO), 170 (COOCH), 172 ppm (COOH). 
FABMS +ve ion, glycerol: ml: 288 ([M + H]+, 100%). FABMS -ve ion, glycerol 
matrix: m/s 322 ([M + Cl]'. 28%), 143 ((CH3(CH2)6000]-, 100%). 
3-PhenylpropionyIcamitine: A yield of 0.23 g (28%) was obtained; mp 162 °C. 
IR: wavenumber, 3300- 2500 (acid O-H stretch), 1710-1730 (ester C=O stretch, 
WW 
C=o stretch), 1190 cm"l (O -C stretch). 
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IH NMR ([2H6]-dimethyl sulphoxide, 90 MHz): S 2.6-2.9 (m, CH2COOH, 
CH2CH2Ph), 3.1 [ss, (CH3)3 acylcarnitine, (CH3)3 isopropyl esterfied 
acyleamitine], 3.7 (d, NCH2), 4.2 (m, (CH3)2CHOC, isopropyl esterified 
acylearnitine), 5.5 (m, CH2CHOCO) and 7.2 ppm (s, Ph). 
13CNMR ([2H6]-dimethyl sulphoxide, 90 MHz): 830 (CH2Ph), 35 (CHZCOO), 
43 (CH2000H), 53 [N(CH3)3], 65 (CH2-NMe3), 67 (CHOCO), 125 (Ph, C-4), 
128 (Ph, C-2 + C-3), 140 (Ph, C-I), 170 (COOCH), 172 ppm (COON). 
FABMS +ve ion, glycerol matrix: m/= 294 ([M + H]+, 100%, acylcarnitine), 336 
([M +Hj*, 53%, esterified acylcamitine). FABMS -ve ion, glycerol matrix: m/2 
328 ([M + CI]-, 40%), 149 ([PhCH2CH2000]', 100%). 
4-Phenylbutanoylcarnitine: A yield of 0.49 g (57%) was obtained, mp 156 °C. 
IR: wavcnumbcr, 3700-2500 (acid O-H stretch), 1740 (ester C=0 stretch), 1720 
(acid C=O stretch), 1180 cm"I (O-C stretch). 
IH NMR ([2H6]-dimethyl sulphoxide, 90 MHz) :81.7-2.0 (m, 2H, 
CH2CH2CH2), 2.2.2.8 (m, 6H, PhCH2, CH2COO, CH2COOH), 31.1 [s, 9H, 
(CH3)3J, 3.8 (d, 2H, NCH2), 5.4 (m, 1H, CHOCO), 7.2 ppm (s, 5H, Ph). 
13C NMR ([2H61-dimethyl suiphoxide, 90 MHz): 5 26 (CH2CH2CH2), 33 
. 
(CH2Ph), 34 (CH2000), 43 (CH2000H), 53 (N(CH3)3], 65 (CH2NMe3), 67 
(CHOCO), 126 (Ph, C-4), 129 (Ph, C-2 + C-3), 141 (Ph, C-I), 170 (COOR), 172 
PPm iCOOH) 
FAB +vc ion, glycerol matrix: mlz 308 ([M + H]+, 100%). FAB -ve ion, glycerol 
matrix: ml: 342 (IM + Cl], "100%). 
Palmitoylcarnitine: A yield of 0.9 g (81%) was obtained, mp 154 °C (commercial 
sample, 157 °C; lit., 111 161 *C). 
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IR: wavenumber, 3500-2500 (acid O-H stretch), 1735 (ester C=O stretch), 1710 
(acid C=O stretch), 1180 cm-1 (O-C stretch). 
1H NMR ([H61-dimethyl sulphoxide, 60 MHz) 8: 0.8 - 1.3 [m, 29H, 
CH3(CH2)131 2.8 (d, 2H, CH2COOH), 3.1 [s, 9H, (CH3)31,3.8 (m, 2H, NCH2) 
and 5.4 ppm (m, 1H, CHOCO). 
FAB +ve ion, glycerol matrix: m// 400 QM + HJ+, 100%). FAB -ve ion, glycerol 
matrix: m/= 434 ([M + CI]-, 21%1,255 ([CH3(CH2)14CO0]-, 100%). 
6.3.4 Fast Atom Bombardment Analysis of Standard and Synthesized 
Acylcarnitines 
FAB mass spectra were recorded for all synthesised acylcarnitines and those 
presented as a gift from Dr. G. A. Mills. 
A beam of fast Xe atoms was directed onto a FAB probe coated with a glycerol 
solution of the acylcarnitine to be analysed in the ion source of a single quadrupole 
mass spectrometer. Typically, around 0.1 mg of sample was dissolved in 
approximately 10 pl of glycerol on the gold plated probe target area. The FAB gun 
was operated with a Xe translational energy of 8 kV and 1 mA beam current. Data 
aquisition was activated immediately on sample introduction into the source and full 
scan spectra over the mass range 50-450 (1 s scan, 0.1 s interscan time) were 
collected over 30 s. 
6.3.5 Synthesis of ß-Hydroxy-y-lactone (4) 
The preparation of P-hydroxy-'-lactone was carried out using a modification of the 
method of Henrot et at. 113 
a) Preparation of Cyclic Anhydride (7) : Scheme 20 
DL-Malic acid (6.7 g, 50 mmol) was dissolved in acetyl chloride (60 ml) and the 
solution stirred at 40 °C overnight. The reaction mixture was filtered and the orange 
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filtrate concentrated under reduced pressure. A crystalline material was obtained 
which was washed with ethanol-free chloroform The off-white crystals were 
filtered, recrystallized from chloroform, washed with dry diethyl ether and dried. A 
yield of 6.9 g (81%) was obtained, mp 82 °C. 1H NMR (CDC13,90 MHz): 6 2.2 
(s, 3H, C113000), 3.0 (dd, IH, H-2a), 3.4 (dd, 1H, H-2b), 5.5 ppm (dd, IH, H- 
3). 
HO2C 1*"4y 
CO2H 
OH 
8 
AcCI 
IN- 
40°C / 16hr 
Scheme 20 
b) Conversion to Diurer-acid Compound (6): Scheme 21 
7 
Cyclic anhydride (7) (6.32 g. 40 cnmol) was stirred with methanol (80 ml) 
overnight at room temperature. The solvent was evaporated under reduced pressure 
to leave a viscous oil. A yield of 5S2 g (809o') was obtained. 1H NMR (CDC13, 
90MHz): 62.1 (s, 3H, CH3000), 2.9 (d. 2H. Ha+b), 3.7 (s, 3H, CH3000), 5.4- 
(t, 1H. He). 9.3 ppm (s. 1H. COOH). 
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O 0 
7 
iMeOH 
Scheme 21 
c) Reduction of (6) to ß-Hydroxyjrtacrone (4): Scheme 22 
6 
Sodium borohydride (4.7g. 0.12 mol) was added to freshly distilled'BuOH (70 
ml) and the mixture heated to reflux. Compound (6) (5.9g, 31 mmol) was 
dissolved in tBuOH (25m1) and McOH (5m1). The solution of (6) was added very 
slowly to the refluxing NaBH4 solution over a period of 1.5 hr. Reflux conditions 
wert maintained for 20 hr. The reaction was quenched by the dropwise addition of 
a solution of acetyl chloride (11 ml) in MeOH (75 ml). Solvents were removed by 
heating under reduced pressure. The product was extracted with EtOAc (100 ml) 
and the salts removed by filtration. The filtrate was neutralized with solid Na2CO3, 
filtered and concentrated under reduced pressure to give a yellow oil. After 
chromatographic purification on silica gel (EtOAc : Hexane, 4: 1), 1.04 g (33%) 
was obtained. 
IR Wavcnumbcr. 3700-3100 (alcohol O-H strctch), 2990,2970,2960 (C-H 
stretch), 1770 (I=one C=O stretch), 1130 cm"t (0"C stretch). 
1H NMR (CDC13,90 MHz): 5 2.3-3.0 (m, 2H, H-2A), 3.9 (d, 1H, OH), 4.2-4.5 
(rn. ZH, H-4alb), 4.7 ppm (m, 1H, H-3). 
H, : Hb 
>CO2Me 
H02C ., 'Hc 
OAc 
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-*ýy HOzC 
CO2Mc 
OAc 
NaBH4 
20hr rtflux 
Scheme 22 
HO 11-3 H_2a 
'H-2b 
H-da 
° H-4D*' ý0 
6.3.6 Synthesis of Acylazy-y buryrolactone Compounds (3): Scheme 12 
Acetyl-, octanoyl-, 4-phenylbutanoyl- and palmitoyl-containing acyloxylactone 
compounds (3) were all prepared from the condensation reaction of P-hydroxy-y- 
butyrolactone (4) with the respective acid chloride. The following method was 
used to prepare octanoyl-containing lactone [3, R= (CH2)6CH3] and similarly the 
other standard lactone compounds were synthesised. 
ß-Hydroxy-y-butyrolactone (4) (03 g, 4.9 mmol) was dissolved in dry 
tetrahydrofuran M IF (10 ml) and added dropwise to a solution of octanoyl 
chloride (136 ml in 10 ml of THF) at 
0 °C. After warming to reflux, the reaction was allowed to proceed for 24 hr. The 
solvent was removed and the product purified by chromatography on silica gel 
(EtOAc : hexane, 1: 1). Traces of octanoic acid were removed by washing a 
solution of the product in diethyl ether with three equal volumes of a saturated 
solution of NaHCO3. The diethyl ether was dried and removed to leave a clear oil 
(0.78 g, 70% yield). 
Sarisfacwry analytical data wam obtained for all four lactones prepared by use of 
IR, 1H and 13C NMR and EI mass spectra. 
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Acetyloary-y-butyrolactone (3, R= CH3), 53% yield. IR wavenumber, 3000-2860 
(C-H stretch), 1790 (tactone C=O stretch). 1740 cm-1 (ester C=O stretch). 
1H NMR (CDCI3,90 MHz) :82.1 (s, 3H, CH3), 2.5-3.0 (m, 2H, CH2CO), 4.4 
(m, 21. CH2000) and 5.5 ppm (m, 1H, CHOCO). 
ELMS: r"!: 144 (Nt+', 1%). 84 (C4H402*', 100%) 
Octanoyloxy)Lburyrolactone (3, R= (CH)CH3j, 70% yield. 
IR: wavcnumbcr. 2980.2860 (C-H stretch), 1790 (lactone C=O stretch), 1740 cm- 
I (ester C=O stretch). 
1HNMR (CDC13,90MHZ): 6 0.8-1.7 [m, 13H, (CHijCH3], 2.3 (t, 2H, side- 
chain CH2CO), 2.5-3.0 (m. 2H, ring CH2CO), 4.4 (m, 2H, CH2000), 5.5 ppm 
(m, IH. CHOCO). 
13C NMR (CDC13.90 MHz): 8 14 (CH3), 23 (C ii), 25 (CH2), 28 (CH2), 29 
(CH2). 32 (cu2). 34 (CH2CO). 35 (CH2CO), 69 (CH2000), 74 (CHOCO), 173 
(ester CzO), 174 ppm (tactone C=O). 
ELMS: J"/: 228 (? tN. 2%). 85 (C4H5O2+. 100%) 
4"Phurylbutanoylazy-Lbutyrolactvne (3, R= CH2CH2CH2Ph), 44% yield. 
M* wavcncmbcr, 3060-3020 (aromatic C=O stretch), 3000-2850 (aliphatic C-H 
stretch), 1795 (lactonc C'Ostretch), 1740 cm's (ester C=O stretch). 
1H NMR (CDC13.90 MHz): 8 1.8-3.0 [m, 8H. (CH2)3 and ring CHZCO), 4.3 (m, 
2H, CHZOCO), 5.4 (m, IH, CHOCO), 7.2 ppm (m, 5H, Ph). 
13C NMR (CDQ3.90 MHz): S 26 (CH2CH2CH2). 33 (PhCH2), 34 (CH2CO) 35 
(CH2CO). 70 (CH2000), 74 (CHOCO), 126 (Ph), 128 (Ph), 141 (Ph), 173 (estcr 
C-0). 174 ppm (lactonc C=O). 
ElMS: "'I, 24 8 (M4". 23%). 144 (C6H O4+', 100%). 
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Palmitoyloxy)Lbutyrolactone [3, R= (CH CH3], 70% yield. 
IR: wavenumbcr. 2960-2860 (Cli stretch), 1790 (lactone C=O stretch), 1740 cm-1 
(ester C=O stretch). 
IH NMR (CDQ3,90 MHz) :80.8.1.7 [m, 29H. (CH2)13CH3], 2.3 (m, 2H, side- 
chain CH2CO), 2.7 (m, 2H. ring CH2CO), 4.4 (m, 2H, CH2000), 5.4 ppm (m, 
1H, CHOCO). 
13C NMR ((D 13. gp MHz): S 11 (CH3), 23-32 (13 x CH2), 34 (CH2CO), 35 
(CH2CO), 69 (CH2000). 74 (CHOCO), 173 (ester C=O), 174 ppm (lactone 
C=O). 
ELMS: '"/s 340 (M4', 7%), 85 (CdH5O2+. 100%). 
63.7 -Atw pled Cyclization of Octanoylcarnitine in Hot Septum Inlet of a 
Mau Spectrometer. 
Commercial octanoylcamitine hydrochloride (100 mg) was dissolved in warm 
ethanol (0.5 ml). The solution (10 }xl) was injected into the septum inlet of a VG 
305 single-focussing mass spectrometer. The temperature of the septum inlet was 
70 °C on injection. The inlet valve was slowly opened to allow any vaporized 
species into the ion source. After the evaporation of ethanol had been completed the 
inlet temper Lure was increased in 10 °C increments whilst continually monitoring 
any products released. 
6.3.8 Use of Ultrasound In Derivazizarion Reaction 
Octanoylcaznitine hydrochloride (6 x 10-5M) solutions in EtOAc, THE and CH3CN 
wem made (20 ml of each). Each solution was subject to ultrasound using an MSE 
Soniprcp 150 Ultrasonic Disintegrator (b power, tuned to 14 microns), for 3 mins. 
A1 ml aliquot was removed and analysed by split injection GC (6.3.13). The 
procedure was repeated five times for the remaining solution, so that the final 
aliquot had experienced 15 min of sonication. 
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6.3.9 Derivadzadon Rewion in DMF 
4-Phenylbutanoyl"DL-carnitine hydrochloride (20 mg, 58 µmol) was placed in a 50 
ml round-bottomed flask. Dimethyl formamide (20 ml, dried over BaO) was added 
and the acykzrnitine allowed to dissolve. (Base was added at this stage, 10-100 
pmol, if required. ) The reaction flask was fitted with a reflux condenser and CaC12 
drying tube. The apparatus was supported with the flask in an oil bath at 100 T. 
The reaction mixture was magnetically stirred for 3 hr at this temperature. 
Reaction monitoring over the 3 hr period was achieved by TLC The mixture was 
spotted onto a silica TLC plate and solvent removed by heating in an oven (- 90 °C, 
90 sec). Chromatography was achieved with EtOAc: hexane, 1: 1 and the spots 
observed under a UV lamp. 
After 3 hr the orangelbrown reaction mixture was concentrated under vacuum to 
give an oil. Dry diethyl ether (0.5 ml, Na-dried) was used to extract the lactone 
product for further analysis by GG 
63.10 Initial Derivruiration Reacsion In CH3CN 
Initial investigations were performed in the same apparatus as for 6.3.9. 
4-Phcnylbutanoyl-DL-carnidne hydrochloride (20 mg, 58 µmol) was dissolved in 
acetonitrile (20 ail). Txiethylaminc (I }tl) was added and the mixture stirred under 
reflux conditions for varying periods from 3 to 18 hr. Solvent was removed under 
vacuum and the product extracted from the remaining colourless oil with diethyl 
ether (0$ ml). Analysis of the product was achieved by TLC, IR and 1H NMR 
Spectroscopy. 
63.11 Optwnized Dcrivarization Conditions 
Quantities of standard acylcarnitincs (c0.1 mg) or acylcarnitines extracted from 
urine (see Section 6.3.15-6.3.17) were placed in a Imi ReactiVial.. When 
quantitative investigations were being attempted aqueous solutions of acylcarnidnes - 
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were concentrated by lyophilization and transferred into a 1-ml ReactiVial for 
complete drying, again by freeze-drying. In all cases the resulting acylcarnitine 
residue was treated with acctonitrile (0.5 ml) and NN-diisopropylethylamine (0.5 
µl) and the ReactiVial Sealed with a Teflon-lined septum. The solution was 
subjected to various reaction times and temperatures until the optimum conditions 
were identified for cyclization of the acylcarnitines. Heating at 125 °C for 35 min 
was found to be the most efficacious method of forming the lactone derivatives. 
After the reaction period, solvent was removed under a stream of nitrogen until a 
damp residue was obtained (Evaporation to complete dryness caused some loss of 
the more volatile lactones (3, Ra Me, Et). ] Ethyl acetate (0.2 ml) was added to 
dissolve any acyloxylactone products. Any remaining solid material was removed 
by filtering through a Gelman Acro LC13.0.45 }un filter unit and the filtrate 
analysed for acylcarnitine derivatives by GC and GCIMS. 
63.12 Estimation of Derivatization Yields by On-Column Injection GC 
Standard solutions of acetyl-, octanoyI- and palmitoyl-containing acyloxylactones 
(3) were made up in F. tOAc 
acetyl-; 114 µg ml't: 0.79 µmol ml-1 
oct moyl"; 116 gg ml"t: 0.51 µmol ml-1 
palmitoyl-; 100 µg ml'1: 0.29 µmol ml-1 
A mixture of acctylcamitine (14 µg. 60 nmol), octanoylcarnitine (14 µg, 44 nmol) 
and palmitoylcamitine (14 µg, 32 nmol) was derivatized and reconstituted in 0.2 ml 
EtOAc as in Section 63.11. The derivatized acylcarnidne mixture and the three 
standard solutions of synthesised acylactones were analysed by cold on-column 
injection capillary GG 
A Carlo Erba Model 5300 Mega series gas chromatograph was used. A BP5 
fused-silica column from SGE. 25 mx0.33 mm id. and with a film thickness of 
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0.5 pm was employed. Helium carrier gas flowed through the column with an 
average linear velocity of 35 cm s-1. The hydrogen and air inlet pressures (for the 
flame ionization detector) were 70 and 120 kPa, respectively. The detector was 
maintained at 280 °G The oven temperature was programmed from 87 to 250 °C at 
a rate of 10 °C mini The temperature ramp rate started immediately after injection 
and on reaching 250 °C was maintained at this temperature for 15 min. Cold on- 
column injections (1 µl in all cases) were performed using a 5µl gas- 
chromatographic syringe (Hamilton; Grob design) with a 7.5 cm needle. Retention 
times were measured from the time of injection and integral peak areas were 
determined by a Spectrophysics integrator. 
63.13 Splic Spliclus Injection Capillary GC 
Experiments which required analysis of products by vaporizing injector (i. e. split 
and splitless injection) capillary GC employed a Perkin Elmer 8410 chromatograph 
with the exception of some GUMS experiments which used splitless injection on a 
Hewlett-Packard 5890 GC (sea Section 6.3.22). 
Split ratios were only estimated because (1) accurate splitting of the caner gas is 
difficult to achieve and ('u) an accurate split ratio was not required since quantitative 
evaluations employed an internal standard or preferably, on-column injection was 
perfornxd. Estimates of the split ratio were calculated from determined values for 
flow rates through the split exit valve and through the capillary column. The flow 
rate of Amer gas through the split exit valve was measured with a bubble meter. 
The flow rate through the column was calculated from the retention time of an 
unretained component (methane). Generally. the split ratio was set around 10: 1, 
that is, only one tenth of the sample injected entered the column, the remainder was 
exhausted through the split exit valve. 
For Increased sensitivity, splitless injection was employed. 
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The carrier gas split was kept closed on injection, and for a pre-selected time 
afterwards, to ensure most, if not all, of the sample entered the column. A splitless 
period between 30 s and 1 min was used before the split valve opened to allow the 
chromatographic process to proceed as with split injection GC. 
With both injection methods, sample was injected using the hot-needle technique 
(see Section 2.6.1.1). Sample volumes varied between 0.1 and 1.5 µl. Injection 
temperatures employed were between 200 and 280 °C, however, see Section 6.3.22 
for an evaluation of the effect of this parameter. 
6 3.14 Attempted Derivatization of Urinary Acylcarnitines Without 
Extraction 
Urine (2 ml) was spiked with acetylcarnitine (3 mg, 13 pmol), octanoylcarnitine 
(4 mg, 12 p. mol) and palmitoylcarnitine (6 mg, 14 µmol). The water was removed 
by lyophilization and the resulting residue derivatized as in Section 6.3.11 (with the 
exception that 8.0 p1 triethylamine was used to facilitate the cyclization process). 
The resulting residue, after removal of the reaction solvent, was extracted with 
diethyl ether (10 ml). The ether fraction was washed with an equal volume of 
saturated sodium bicarbonate solution and then concentrated under reduced pressure 
to give an oil with a white suspension. Diethyl ether (1 ml) was added and the 
immiscible oil removed with a pipette. The ether was concentrated by blowing off 
approximately 80% of the solvent with dry argon. 
Analysis was performed by cold on-column injection GC using similar conditions 
to Section 6.3.12 on a Carlo Erba 4160 imstrurnent. 
6.3.15 Extraction of Urinary Acylcarnitines Using Anion-Exchange Resin 
Bio-Rad AG1-X8,100-200 mesh, anionic-exchange resin (1.3 cm3) in either the 
chloride or formate ion form was used to pack a column of 1 cm diameter. The 
column was equilibrated with distilled-deionized water and the urine sample 
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(0.5 ml) applied to the head of the column. Acylcamitines and other cationic, 
neutral and weakly bound anionic species were eluted with distilled-deionized water 
(2 ml). The water was removed by Iyophilization and the resulting residue subject 
to derivatization (Section 6.3.11) and GC analysis of any lactone compounds 
formed (Section 6.3.12). 
6.3.16 Extraction of Urinary Acylcarnitines Using Cation-Exchange Resin 
(i) Bio-Rad AGIX8,100-200 mesh, hydrogen form, cationic-exchange resin 
(1.3 cm3) was used to pack a column of 1 cm diameter. After equilibrating the 
column with distilled-deionized water, 1M pyridine solution was applied to the 
head of the column and allowed to flow through until a permanent pyridine 
smell could be detected in the column effluent. Excess pyridine was washed 
out with distilled-deionized water. 
Urine (1 ml) spiked with acetylcamitine (0.25 mg, 1.0 µmol) and 
octanoylcamitine (0.25 mg, 0.8 µmol) was applied to the cationic-exchange 
column prepared as above. Neutral and anionic species were eluted with HCI 
(1 ml, 0.01 NO and distilled-deionized water (2 ml). Acylcarnitines were 
eluted with a 50/50 (V/V) mixture of methanol and 1.5M, pH 6 pyridinium 
acetate, (3.5 ml). The eluent was lyophilized, derivatized (Section 6.3.11) and 
analysed by capillary GC (Section 6.3.12). 
(ii) An alternative extraction procedure, applied to spiked urine and aqueous 
solutions of acylcarnidnes was the same as (i) detailed above with the 
exception that the acylcarnitines were eluted from the column with O. SM 
NH4OH (3 x5 ml fractions). 
6.3.17 Optimum Extraction Procedure for Urinary Acylcarnirines 
The double ion-exchange procedure detailed here was based on the method of 
Millington et 102 
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Bio-Rad AGI-X8.100-200 mesh, formate (or chloride) form, anion-exchange 
resin (2 cm3) was used to pack a column of 1 cm diameter. The column was 
equilibrated with distilled-dcionized water and the urine sample (0.5 ml) applied to 
the head of the column. Acylcarnidnes and other cationic and neutral species were 
eluted with distilled-deionized water (2 ml). The eluent was acidified with 1M HCl 
(0.2 ml). 
Bio-Rad AGSO-X8,100-200 mesh, hydrogen form, cationic-exchange resin (2 
an3) was used to pack a1 cm diameter column. The acylcarnitine-containing eluent 
from above was applied to the column. Neutral and loosely bound cationic species 
were washed off with HCl (5 ml, 0.01 M) and distilled-deionized water (5 ml). 
Acylcarnitines were eluted with NH4OH (2M, 20% aqueous ethanol), the first 1 ml 
being discarded and the following 6 ml collected and freeze-dried. 
The resulting residue was dissolved in distilled water (0.5 ml), transferred into a1 
ml ReactiVial and freeze-dried in this vessel. The residue was then subject to 
derivatization (Section 6.3.11) and analysis by capillary GC (Section 6.3.12). 
6.3.18 Estimation of Aeylcarnitine Recoveries from Double Ion-Exchange 
Method 
Urine (0.5 ml) was spiked with acetylcarnitine (0.25 mg, 1.0 µmol) and 
octanoylcarnitine (0.25 mg, 0.8 µmol) and extracted as detailed in Section 6.3.17. 
Similarly an aliquot of distilled-dcionized water (0.5 ml) was spiked and extracted. 
A third, aqueous solution of acetylcamitine and octanoylcarnitine, at the same 
concentrations as for the extracted urine and water samples, was simply freeze- 
dried. 
AU three samples were derivatized (Section 6.3.11) and analysed (Section 6.3.12) 
under identical conditions. Recoveries were estimated by comparing the FID 
responses of derivatives from the extracted and unextracted acylcarnidncs. 
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6.3.19 Relative Extraction Efficiencies from Control Urines 
A stock solution of four acylcarnitines in distilled-deionized water was made: 
Acetylcarnitine: 0.2 mg m1-1 (0.84 µmol ml-1) 
Isovalerylcarnitine: 0.2 mg m1-1 (0.71 µ mol ml-1) 
Octanoylcarnitine: 0.2 mg m14 (0.62 gmol ml-1) 
4-Phenylbutanoylcamitine: 0.2 mg ml-1 (0.58 µmol ml-1) 
The above stock solution (0.1 ml) was used to spike each of four control urines 
(0.5 ml); Cl, C2, C3 and C4. Each spiked urine sample was extracted as in 
Section 6.3.17, derivatized as in Section 6.3.11 and analysed by capillary GC as in 
Section 6.3.12. An aliquot (0.1 ml) of the stock solution was also freeze-dried, 
derivatized and analysed, as for the spiked urine sample. In accordance with 
Section 63.18, recoveries were determined by comparing analysis results from the 
extracted urines with those from the matrix-free, unextracted sample. 
63.20 FID Responses for Derivatives of Acylcarnitines Spiked into Urine 
Before and After Extraction 
Urine (0.5 ml) was spiked with isovalerylcamitine (20 µg, 71 nmol), 
octanoylcarnidne (20 µg, 70 nmol), and 4-phenylbutanoyl-carnitine (20 µg, 58 
nmol). The urine was then extracted, derivatized and analysed by GC as described 
previously. A second aliquot of the same urine (0.5 ml) was also spiked with the 
same quantities of isovalerylcarnidne and octanoylcarnidne but the phenyl- 
containing acylcarnitine was not introduced until the sample had been extracted and 
was ready for derivatization. The same quantity of 4-phenylbutanoylcarnitine (20 
µg, 58 n mol) was then added and the sample derivatized and analysed as 
previously. 
-- 208 
6.3.21 Attempted Extraction Using Bond Elut CERTIFYTM Columns 
The attempted extraction procedure was based on the established method of 
extracting basic drugs of abuse (e. g. amphetamines, LSD and codeine) from urine 
using Bond Elut CERTIFY columns. 
Urine (5 ml) was spiked with octanoylcamitine (0.9 mg, 2.8 µmoI) and 4- 
phenylbutanoylcarnitine (1.2 mg. 3.5 tmol). Potassium orthophosphate buffer (2 
ml, 0.1M, pH 6.0) was added and the sample vortex mixed and the pH checked to 
be between 5.0 and 7.0 with pH paper. 
The column was prepared by drawing through, under vacuum, methanol (2 ml) 
then phosphate buffer (2 ml, 0.1M, pH 6.0) ensuring that the column did not run 
dry at this stage. Sample, prepared as above, was applied to the head of the column 
and allowed to pass through under gravity. Neutral and weakly bound species 
were washed from the resins with phosphate buffer (0.1M, pH 6.0): methanol, 
80: 20 (1 ml) then dried for 5 min by drawing through air, followed by acetic acid (I 
ml, 1. OM) and a further drying period of 5 min. The column was fully dried by 
rinsing with hexane (I ml) then drying for 2 min. Dichioromethane (4 ml) and 
methanol (6 ml) were passed through the column and these two fractions collected 
for analysis. The fraction expected to contain acylcarnitines was obtained by 
elution with NH4OH (20% in EtOH, 2 ml) to give a yellow solution. Aliquots of 
this fraction were freeze-dried and analysed for acylcarnitine content by 
derivatization (Section 63.11) and on-column injection GC (Section 6.3.12). 
6.3.22 Effect of Injector Temperature on GC Behaviour of Cyclized 
Acyl=rnitines 
A standard (0.1%) solution of synthesised octanoyIoxy-Y butyrolactone (3, R 
(CH)6CH3] was prepared. This sample was analysed using splitless-injection 
GGMS at four injector temperatures, 150,230,250 and 280 °G 
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Analysis was performed with a VG 20-250 quadrupole instrument coupled to a 
Hewlett-Packard Model 5890 gas chromatograph equipped with a fused-silica BP5 
capillary column of dimensions 12.5 mx0.25 mm U. and a stationary phase film 
thickness of 0.25 pm The direct-line interface was maintained at 260 °C and a 
source temperature of 200 °C was used. Electron ionization (EI) with an electron 
energy of 70 ev and an ion current of 100 pA was used. Splitless injection (0.2µI) 
were performed using a closed split valve period of 45 s. Other GC conditions 
were as in Section 6.3.12. 
Peak heights, areas and shapes were determined from the total ion current 
chromatogram. 
6.3.23 Free Zone Capillary Electrophoresis 
Capillary zone electrophoresis (GZE) methods were performed using a Beckman 
P/ACE System 2000. Using this apparatus, initial attempts were made to separate 
various aqueous mixtures of acylcarnitines. The use of CZE to analyse 
acylcarnidnes has not been reported to date and therefore the approach was one of 
method development, investigating the effect of the operational parameters on any 
signal responses and separations achieved. 
Attempts were made to analyse standard aqueous solutions of individual 
acylcamitines and mixtures of several standard acylcarnitines. Concentrations of 
the solutions varied from 10-1000 tg/ml for each carnitine ester. Uncoated, 
deactivated silica capillaries were employed with dimensions of 50 cm length (43 
cm effective length) and 75 pm internal diameter. Standard electrolytic buffer 
systems of 0.1 M sodium phosphate/sodium borate adjusted to pH values from 2.0 
to 8.0 were obtained with the P/ACE System 2000 instrument and used in these 
initial studies. Detection was performed at either 200 or 210 nm using the inbuilt 
UV detection system. Electrophoresis was achieved when 8 -12 kV was applied 
across the capillary column. Sample was introduced into the capillary by either 
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positive pressure injection for fixed time periods of 2-8s or by electrokinetic 
injection using the running potential for similar time periods as the pressure 
injections. Data were recorded and manipulated by an IBM PS/2 PC with Beckman 
System Gold software package. 
Between injections the capillary column was conditioned with 0.1 M NaOH, 
flushed through the column by positive pressure for 15 s. followed by distilled- 
deionised water for 20 s and then re-equilibrated with the run buffer before the next 
injection. 
6.3.24 Micellar Ekc rokinetic Capillary Chromatography (MECC) 
The same C. LE equipment as that used in the experiments of Section 6.3.23 was 
used for MECC investigations. Similar acylcarnitine solutions were also subject to 
MECC analyses. The essential difference from the free zone capillary 
electrophoresis studies, was the presence of sodium dodecyl sulphate (SDS) in the 
electrolytic run buffer. SDS concentrations of 20-400 mM (i. e. above the critical 
mice liar concentration) were employed during the studies conducted. Other 
operating parameters and procedures were as for the experiments of Section 6.3.23. 
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